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Abstract
The study of multi domain proteins and their complexes in solution using X-ray and 
neutron solution scattering data is a valuable tool for structural biologists. This thesis 
describes how a novel automated computer modelling technique combined with high 
quality solution scattering data and biochemical knowledge can be used to give biologically 
significant information. In this study the use of this technique as applied to two biochemical 
systems is described.
The first system to be studied was the interaction between tissue factor (TF) and blood 
coagulation Factor Vila (FVIIa), an interaction essential as an initiator of the blood 
coagulation cascade. FVIIa is a four domain plasma protein consisting of a serum protease 
domain with two glycosylation sites, two epidermal growth factor domains and a C- 
terminal Gla domain (a domain rich in y-carboxyglutamic residues). TF has two 
extracellular Fn-III domains which are bound to the cell membrane by a transmembrane 
region. In initial studies we were able to show how FVIIa complexed with sTF, formed a 
compact conformation in solution, confirming the findings of biochemical studies which 
had implicated numerous residues involved in complex formation. Modelling allowed us to 
propose domain models for free FVIIa and the complex between sTF and FVIIa which was 
subsequently confirmed by the crystal structure for this complex.
The second protein to be studied was the pentameric ring structure of serum amyloid P 
(SAP). Although SAP is a plasma protein with no known biological function, SAP is found 
in all amyloid deposits and is believed to play a protective role in preventing normal body 
responses to removing such plaques. Previous studies had shown that SAP could exist as a 
pentamer or a decamer in solution. Even though the crystal structure of the pentameric form 
was known there were no details of how the decamer was formed. Using solution scattering 
data, along with the high resolution crystal structure of the stable pentameric ring, it was 
possible both to produce a model for the decamer, and to assess critically the parameters 
used in the modelling procedure.
This study has advanced the method of scattering analysis. The ease of modelling solution 
scattering data makes it a valuable technique which is now becoming a routine procedure in 
structural and functional analysis of proteins.
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CHAPTER 1
Protein Structure And Its Solution.
1
1,1 Protein structure introduction.
The study of macromolecular structures is a process of harvesting results from a variety 
of techniques in order to determine functional roles within the host organism.
In most organisms the genetic information needed to code for a protein is stored in the 
nucleotide chain known as DNA or RNA. The DNA of an organism will undergo 
transcription to RNA. The RNA in turn undergoes translation to create the protein. 
Nature has given us a diverse range of organisms, and an even more diverse range of 
proteins, but the basic building blocks of all proteins are 20 amino acids (Appendix A). 
We now understand the way in which amino acids associate to form a polypeptide 
chain, and projects such as the Human Genome Mapping Project (HGMP) have given us 
the complete genetic code of an organism that will be transcribed to produce proteins. 
However, in most cases we are still unable to reliably predict or determine the way in 
which the polypeptide chain will fold to become the functional protein and how proteins 
interact with each other.
1,1.1 Protein domains.
If a polypeptide chain can fold to form a distinct compact region, it is known as a 
domain (Wetlaufer, 1973). The definition of a domain is a part of the protein that can 
fold up independently of its neighbouring sequences (Doolittle, 1995) and can therefore 
be considered as the basic subunit within the protein tertiary structure. The amino acid 
sequence of a domain will have the appropriate physical and chemical properties to fold 
into a compact and functional three-dimensional structure. The critical sequence length 
necessary for the formation of a globular domain is in the region of about 40 amino 
acids, e.g. the epidermal growth factor domain (Montelione et al., 1987). The upper 
domain size is estimated to be in the region of 400 residues (Islam et al., 1995), e.g. 
cytochrome p450eryf (Cupp-Vickery & Poulos, 1995).
Inspection of the structures of known globular domains will reveal that they have a core
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that consists predominantly of non-polar, hydrophobic amino acids such as leucine, 
valine, phenylalanine and tryptophan (Appendix A). The solvent accessible surface is 
more likely to be composed of amino acids with polar or hydrophilic side chains e.g. 
serine. This phenomenon is due to the hydrophobic effect, which is entropic and 
describes the association of non-polar groups in order to reduce their contact with water. 
Close atomic packing within the core is the result of Van der Waals interactions (for a 
review see Levitt et al., 1997).
The structure of a domain can be further subdivided. The formation of hydrogen bonds 
between main chain amide and carboxyl groups will give rise to the secondary structure 
elements, a-helix and p-sheets. An a-helix is localised to a region of consecutive 
residues, and is formed by a hydrogen bond between each mainchain carboxyl group and 
the amide group which is found 4 residues towards the C-terminal end of the 
polypeptide (Figure 1.1a). A p-sheet is formed by reciprocal hydrogen bonds between 
the mainchain carboxyl and amide groups on separate regions of polypeptide chain that 
run parallel or antiparallel to each other (Figure 1.1b). The strict mainchain geometries 
required to form a-helices and P-sheets can be considered to produce rigid structural 
elements that pack, by means of sidechain interactions, to form the domain core. The 
folding pattern of a globular protein is then the arrangements and connections of these 
secondary structure elements (Chothia & Finkelstein, 1990). Salt bridges between 
oppositely charged amino acids and covalent disulphide bridges between pairs of cystine 
(Cys) residues can further stabilise the domain structure.
1.1.2 Domains and protein evolution
The domain has played an integral role in protein evolution. It is proposed that once the 
genetic information for a domain was available, selection forces caused its propagation 
throughout evolution by continuous duplication, shuffling and modification events. This 
theory suggests, all naturally-occurring proteins have originated from a relatively small
3
a)
b)
Figure 1.1: Cartoon representation of the secondary structure elements of a protein, 
produced with MOLSCRIPT (Kraulis, 1991). Figure a) shows a stereo view of the a-helix 
from the A chain of the pentameric structure of SAP (PDB code lsac). The transparent 
blue ribbon shows the cartoon representation of the residues shown in solid stick. Carbon 
in the backbone is shown in white, oxygen is in red and nitrogen in blue. The dashed dark 
green lines show the hydrogen bonding holding the helix together. Figure b) shows in 
transparent green an anti parallel p-sheet also from the A chain of SAP with the residue 
elements making up the strands shown as in a) (Emsley et al., 1994).
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number of primordial domain genes and the existence of ubiquitous folds, such as the 
nucleotide-binding fold (Rossman et a l , 1974), the flavin-binding fold (Correll et al., 
1993) and the haem-binding domains (Vasudevan et a l , 1991), supports this view. 
Comparing both the amino acid sequence and the secondary structure elements can be 
used to identify related domains. Terms such as families and superfamilies are employed 
to classify the relationships between domains, where two proteins in the same family 
may share a sequence similarity of about 50%, two proteins in the same superfamily 
may only share a sequence identity of about 30% (Dayhoff et a l , 1972).
The definition of family and superfamily is frequently more flexible where evolutionary 
relationships are established by refining the sequence comparison using matrices to 
quantify amino acid differences, e.g. the Dayhoff matrices (Dayhoff et a l , 1978). 
Alternatively, esoteric knowledge such as functional similarities or important sequence 
motifs may be used to identify related sequences. It is generally estimated that there are 
about 1000 protein superfamilies (Chothia, 1992).
Evaluating the three dimensional structures of known domains and proteins has led to a 
degree of order to databases such as the PDB. This has le d to the discovery of 
structural patterns being noticed e.g. possible rules of protein folding (Chothia & 
Finkelstein, 1990). This can lead to the identification of important sequence motifs that 
are not apparent from sequence data alone. A good example of the value of rigorous 
structural classification is the success that has been achieved in modelling the three- 
dimensional structures of the antigen-binding domains of antibodies using template loop 
structures (reviewed in Rees et a l , 1996).
The number resources and databases available that classify domains and their structures 
has increased dramatically over recent years (Table 1.1). A good evaluation of available 
resources is available in the Proceedings of the CCP4 Study Weekend, 1998 (Acta D, 
Volume D54, Part 6).
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Table 1.1: A summary of WWW resources that classify domain structures (Grey et 
al., 1996; W eissigetal., 1998).
Name (and function)
Reference
URL
The Protein Kinase Resource
Smith et al., (1997)
PDBObs (Obsolete PDB Entries)
Weissig & Bourne (1999)
EF-hand Calcium Binding Proteins 
Nelson, unpublished work 
G-coupled Protein Receptors
Kolakowski & Zhuang, unpublished work 
HIV Proteases http://www-fbsc.ncifcrf.gov/HIVdb/
Vondrasek & van Buskirk, unpublished work
http://www.sdsc.edu/kinase/
http://pdbobs.sdsc.edu/
http://chazin.scripps.edu/cabp_database/
http://www.gcrdb.uthscsa.edu/
Lipid Structures
Caffrey, unpublished work 
Biological Relevant Structures
Hendrick, unpublished work 
Olderado (NMR ensembles)
Sutcliffe, unpublished work 
Peptidases
Rawlings & Barrett, unpublished work 
ReLiBase (receptor-ligand complexes) 
Hendlich, unpublished software 
TOPS (Protein Topology)
Westhead et al., (1998)
Esterases and Lipases (structure alignments)
http://www.lipidat.chemistry.ohio-state.edu/
http://www2.ebi.ac.uk/msd/mm_search.shtml
http://neon.chem.le.ac.uk/olderado/
http://www.bi.bbsrc.ac.uk/merops/
http://www2.ebi.ac.uk:8081/home.html
http://www3.ebi.ac.uk/
http://cl.sdsc.edu/align_db.html
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Since domains have been structurally classified, the existence of domains that have 
similar fold structures but do not exhibit an evolutionary relationship has emerged. This 
phenomenon was first recognised in the 1970 s when similarities were observed between 
the domain structures in flavodoxin and lactate dehydrogenase (Rao & Rossman, 1973). 
A systematic classification of the available structures in the PDB (Orengo et al., 1994) 
led to the conclusion that there are nine domain “superfold” structures which are 
adopted by domains with neither sequence nor functional similarity (Figure 1.2). 32% of 
domains in the PDB database adopted one of these “superfold” structures. The nine 
“superfolds” could be due to divergent evolution where they represent stable structures 
that have tolerated high levels of sequence mutations, which mask the relationships 
between domains.
An alternative explanation is convergent evolution where the high stability of the 
“superfold” has evolved independently on more than one occasion. The existence of 
“superfold” structures has prompted the development of analogy modelling techniques. 
This type of modelling relies on identifying whether a domain sequence without 
structural homologues is compatible with a seemingly unrelated structure. An example 
of the successful application of analogy modelling has been the prediction that the von 
Willebrand factor type A domain adopts a similar fold to the GTP binding domain of 
ras-p21 (Edwards & Perkins, 1995; reviewed in Perkins et a l , 1998b).
A polypeptide chain may fold into a single domain or into many domains strung 
together. The sequence of titin, a human muscle filament protein, predicts a 3,000,000 
Da polypeptide containing more than 240 globular domains (Labeit & Kolmerer, 1995). 
It is often convenient to consider multidomain proteins as being constructed from the 
fusion of distinct structural and functional subunits (Campbell & Downing, 1994; 
Doolittle, 1995). This is particularly true for “mosaic” proteins that consist of more than 
one type of domain fold. It is also a feature of many biological pathways that a few
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Figure 1.2. The nine “superfolds”. An example for each of the nine “superfold” 
structures is shown as a ribbon representation. The PDB accession code for each 
structure is given (Adapted from Orengo et al., 1994).
domain fold types, which perform the characteristic functions of the pathway, dominate 
their constituent proteins. For example, blood clot haemostasis proteins have a high 
incidence of several domain types including serine protease and epidermal growth 
factor-like domains (Pathy, 1993).
A protein may also consist of more than one polypeptide chain. This protein tertiary 
structure may be important for fashioning active sites by the association of domains 
from more than one chain. Disulphide bridges and non-covalent interactions between 
domain surfaces are utilized in holding chains together.
1.2 Introduction to protein structure determination.
Unless a protein is closely related to another protein with a known structure, its three- 
dimensional structure can only reliably be determined experimentally. Experimental 
techniques vary in the information determinable ranging from low resolution envelopes 
through to atomic resolution structures.
The experimental techniques of Nuclear Magnetic Resonance (NMR) and X-ray 
crystallography (PX) have jointly produced over 24168 publicly available atomic 
structures of macromolecules (PDB Homepage http://www.rcsb.org/pdb, as of the 4th of 
February 2004). The information gained from the analysis of these structures has not 
only greatly improved our understanding of protein structures but also the biological 
role accomplished by a protein. There are currently a myriad of projects underway using
both NMR and more notably PX to exploit the information within the known genomes 
to determine a large amount of structures using advances in high throughput techniques 
and synchrotron radiation facilities.
But despite significant advances in high-resolution techniques, these techniques 
frequently fail both to produce results and determine the function of a protein. 
Regardless of this, there are numerous other techniques that can be employed to
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elucidate biologically relevant structural information, and these are now summarised;
1.2.1 Determination of secondary structure
The main techniques for experimentally determining secondary structures within a 
protein are circular dichroism (CD) and Fourier transform infrared (FT-IR). In CD 
spectroscopy, the effect of an asymmetric molecule (such as a protein) on plane 
polarized light is measured (Campbell & Dwek, 1984). A plane polarized wave is 
produced from two circularly polarized light beams that have equal amplitudes but 
rotate in opposite directions. Upon interaction with an asymmetric molecule, the 
amplitude of one beam changes relative to the other to produce an elliptically polarized 
beam. The degree of ellipticity is measured as a function of wavelength and 
characteristic values are observed for a-helix and P-sheet conformations at wavelengths 
between 180 and 250 nm. In FT-IR spectroscopy, the absorption of a protein sample is 
measured over the infrared spectrum (Haris & Chapman, 1994). Of particular 
importance is the frequency range from 1690 to 1600 cm'1, which results mainly from 
C=0 stretching although N-H bending and C-N stretching also contribute. The precise 
frequencies of maxima or bands are determined by the nature of the hydrogen bonding 
schemes involving C=0 and N-H groups. Thus the secondary structure content of a 
protein can be determined by analysing the band frequencies in this region. The bands 
are resolved using mathematical second derivative and deconvolution procedures and it 
is possible to assign different mainchain conformations according to these bands. Bands 
between 1620 and 1640 cm'1 and between 1648 and 1657 cm'1 are usually assigned to 
P-sheet and a-helix structures respectively. Both CD and FT-IR spectroscopy enable an 
estimate of the relative proportions of secondary structure types to be obtained.
1.2.2 Low resolution structure determination.
The main low resolution structural techniques that provide information on the overall 
dimensions of a molecule include small angle X-ray and neutron solution scattering 
methods and electron microscopy. Small angle X-ray and neutron methods examine the 
scattered waves produced from the diffraction of an incident beam by protein molecules
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in solution. A detailed account of small angle solution scattering is given in Section 1.3. 
Electron microscopy uses the same principle as light microscopy and enables the shape 
of a protein molecule to be visualized directly. In a transmission electron microscope, 
the protein sample is studied using an electron beam that is focussed by a series of 
lenses to produce magnification factors in the region of x 100,000. Information on the 
gross structure of a protein molecule can also be obtained from hydrodynamic analyses. 
The basis of hydrodynamic experiments is that, for a solution subjected to a centrifugal 
force, the movement of protein molecules is dependent on the size and shape of the 
molecule (see also section 1.3.6).
1.2.3 High resolution structure determination.
The experimentally determined atomic coordinate protein structures that are currently 
deposited in the PDB have been determined by either X-ray crystallography or multi­
dimensional NMR. X-ray crystallography of proteins requires a protein to be organised 
in a precise crystal lattice and this is often the limiting factor of this technique (Figure 
1.3a and 1.3b). The basis of the X-ray diffraction technique is that electrons of the atoms 
in the crystal scatter an incident X-ray beam to produce a characteristic pattern of 
reflections (Figure 1.3d) that can be observed with an X-ray detector (Figure 1.3c). The 
intensities of the reflection are dependent on whether the waves scattered by all the 
atoms in the crystals combine in or out of phase to reinforce or cancel each other out. X- 
ray scattering experiments can be conducted either ‘in house’, where equipment tends to 
produce less intense X-rays or alternatively can be done at specialised instrument sites 
such as the SRS at Daresbury Laboratory, UK. Here a very bright beam will 
dramatically reduce the time required to collect a dataset and frequently improves the 
resolution of the experiment. Combining the intensities and the phases of the reflections 
in a Fourier transform will produce maps of electron density of the protein (Figure 1.3e).
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a) b)
Figure 1.3: High resolution structure determination using X-ray crystallography, a) and 
b) show crystals of the pentraxins C-reactive protein and serum amyloid protein 
respectively (courtesy of Dr. D. Thompson, University of Southampton), c) shows a 
schematic diagram of a typical X-ray diffraction experiment on a protein crystal. The 
diagram shows an X-ray beam incident on a crystal. The X-ray beam can be produced by 
either a facility such as the SRS at Daresbury Laboratory or ‘in house’ with specialised 
laboratory equipment. The beam is scattered by the crystal and is measured by a detector 
and the angle of diffraction is 20. Figure d) shows a typical scattering pattern for a 
protein (courtesy of Daresbury Laboratory web site, http://www.dl.ac.uk). Once the 
phases of the reflections are calculated and combined with the intensities in a Fourier 
transform it is possible to create an electron density map as in e). Here we can clearly
12
osee the active site of a metalloprotease at atomic resolution (1 A) with a histidine residue 
projecting from the main chain and helping to co-ordinate a zinc ion (green) (courtesy of 
Dr. K. McAuley, Diamond Light Source).
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The phases must be obtained indirectly using techniques such as isomorphus 
replacement or molecular replacement. Once an electron density map is obtained it is 
possible to position the heavy atoms and waters, and to trace the polypeptide chain to 
obtain a three dimensional model of a structure (see a Zn atom and a histidine residue in 
Figure 1.3e).
In NMR spectroscopy, the effect of an applied magnetic field on nuclei that possess a 
magnetic moment or spin is determined. Nuclei that possess spin include !H, 13C and 
15N. When a strong external magnetic field is applied to a protein solution, these spins 
reach an equilibrium in which the net spin is aligned in the direction of the magnetic 
field. Radiofrequency pulses are used to apply a second magnetic field perpendicular to 
the first, which converts the equilibrium alignment to an excited state. 
Radiofrequencies are emitted by the nuclei as they revert to the equilibrium state, and 
the exact frequency of radiation emitted from a nucleus depends on its molecular 
environment. This forms the basis of structure determination by NMR. Two- 
dimensional NMR experiments are used for structure determination, and different two- 
dimensional experiments reveal different interactions between hydrogens that are 
spatially close to each other. The major two-dimensional experiments are the COSY 
experiment, which gives signals that correspond to hydrogen atoms that are covalently 
connected through one or two other atoms (known as J-couplings), and the NOESY 
experiment, which gives signals that correspond to hydrogen atoms that are close 
together in space but may be far apart in the sequence (known as nuclear Overhauser 
effects). The signals from these experiments are assigned to the protein sequence in 
order to obtain distance constraints from specific hydrogen atoms in one residue to 
hydrogen atoms in a second residue. A series of models are constructed that are 
consistent with these distance constraints.
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1.3 Small angle solution scattering
In the following section, an overview of small angle X-ray and neutron scattering is 
given. This describes the basic theory and practice behind the solution scattering 
experiment, and concludes with some of the useful measurements of macromolecular 
dimensions that can be obtained from solution scattering data. For a more 
comprehensive description of the theory of solution scattering, the reader is referred to 
the texts of Glatter & Kratky (1982) and Perkins (1988).
1.3.1 X-rav scattering theory
Solution scattering is a diffraction technique that can be used to study the low-resolution 
structure of proteins. An X-ray scattering experiment is performed by irradiating a 
sample with a highly collimated beam of monochromatic X-rays, and measuring the 
intensity of scattering I  against Q, where Q is a function of the scattering angle 20, from 
which the scattering curve 7 ( 0  is obtained (Figure 1.4). Scattering is due to interaction 
of X-rays with electrons in the sample: upon irradiation each electron oscillates and 
emits electromagnetic waves of the same wavelength X in all directions, but phase- 
shifted by n  with respect to the incident X-ray beam. This type of scattering is known as 
coherent scattering.
The intensity of scattering by an electron is proportional to the X-ray scattering length /  
of the electron, which has a value of 2.81 fin (2.81xl0'15m; this is known as the classical 
Thompson electron radius). The X-ray scattering length for small angle scattering 
studies of an atom is the atomic number (the number of electrons it contains) multiplied
1 9by the electron scattering length. Accordingly, the hydrogen isotopes, H and H, both
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Figure 1.4: General features of a solution scattering curve I(Q) measured over a Q 
range. The scattering curve is analysed in two regions, that at low Q giving the Guinier 
plot from which the overall radius of gyration Rg and the forward scattering intensity 
1(0) values are calculated, and that at larger Q from which more structural information is 
obtained. At low Q, the scattering curve is truncated for reason of the beamstop 
(Adapted from Perkins, 1994).
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have the scattering length of an electron of 2.81 fin, while the atoms 12C, 14N, 160  and 
32S, which are also relevant to proteins, have/ values of 16.9 fin, 19.7 fin, 22.5 fin and
45.0 fin respectively.
1.3.1.1 The Debve equation
The form of the scattering curve 7 (0  can be described by the Debye equation. 
Diffraction phenomena arise from interference between scattered waves and 
consequently the scattering curve I(Q) is determined by the spatial arrangements of 
electrons in the protein. The X-ray scattering from two points in a protein is depicted in 
Figure 1.5. The incident X-ray beam is defined by the unit vector so and is scattered 
from an origin point O in a direction denoted by the unit vector s. Since scattering is 
elastic, sq and s have the same amplitude, and for convenience this is set as 2nJX. Q is 
the scattering vector (s - so), and its amplitude is 4rcsin0/A, (Figure 1.5). When the 
scattering angle is zero, waves scattered from all points in the protein will be in phase 
and the intensity of scattering is the sum of all scatterers. When the scattering angle is 
non-zero, interference is produced by phase differences between scattered waves, and 
this can be considered using the path difference between scattering points. In Figure 
1.5, the incident X-ray beam is scattered by a second point P, and the path difference 
between waves scattered by points O and P  is AO  + OB. This path difference 
corresponds to a phase difference of 2n(AO + OB)/X. If the vector between O and P  is r, 
then AO  = -rso and OB = rsj and the phase difference is r{si - so), or more simply rQ. 
The phase difference rQ between each individual scatterer in a macromolecule 
determines its scattering curve 7 (0 , and this relationship is contained within the Debye 
equation:
where 7 ^ (0  is the square of the structure factor F(Q) of the macromolecule, F(Q) is a 
regularisation of the scattering curve 7 (0  to the intensity of scattering by one electron at
s in ( r0
rQ
Eq. 1.1
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Figure 1.5. Schematic representation of X-ray scattering from two points in a protein 
molecule. Diffraction is by two points O and P  separated by a distance r within a single 
particle in a solution scattering experiment. A and B correspond to the perpendiculars to 
the incident and scattered beams. The unit vectors so and s define the incident and 
scattered radiation, and Q defines the scattering vector (s-so) (Adapted from Perkins, 
1988).
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zero scattering angle Ie [7 (0  = 4 /^ ( 0 ] ,  and the summations are performed over all 
atoms p  and q, where f p and f q are the respective X-ray atomic scattering lengths. The 
Debye equation gives the average of 7 ^ ( 0  for all possible orientations of the molecule, 
and this would therefore require that scattering is spherically symmetrical about the 
incident beam. It can be seen that the Debye equation is only dependent on the 
magnitude of Q. For this to be true in a scattering experiment, the scattering sample 
would have to consist of a monodisperse solution of identical molecules that occupy all 
orientations equally, and act as independent scattering entities. A limitation of the 
Debye equation is that it describes particles in vacuo and it therefore needs to be 
modified in order to consider aqueous protein solutions.
1.3.1.2 Two-phase model of solution scattering
The simplest consideration of an aqueous protein solution is as a two-phase system of 
solute and solvent. The Debye equation is modified to consider the contrast Ap between 
the scattering density of the macromolecule in vacuo pv and the scattering density of the 
solvent ps, where Ap = pv - ps. The Debye equation can also be revised according to the 
resolution limits of the solution scattering experiment. In an X-ray solution scattering 
experiment, data will typically be collected to a maximum usable Q of approximately
2.0 nm'1. The maximum Q value can be used to calculate the structural resolution of 
scattering, i.e. the smallest distance d  measured in the experiment. Bragg’s Law (X = 
2dsin0) is used for this calculation. A Q value of 2.0 nm'1 corresponds to a resolution of 
around 3 nm. At this resolution, a few large volume elements dvp o f scattering density 
p(rp) can be used to replace individual X-ray atomic scattering lengths f p in the Debye 
equation (fp = p(rp)dvp = p(rp)d rp). Thus the intensity of scattering is:
F 2(Q) = \v \v (P (rP) - Ps) (P (r q) - P j  S1" ^ p  d 3rPd 3r, Eq 1.2
where the integration is taken over the macromolecular volume V.
19
1,3.2 X-rav solution scattering
1.3.2.1 Sample preparation
X-ray solution scattering experiments were designed according to the two-phase model 
of solution scattering expressed in Equation 1.2. The first requirement was for a pure, 
monodispersed solution of protein at a concentration that was high enough for its 
scattering curve to be measured. The tendency of protein samples to aggregate 
necessitated that each sample was subject to gel filtration to remove non-specific 
aggregates, and then reconcentrated as shortly before data collection as possible. The 
choice of buffer is also important. In X-ray scattering experiments, the closer the buffer 
is to pure water, the higher the sample transmission becomes, and hence better counting 
statistics can be obtained. Phosphate buffered saline (PBS; 12 mM phosphate, 140 mM 
NaCl, pH 7.4) was used for X-ray scattering experiments. To ensure appropriate 
corrections were made for solvent scattering, the protein sample was dialysed against its 
buffer, and the scattering of the buffer was subtracted from the scattering of the protein 
solution. Ideally, a sample of volume 0.5 ml and concentrated to 10 mg/ml would be 
used for X-ray experiments. The concentration of a protein solution can be determined 
from its tryptophan content by measuring its absorbance at 280 nm, and using an 
absorption coefficient (1%, 1cm) calculated from its amino acid and carbohydrate 
composition by the corrected Wetlaufer procedure (Perkins, 1986).
1.3.2.2 X-rav scattering at SRS Daresbury.
X-ray scattering experiments were performed at the Synchrotron Radiation Source 
(SRS) at Daresbury, Warrington, U.K.. Synchrotron radiation is emitted from electrons 
that are accelerated while moving at speeds close to the speed of light. Several stages 
are used in the production of synchrotron X-rays at Daresbury (Figure 1.6a). Electrons 
are produced by a hot cathode source and then accelerated to almost the speed of light in 
a linear accelerator (LINAC). The energy of the electrons leaving the LINAC is
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Figure 1.6. X-ray solution scattering at the SRS Daresbury. (a) Schematic 
representation of the synchrotron. The linear accelerator (LINAC), booster synchrotron 
and the storage ring are shown. Synchrotron radiation is emitted by electrons in the 
storage ring which is transmitted down beamlines to the different experimental stations. 
The small-angle scattering instruments are located on beamlines 2 and 8 (Adapted from 
the Daresbury Laboratory World Wide Web Site http://www.dl.ac.uk). (b) Schematic 
representation of the layout of the X-ray solution scattering camera at Station 2.1. This
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operates at a wavelength of 0.154 nm using a monochromator-mirror optical system. A 
focal spot of size 0.3 x 2.2 mm is produced, with a beam cross-section of 1 x 5 mm at 
the sample position. The optics are in vacuum and built on a vibration-isolation system. 
Between the sample and the detector (not shown) are sections of vacuum tubing of 
length between 0.5 and 5 m mounted on an optical bench. The scattering pattern is 
measured using an area detector that is interfaced to a minicomputer. Inset at the lower 
left is an overall view showing how the X-ray beam is taken from the synchrotron 
storage ring (Adapted from Perkins, 1994).
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increased in a booster synchrotron from 12 to 600 million electron volts (MeV). The 
electrons are then injected into the storage ring, where a high power radiofrequency 
accelerating system increases their energy to 2,000 MeV. In the storage ring, 16 dipole 
magnets force the electrons to follow a near circular path, and they travel around the 96 
m circumference 3.12 million times a second. The beam current at the start of its “life­
time” is typically between 200 and 300 mA, but the current continually decreases as 
electrons are lost. The electrons can be kept in orbit for up to 24 hours before the beam 
has to be regenerated. As the electrons are deflected by the magnetic field, they emit 
“white” X-rays of all wavelengths down tangentially located beamlines where 
experimental stations are set up to use the X-ray beams for dedicated experiments 
(Figure 1.6a). For this thesis, small angle X-ray solution scattering experiments were 
performed on stations 2.1, 7.3 and 8.2. A perfect Ge or Si crystal is used to horizontally 
focus and monochromate the X-ray beam to a wavelength of 0.154 nm. The X-ray beam 
is then vertically focused by a curved mirror, and collimated by sets of slits (Figure 1.6b; 
Towns-Andrew et al., 1989). This monochromatisation method produces an X-ray beam 
that has negligible wavelength spread.
Samples were placed in a specially designed Perspex cell with 10 to 20 pm thick ruby 
mica windows. The mica windows were held in place with Teflon plugs, and the mica 
windows were regularly changed during data collection sessions. The sample cell had a 
1 mm path length, a surface area of 2 mm (vertical) by 8 mm (horizontal), and held a 
volume of 25 pi. The sample cell was held in the X-ray beam by a brass sample holder, 
which was maintained at 15°C using a water bath. Prior to data collection, the sample 
holder was aligned in the beam using X-ray sensitive “green paper” that turns red on 
exposure. The scattering intensities of the sample were measured using a 500-channel 
quadrant detector (Worgan et al., 1990). A quadrant detector measures intensities in a 
70° angular sector of a circle. This setup gives good counting statistics at large Q values 
where the intensities are weaker. The nominal position of the main beam is located at 
the centre of the circle, and a lead beam stop was used to protect the detector. The 
response of the 500 detector channels is not uniform, so for each data collection session 
the detector response was measured for several hours using a uniform 55Fe radioactive
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source, and this was used to correct the experimental X-ray scattering measurements. 
The distance between the detector and the sample was set so that intensities were 
measured to a maximum Q value of 2.0 to 2.2 nm'1. On station 2.1 sample-to-detector 
distances of 3.36 m to 3.79 m were used, while on station 8.2 sample-to-detector 
distances of 3.26 m to 3.54 m were used. Scattering intensities were measured as a 
function of detector channel number, so for each data collection session the X-ray 
diffraction pattern of fresh, wet, slightly stretched rat tail collagen was measured for 
calibrating the Q range of the detector.
X-rays produce free radicals that can be destructive to proteins, causing them to 
aggregate quickly on exposure. To check for this, the scattering intensity of each 
sample was measured for 10 minutes in 10 equal time frames, and the time frames were 
inspected to check for radiation-damage effects. The protein samples were measured in 
alternation with their respective buffers in order to minimize buffer subtraction errors as 
the incident beam decreased in intensity. For each sample, an ion chamber monitor 
positioned before the sample holder was used for monitoring of the X-ray beam 
intensity, while measurements from a second ion chamber monitor positioned after the 
sample holder automatically allowed for the sample transmission and incident flux in 
data reduction.
1.3.2.3 Reduction of SRS scattering data.
SRS scattering data were reduced to obtain scattering curves I(Q). The SRS scattering 
data were written as binary files, which contained ten time frames of scattering intensity 
as a function of detector channel number. Data reduction was performed using the 
OTOKO software (Figure 1.7; Bendell, P., Bordas, J., Koch, M.H.C., and Mant, G.R., 
EMBL Hamburg and CLRC Daresbury Laboratory, unpublished software). All 
scattering data were normalised to the counts measured by the ion chamber positioned 
after the sample holder using the .DIN procedure. This corrected for beam flux,
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Figure 1.7. Flow diagram of the reduction procedure for SRS Daresbury X-ray 
scattering data. The majority of data processing was performed using OTOKO. The 
spectra were normalised against the counts measured at the back ion chamber using 
.DIN procedure. The buffer background was subtracted from the sample plus buffer 
spectra using .ADD. The resultant spectra were normalised to the detector response 
using .DIV and finally the 10 individual time-frames were averaged together with .AVE. 
The spectra could be plotted either with .PLO (plots out the averaged spectrum) or .PL3 
(plots out the individual time-frames). Prior to July 1997, a gap had to be removed from 
the spectra using the program .XSH. The resulting spectra were converted to ASCII text 
format using the .PRT command. The Q axis is calculated using .XAX from the 
diffraction pattern of wet, slightly stretched rat tail collagen. DOTOKO combines the Q 
axis file with the spectrum intensity files for final analyses using SCTPL5.
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transmission of the sample and exposure times. Each protein sample spectra had the 
scattering of the appropriate buffer subtracted from it using .ADD to give the scattering 
curve of the protein only. The resulting spectra were normalised against the detector 
response using the .DIV procedure. For each protein sample, the spectra from the ten 
individual time frames were plotted with .PL3 to determine whether there were any 
obvious time-dependent effects of the X-rays on the protein. If the protein spectra did 
not exhibit any radiation-damage effects, the ten time frames were averaged using 
.AVE, and the averaged intensities were plotted using .PLO. Prior to July 1997, the 
spectra exhibited a gap in the X-axis, which was due to the timing of the electronics of 
the detector (Figure 1.8). This was removed using .XSH by specifying the channel 
number at the beginning of the gap and the size of the gap. From July 1997 onwards, 
this gap was automatically removed by an improved electronic configuration. The 
diffraction pattern of collagen was used to calculate the Q values of the detector 
channels. The collagen diffraction pattern consists of a series of peaks (Figure 1.8). 
The major peaks are the 1st, 3rd, 5th and 9th order peaks, and the regular spacing 
between peaks enabled the beam centre (zero order peak) to be determined. The spacing 
between successive peaks corresponds to a diffraction spacing d of 67 nm in the 
collagen fibre, and this enabled the Q values of the detector channels to be calculated (Q 
= 2nld) for merging with the intensities. The .XAX command was used to produce a Q 
axis file, which related the detector channel number to its Q value. The binary OTOKO 
data files were converted to ASCII text files using .PRT, and DOTKO was used to 
combine the resulting intensity data files with the Q axis file to produce scattering curve 
files.
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Figure 1.8. The X-ray diffraction pattern of collagen. A total of 21 diffraction peaks 
are visible here. The spacing between successive peaks corresponds to a real-space 
diffraction spacing of 67 nm, which is used to calibrate the Q range of X-ray scattering 
data. The gap between peaks 11 and 12 is an artefact produced by the detector 
electronics, and is removed during data reduction by determining the position of the 
beginning of the gap and the size of the gap in channel numbers. This gap did not exist 
for data collected after June 1997 (Adapted from Meyer, 1994).
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1,3.3 Neutron scattering; a comparison to X-rav scattering
1.3.3.1 Neutrons are scattered bv atomic nuclei
The principles of coherent neutron scattering are the same as for coherent X-ray 
scattering and consequently neutron coherent scattering is also described by the Debye 
equation (Equation 1.1). However, there are some significant differences between 
neutron and X-ray scattering. Neutrons are scattered by the nuclei of atoms, unlike X- 
rays which are scattered by electrons. The neutron atomic scattering length b, which 
replaces the X-ray scattering length /  in the Debye equation, does not exhibit a simple 
relationship to the atomic number. The atoms 12C, 14N, 160  and 32S, which are 
important in proteins, have similar b values of 6.651 fin, 9.400 fin, 5.804 fin and 2.847 
fin respectively. A similar neutron scattering length is observed for the H isotope 
(6.671 fin), however the *H isotope has a large negative b value (-3.742 fin). A negative 
scattering length value implies that there is no phase-shift of the scattered waves relative 
to the incident wave. The large difference of the neutron scattering of these two 
hydrogen isotopes is very important in neutron solution scattering experiments. In small 
angle X-ray scattering experiments, a second type of scattering known as incoherent 
scattering is negligible, but incoherent neutron scattering exists for nuclei with spin. In 
terms of protein atoms, incoherent scattering is only significant for !H nuclei where it 
becomes very large.
1.3.3.2 The hydration shell
The neutron scattering properties of *H atoms necessitate that neutron experiments are 
performed in 100% 2H2 0  buffers in order to obtain scattering curves that are comparable 
in signal and noise to those measured in X-ray experiments. However, even under these 
conditions, small differences are often observed between measurements from neutron 
and X-ray experiments and these are attributed to the hydration shell that surrounds 
protein molecules. The hydration shell refers to solvent water molecules that are closely 
associated with the protein by means of hydrogen bonds. In X-ray solution scattering 
experiments, this hydration shell is detectable around the protein, but it is invisible in
28
neutron experiments. The model of scattering by an aqueous protein solution that is 
described by Equation 1.2 assumes that the solute and solvent are discrete entities, but in 
actuality water molecules hydrogen bond to the surface of the protein. A water 
molecule hydrogen-bonded to the surface of a protein is electrostricted and has a smaller 
volume (0.0245 nm3) than a water molecule in the bulk solvent (0.0299 nm3) (Perkins, 
1986). Consequently, the X-ray scattering density of a water molecule hydrogen-bonded 
to the surface of the protein is increased relative to that of a bulk solvent water 
molecule, so that it has a value similar to the X-ray scattering density of protein. The
hydration shell detected by X-rays is typically 0.3 g of H2O for every gram of protein
1 0(Perkins, 1986). In neutron experiments, the hydration shell contains H and H which 
exchange freely and rapidly with bulk solvent, and consequently there is almost no 
difference between the scattering density of bulk water molecules and those in the 
hydration shell, and this means that the hydration shell is not detected.
1.3.3.3 Contrast difference Ao
In the two-phase model of solution scattering (Equation 1.2) it is assumed that the 
macromolecule has a uniform scattering density, but in reality biological 
macromolecules can exhibit distinct regions of different scattering density. The four 
major classes of biological macromolecules, protein, carbohydrate, lipid and nucleic 
acids, all exhibit distinct X-ray and neutron scattering densities. For complex 
macromolecules, which consist of more than one class of macromolecule, e.g. 
glycoproteins, lipoproteins and ribosomes, it is possible to alter the contrast of the 
solution scattering experiment in order to study the component macromolecules 
individually. Methods for altering the contrast include adding sucrose to X-ray 
scattering buffers, chemical labelling of the solute and in vivo deuteration of non-labile
solute hydrogen atoms (Worcester, 1988), but the most convenient method is to alter the
0 1scattering density of neutron buffers using different ratios of H2 O to H2O. Due to the 
low amounts of non protein macromolecules studied, the work presented in this thesis 
did not involve contrast variation experiments. Instead complementary studies were 
performed in a high positive solute-solvent contrast Ap by X-ray scattering and in a high 
negative solute-solvent contrast by neutron scattering in 100% H2O buffers. The
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combination of these approaches provided controls for the presence of significant 
inhomogeneity within the glycoprotein protein and carbohydrate scattering.
1,3.4 Neutron solution scattering
1.3.4.1 Sample preparation
Samples for neutron scattering experiments were prepared in the same way as X-ray 
samples, except that PBS buffer in 100% 2H20 was used. After gel filtration and
reconcentration, each sample was dialysed with stirring against this H2O PBS buffer for
1 0a minimum of 36 hours, in which the buffer was changed four times to ensure full H- H 
exchange.
1.3.4.2 Neutron scattering on LOO at the RAL
Neutron scattering experiments were performed on the LOQ instrument at the pulsed 
neutron source ISIS at the Rutherford Appleton Laboratory (RAL), Didcot, UK (Figure 
1.9a) (Heenan and King, 1993). At ISIS, neutrons are produced by a spallation process. 
An ion source produces H' ions, which are initially accelerated to 665 keV. In the 
second stage, the H' ions pass through a linear accelerator (LINAC), where they reach an 
energy of 70 MeV. Stripping the electrons from the H- ions using a very thin alumina 
foil then produces protons. Pulses of protons are accelerated to 800 MeV in a 52 m 
diameter synchrotron, extracted and then sent to the heavy metal target station, at a rate 
of 50 times a second (50 Hz). Bombardment of the uranium or tantalum heavy metal 
target with high energy protons produces neutrons by chipping these from its nuclei. 
The neutrons are slowed by moderators to increase wavelengths. On LOQ the 
moderator is liquid hydrogen (25 K). The layout of the LOQ instrument is shown in 
Figure 1.9b. A supermirror bender removes neutrons with wavelengths less than 0.2 
nm, while a frame overlap mirror removes neutrons with wavelength greater than 1.2 
nm. Every other neutron pulse is cut out by a chopper, producing an operational
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Figure 1.9. Neutron solution scattering on LOQ. (a) Layout of the LINAC, 
synchrotron and target station at ISIS located at the Rutherford-Appleton Laboratory, 
Didcot. Pulses of protons are accelerated to 800 MeV in the synchrotron, extracted and 
then sent to the heavy metal target station. As the high energy protons hit the uranium 
or tantalum target, fragments are chipped from its nuclei, producing neutrons. Neutron 
pulses are used at the experimental stations which emanate from the heavy metal target. 
(b) Schematic diagram of the LOQ diffractometer. A chopper is set so that wavelengths 
in the range 0.22 to 1.00 nm are used in scattering experiments. The neutron beam is 
collimated by two apertures, and the beam used in solution scattering experiments had a 
diameter of 8 mm. Monochromatization of the neutron beam is achieved by time-of- 
flight techniques. Scattering intensities were measured using a 3He ORDELA detector. 
(Taken from the Rutherford-Appleton Laboratory Web Site http://www.rl.ac.uk).
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frequency of 25 Hz, and the phase of the chopper is set so that wavelengths in the range 
0.22 to 1.00 nm are used in scattering experiments. The neutron beam is collimated by 
two apertures and the beam used in solution scattering experiments had a diameter of 8 
mm. Monochromatization of the neutron beam is achieved by time-of-flight techniques, 
based on a distance of 15.15 m from the heavy metal target to the detector.
The time-of-flight techniques are advantageous because they enable neutron scattering 
data to be measured over a Q range of 0.08 to 2.5 nm'1 in one experiment, and utilize 
fully the abundance of shorter wavelength neutrons, which contribute most to the 
scattered curve at large Q where the intensities are the lowest.
Samples were placed in 2 mm thick rectangular quartz Hellma cells, which were held in 
a motorised rack at a constant temperature of 15°C. Neutron scattering intensities were 
measured using a 3He ORDELA detector, which had an active area of 64 cm x 64 cm, 
and was positioned at a fixed distance of 4.3 m from the sample. The sample rack held 
multiple samples, enabling the data collection procedure to be automated. Scattering 
intensities were measured for proteins and their corresponding buffers. The scattering 
from a partially deuterated polystyrene standard was also measured, and this was used to 
normalise the spectral intensities (Wignall & Bates, 1987). Neutron transmissions were 
measured for each protein sample and buffer, and for the polymer standard and an empty 
beam position, and these were also used to normalise the scattering data.
1.3.4.3 Reduction of LOO scattering data
Raw data were collected in 100 time frames of 64 x 64 cells, and reduced using the 
standard ISIS software package COLETTE (Figure 1.10; Heenan et al., 1989). The 
MASK file is routinely updated by the LOQ instrument scientists, and controls essential 
information on the properties of the detector. After ensuring that the beam size, the
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Figure 1.10: Flow diagram of LOQ data reduction using COLETTE. The diagram 
follows the stages of data reduction from the raw data files to the final transfer of the 
scattering curve spectra as ASCII text files to London. @MASK executes a file 
(mask.com), which is updated by the instrument scientists to account for fluctuations in 
the behaviour of the detector and changes in instrument configuration (Adapted from 
Meyer, 1994).
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sample thickness, the moderator-to-sample distance and sample-to-detector distance had 
been assigned correctly, the raw scattering data were processed. The data were 
corrected for detector efficiency, transmission of the direct beam, and transmission of 
the sample. Absolute scattering intensities were calculated by normalisation of the 
spectra against a “LOQ standard sample” of partially deuterated polystyrene (Wignall & 
Bates, 1987), and protein spectra were corrected by buffer subtraction. The time-of- 
flight techniques were used to bin the scattering intensities into individual diffraction 
patterns, either for linear wavelength steps of 0.02 nm, or for logarithmic wavelength 
steps of 0.08%, over the wavelength range of 0.22 to 1.00 nm. These individual 
diffraction patterns were merged, using 0.04% logarithmic binning increments for Q, to 
give the full scattering curve I(Q) in an approximate Q range of 0.08 to 2.5 nm'1. 
Logarithmic steps were optimal for analyses of the Guinier and wide angle regions of 
the scattering curves.
1.3.4.4 Neutron scattering at the ILL
Neutron scattering experiments were also performed using the high-flux reactor at the 
Institute Laue-Langevin (ILL) in Grenoble, France (Figure 1.11a). High energy neutrons 
are produced in the reactor core by the fission of U235. The thermal neutron flux from 
the reactor core is in equilibrium with a 2H20 moderator (300K), and has a distribution 
of neutron wavelengths that peaks at 0.12 nm. Neutron flux wavelengths greater than 
0.3 nm are enhanced by cold liquid 2H moderators (25K). Instruments are set up to 
perform specific experiments using neutron beams as shown in Figure 1.11b. Small 
angle scattering experiments were performed using a large wavelength neutron beam 
from a cold liquid 2H moderator on Instrument D17 and D11 (Figure 1.1 lb). On D17, 
the incident beam is monochromatized using a rotating drum velocity selector. The 
velocity selector has a helical slot, through which only neutrons of a specified 
wavelength can pass. Sample-detector distances of 1.40 m and 3.46 m with a main 
beam-detector angle of 0° and 20° were used and this typically produces a spread AAA 
of 9% around the selected wavelength. The wavelength A, was usually set as 1.10 nm, 
but sometimes was 1.00 nm, 1.20 nm or 1.39 nm.
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Figure 1.11: Neutron solution scattering at the ILL, Grenoble, (a) Layout of beam- 
tubes and instruments at the High Flux Reactor, ILL. High energy neutrons are 
produced by the fission of U235. Neutron guides transfer the neutrons from the reactor 
core to the external instruments. (b) Schematic representation of Instrument Dl l ,  one 
of the stations on which small-angle solution scattering experiments were performed. 
(Taken from the ILL Web Site http://www.ill.fr).
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The three detector settings resulted in three subcurves with a maximally usable Q range
— 1 0 of 0.08 to 3.3 nm . Data acquisition times were typically ten minutes in H2 O buffers
and 60 minutes in H2O buffers. Samples were measured at 20°C in rectangular quartz
cells of thickness 2 mm for H2 O samples and 1 mm for H2O samples. Scattering
intensities were measured using a 3He detector which had an active area of 64 cm x 64
cm, composed of cells of size 0.1 cm x 0.1 cm. The increased flux on Instrument D ll
(Lindley et al., 1992) was better suited for data collection in H2O buffers, and D ll used
sample-detector distances of 2.00 and 5.00 m with the collimation set at 2.5 and 5.5 m,
respectively. The wavelength X of 1.00 nm gave a usable Q range of 0.06 to 1.1 nm-1.
Data acquisition times were five to ten minutes in 2H20 buffers and 30 to 45 minutes in
H2 O buffers at 15°C. The background neutron counts were determined by blocking the
neutron beam with a cadmium sample. In order to convert the scattering intensities to
an absolute scale, the incoherent scattering of H2O and the scattering of an empty
sample cell were also measured.
1.3.4.5 Reduction of ILL scattering data
A number of calibration and normalisation measurements were performed during the 
processing of any ILL data run (Figure 1.12; Ghosh, 1989). The raw counts for each 
detector cells were listed using DETEC, from which the position of the beam stop and 
the beam centre was calculated. RNILS was used to calculate Q values for the detector 
cells, and the intensity /  was calculated as a function of Q by taking the average values 
for detector cells over a given radial step length spacing of 1 cm. SPOLLY was used to 
combine the individual spectra for sample, buffer, water, empty cell and cadmium to 
obtain the protein scattering curves I(Q). All spectra were normalised against the 
number of monitor counts. In SPOLLY, spectra were corrected for their neutron 
transmissions, the scattering intensities were converted to an absolute scale using the 
incoherent scattering of H2 O and an empty sample cell, and the scattering of the buffer 
was subtracted from each protein spectrum. Preliminary Guinier analyses (Section 
1.3.5.1) were performed using RGUIM to ensure that samples were measured for long
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Figure 1.12: Flow diagram showing the data reduction procedures for neutron
scattering at D11 and D17. (Adapted from Meyer, 1994).
• DETEC Lists the raw counts from the detector cell by cell.
• RNILS Calculates the radial intensities function I(Q) of the detector.
• SPOLLY Corrects and normalises the sample spectrum I(Q).
• RPLOT Plots out two spectra on the same graph.
• RCARD Produces a card image disc file of formatted data.
• RGUIM Calculates the Guinier plot.
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enough during data acquisition. RPLOT was used to plot spectra measured from the 
two sample-to-detector distances to check that their intensities overlapped sufficiently in 
the two Q ranges during measurements. RCARD produced the scattering curves 7 (0  in 
ASCII text format for further analysis in London. The two scattering curves for each 
protein sample were combined to obtain the full scattering curve 7 (0 .
1.3.5 Analyses of reduced scattering curves 1(0)
Measurements of the gross structural details of a protein can be determined from its X- 
ray and neutron scattering curves.
1.3.5.1 Guinier analyses
At low Q values, the Debye equation (Equation 1.1) is reduced to a Gaussian curve, 
which becomes the Guinier approximation:
In I(Q) = In 1(0) - Eq 1.3
where Rg is the radius of gyration and is defined as the root-mean-square distance of all 
scattering centres in the macromolecule from its centre of gravity, and 7(0) is the 
intensity at zero scattering angle. This expression is valid in a Q.Rg range up to 0.7-1.3 
depending on the macromolecular shape. Rg and 7(0) are determined from an 
experimental scattering curve by plotting In 7 (0  against Q1 to give a straight line of 
slope -Rg2/3 and intercept In 7(0). Rg is a measure of elongation if the internal 
inhomogeneity is negligible, and a useful application of Rg is in the calculation of the 
anisotropy ratio of a macromolecule. The anisotropy is Rg/Ro, where Ro is the Rg of the
sphere of volume equal to that of the macromolecule (the Rg of a sphere = ^ (3 /5 )r2 ;
where r is the radius of the sphere). For typical globular proteins, the anisotropy ratio is 
approximately 1.28 (Perkins, 1988). The intensity at zero scattering angle 7(0) is 
proportional to the square of the molecular weight (Mr ). The scattering intensities of 
neutron data measured on LOQ are normalised relative to a partially deuterated
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polystyrene standard, and consequently LOQ 7(0)/c values (c = sample concentration) 
are used to calculate protein Mr values. There is a linear relationship between the Mr 
determined from composition analyses, and 1(0)1 c (Figure 1.13), which was used to 
determine the Mx and hence the oligomeric state of a newly-measured protein. The 
neutron data measured on D ll and D17 are normalised relative to the incoherent 
scattering of H2 O, and the protein Mr values can be calculated by reference to the 
instrument geometry (Jacrot & Zaccai, 1981).
Guinier plots for this study were performed using the FORTRAN program SCTPL5 (A. 
S. Nealis & S. J. Perkins, unpublished software). The Q  range selected for line-fitting 
went from the smallest possible Q to a maximum Q.Rg of approximately 1.5. 
Nonspecifically aggregated proteins were identified by steeply curved Guinier plots at 
low Q  values and were discarded.
1.3.5.2 Cross-sectional radius of gyration
If the protein has an elongated structure, Guinier-type analyses of the scattering curve at 
larger Q  will give the mean radius of gyration of the cross-section R xs and the mean 
cross-sectional intensity at zero scattering angle \I(Q)Q\q-+0 (Hjelm, 1985):
WI(QJQ] = M I(Q )Q )]q^„ - Eq 1.4
R xs and [I(Q)Q]q-+0  are determined from an experimental scattering curve by plotting 
In[I(Q)Q] against Q1 to give a straight line of slope -Z?xs2/2 and intercept 
[\n(I(Q)Q)]Q^ o.
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Figure 1.13: Plot of the molecular mass Mr against l(0)/c for proteins measured on 
LOQ. The proteins used for this plot are bovine IgGl and IgG2 (mean Mr is 143400, 
mean l(0)/c is 0.181; Mayans et al., 1995), IgE Fc (Mr is 75300, l(0)/c is 0.093; Beavil 
et al., 1995), factor Vila (M, is 51400, l(0)/c is 0.0525) and factor Vila complexed with 
tissue factor (Mr is 76150, l(0)/c is 0.0735; Ashton et al., 1995), SAP-5 (Mr is 127070, 
l(0)/c is 0.146) and SAP-10 (Mr is 254140, l(0)/c is 0.247; Ashton et a l , 1997), and 
MFE-23 (Mr is 27150, l(0)/c is 0.032; Boehm et al., 1996). For each new protein 
studied on LOQ, the Mr value of the scattering sample was determined from the linear 
regression line. Comparison of the resulting value to the value calculated for a 
monomer from its composition enabled the oligomeric state of the sample to be 
determined.
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For ‘T-shaped” protein structures such as the immunoglobulins, the cross-sectional plot 
exhibits two linear regions, a steeper innermost one and a flatter outermost one (Pilz et 
al., 1973), and in this type of analysis the two regions are referred to as Rxs i and Rxs-2 
respectively.
Cross-sectional plots were performed using SCTPL5. The Q range selected for line- 
fitting went from a minimum Q value which was greater than the Q values used in the 
Guinier fits to a maximum Q.Rxs of 1.5. If the cross-sectional plot exhibited two Rxs 
regions, the Q range selected for calculating Rxs-2 went from a minimum Q value that 
was greater than the Q values used in the Rxs-i fit to a maximum Q.Rxs-2 of 1 .5.
1.3.5.3 Estimations of macromolecular dimensions
Assuming a protein is shaped like an elongated elliptical cylinder, the and Rxs 
analyses can be combined to determine its length L (Glatter & Kratky, 1982):
£  = V 12( Rq - tfxs) Eq 1.5
Alternatively, L is given by (Perkins et al., 1986):
L = ---- ^ 2 1 ----  Eq 1.6
[I(Q)Q]q^ o
The consistency of these two calculations of L is a useful control of a correct cross- 
sectional analysis for a rod-like particle. For an assumed elliptical cylinder with length 
L, the two shorter dimensions A and B can be calculated from the unhydrated protein 
volume for neutron analyses, or from the hydrated protein volume for X-ray analyses:
V = jcABL; Rxs = J (A 2 + B2) / 4  Eq 1.7
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1.3.5.4 Real space distance distribution function
The scattering curve I(Q) represents the macromolecular structure in reciprocal space. 
The experimental I(Q) curve can be converted into real space by a Fourier transform 
over 0 < Q < °° :
m  = y ^ J  I(& Q r sin(Qr)dQ Eq 1. 8
where P(r) is the distance distribution function and corresponds to the number of 
distances r between any two volume elements within the macromolecule weighted by 
the product of their respective scattering densities. The maximum in P(r) is the most 
frequently occurring intermolecular distance. P(r) offers an alternative calculation of 
Rg.
oo
jp ( r ) r!dr 
Rh — ------------------ E q l.9
2 j  P(r)dr
0
P(r) termination errors occur because the experimental I(Q) curve cannot be measured 
at zero angle or at very large Q, and in addition high signal to noise ratios are associated 
with measurements at large Q. The Indirect Transform Procedure (ITP) minimizes these 
termination errors, and was performed using the ITP-91 program (Glatter & Kratky, 
1982). Another program was GNOM, which is more automated and easier to use 
(Svergun et al., 1988; Semenyuk & Svergun, 1991; Svergun, 1992). A nax is the 
maximum macromolecular dimension, and therefore corresponds to the length L. In 
GNOM, the P(r) curve was calculated from I(Q) for a range of estimated Anax values, 
and the P(r) curve was selected according to several criteria: (1) P(r) should exhibit 
positive values; (2) the Rg from ITP and Guinier analyses should agree; (3) P{r) should 
be zero when r is zero; (4) P(r) should be stable and reproducible for different 
experimental I(Q) curves when Anax is varied over a reasonable range. The length L 
was determined from P(r) when this became zero at large r, however errors in L can be 
significant as a result of the low intensity of P(r) in this region.
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1.3.6. Hydrodynamic analyses
Hydrodynamic analyses can be used to relate the effect of a centrifugal force on a 
protein in solution to the size and shape of the protein. Therefore the sedimentation
measurements determined by solution scattering (Perkins, 1988). The sedimentation 
coefficient is determined experimentally by analytical centrifugation of the glycoprotein 
in aqueous solution, by measuring the movement of sedimenting particles in a given 
time:
where t is time; co is the angular velocity of the rotor in radians per second; r - r0 is the 
distance travelled by the particles. Published values of s°2o,w were used when available. 
If literature s°2o,w values were not available or if  they were ambiguous, the s°2o,w was 
measured on a Beckman XL-A analytical centrifuge by Dr O. Byron at the National 
Centre for Macromolecular Hydrodynamics, Leicester.
The sedimentation coefficient is a measurement of the result of three forces acting on a 
sedimenting particle. The centrifugal force is the product of the mass of the particle and 
the centrifugal acceleration of the particle and causes the particle to sediment. The 
centrifugal force is opposed by a buoyancy force that results from the displacement of 
solvent molecules by the particle. The third force is the frictional force of the solvent 
acting on the particle, and it is the product of the frictional coefficient and the 
sedimentation velocity. In terms of these three forces, the sedimentation coefficient is 
expressed using the Svedberg equation as:
coefficient s°2o,w of a protein provides structural information that is complementary to
Eq 1.10
M r(l-V P 2Q,J
N a f
Eq 1.11
where Mr is the molecular weight of the macromolecule; v is the partial specific volume
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of the particle; p2o,w is the density of water at 20°C; Na is Avogadro's constant (6.023 x 
1023); an d /is  the frictional coefficient. The sedimentation coefficient of a glycoprotein 
is useful as this leads to the calculation of its frictional coefficient /  which can then be 
compared with /  calculated for a molecular model. Mr and v values can be calculated 
from the molecular composition using SLUV (Section 1.4.1.1; Perkins, 1986), and p2o,w 
has an assumed value of 0.9982 ml/g. The frictional coefficient can then be used to 
calculate the frictional ratio f/f0 of the glycoprotein. f 0 is the frictional coefficient of the 
sphere with the same volume as the glycoprotein, which is given by Stokes law:
f o  =  67rn rs  Eq 1.12
where r) is the viscosity of the solvent, which is assumed to be 0.001002 N s m '  for 
aqueous protein solutions; and rs is the radius of the sphere. The frictional ratio is a 
measure of the elongation of the glycoprotein, and it is analogous to the solution 
scattering anisotropy ratio Rg/Ro-
1.4 Introduction to biomolecular modelling.
As the term intimates, biomolecular modelling is concerned with creating models that 
represent the real structures of biological molecules. An atomic coordinate model 
represents the most detailed type of model for a protein molecule. X-ray crystallography 
or NMR can determine these experimentally. The models deposited in the PDB are 
examples of atomic coordinate models, in which Cartesian x, y, z coordinates specify 
the position of each atom. An important function that can be performed using an atomic 
coordinate model is the development of hypotheses regarding the function of a protein 
based on the spatial organization of amino acid residues. It is for this reason that, when 
a crystallography or NMR model is not available, an approximate atomic coordinate 
model can provide a useful substitute when interpreting a protein’s function. This 
section describes the method that has been used to develop atomic coordinate models of 
proteins in the course of this thesis. In Section 1.4.1, an account is given of an 
automated technique for modelling the structures of multi-domain proteins, which is
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based on constraints from X-ray and neutron solution scattering data and domain fold 
structures.
1.4.1 X-rav and neutron solution scattering curve modelling
Experimental scattering data present an important means of validating low resolution 
models of proteins and glycoproteins in solution. Full atomic models are converted into 
X-ray and neutron scattering curves, and these modelled scattering curves are compared 
to experimental scattering data. The models that show the best agreement to the 
experimental data are selected. Hydrodynamic analyses can be used to further validate 
solution scattering models. The methodology of X-ray and neutron scattering curve 
modelling has been reviewed recently (Perkins et al., 1998a; Svergun & Koch 2003), 
and an outline of the modelling procedure is shown in Figure 1.14. This section 
provides a description of this methodology. For convenience, the term protein is used 
loosely to describe the protein or glycoprotein under study, unless the protein and 
carbohydrate moieties of a glycoprotein are being specifically considered.
1.4.1.1 Analysis of glycoprotein composition
Prior to solution scattering modelling, essential information was extracted from the 
amino acid and monosaccharide composition of the protein using SLUV, which is a 
FORTRAN program (Perkins, 1986). Thus the volume of an unhydrated protein is 
calculated from standard crystal structure volumes for each of the amino acid and 
monosacharide residues (Chothia, 1975; Perkins, 1986). The extinction coefficient, for 
a wavelength of 280 nm, is calculated from the tryptophan, tyrosine and cysteine content 
of a protein by a correction of the Wetlaufer procedure (Perkins, 1986).
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Figure 1.14: Flow chart of the procedure for the automated generation of multidomain 
models and analysis by scattering curve fits. Each box describes either a stage in the 
modelling procedure, or how additional information is included to evaluate the models. 
The automated procedure utilises INSIGHT II and UNIX executable script files on 
Silicon Graphics workstations. The resulting parameters are filtered and sorted using 
Excel spreadsheets. (Adapted from Perkins et al., 1998a).
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Electron densities and neutron matchpoints are calculated for the individual protein and 
carbohydrate components of a glycoprotein. Electron densities are calculated using the 
partial specific volume, which is derived from a consensus volumes data set that is 
based on the sum of the dry volume and the electrostricted water shell volume as 
calculated from the amino acid and carbohydrate composition (Perkins, 1986), and gives 
values close to the Cohn & Edsall (1943) densitometric calculation. Matchpoints are 
calculated using the neutron scattering length density, which is derived from the 
summation of scattering lengths divided by the dry volume of the macromolecule, 
assuming a 1 0 % nonexchange of the protein mainchain amide protons with solvent.
1.4.1.2 Small sphere modelling
To calculate a theoretical scattering curve from an atomic model of a protein, the protein 
may be first converted into a sphere model consisting of small non-overlapping spheres 
of the same total volume as the original atomic model. To do this, the atomic coordinate 
model is placed within a three dimensional grid and every grid point that contains a 
minimum number of atoms has a sphere, of volume equal to the grid point, placed at its 
centre. The minimum number of atoms required to assign a sphere is tested empirically 
by trial and error against the length of the cube side so that the resulting sphere model 
has a volume close to the unhydrated volume calculated for the protein. The unhydrated 
volume is calculated from the actual protein composition rather than from the model 
composition, for reason of compensating for any discrepancies between these two 
values. Such discrepancies may occur if the crystal structure is incomplete due to 
disorder or if homologous domain structures are used in the model as opposed to the 
actual domain structure. The length of the cube side that is used to produce an 
unhydrated sphere model is typically about 0 . 6  nm, which is much less than the 
maximum resolution of a normal scattering curve at around 3.1 nm. The resolution d is 
calculated from 2idQ\ which is derived from X = 2d sin 0 and Q = 4n sin 0/X; and for a 
scattering curve with a maximum Q of 2.0 nm' 1 the maximum structural resolution is
3.1 nm. Once a grid size has been determined, this is kept fixed during an automated 
curve fit search.
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Neutron scattering experiments do not detect a hydration shell around proteins, so 
unhydrated sphere models can be used for neutron scattering curve calculations (Smith 
et al., 1990; Perkins et al., 1993; Ashton et al., 1997). However, a hydration shell is 
detected around proteins in X-ray scattering experiments, and therefore calculation of an 
X-ray scattering curve requires that an unhydrated sphere model is modified according 
to the volume of the hydration shell. The hydrated volume of a protein is calculated 
assuming a hydration of 0.3 g of water/g protein and an electrostricted volume of 0.0245 
nm per bound water molecule (Perkins, 1986). Two methods have been used to 
produce a hydrated sphere model from an unhydrated sphere model. The simplest 
method is to increase the size of each sphere in the unhydrated model so that the 
resulting volume equalled the hydrated volume. Although this procedure is satisfactory 
for globular proteins of compact structure, it can significantly distort the protein 
structure if it contains a void space at its centre. To overcome this problem, an 
alternative method was developed as part of this study (Ashton et al., 1997). In this 
second method, spheres corresponding to water molecules are added evenly over the 
surface of the unhydrated sphere model, so that the desired hydration volume is 
achieved. Hydrated sphere models are used for X-ray scattering curve calculations.
1.4.1.3 Debve scattering curve calculation
A sphere model containing spheres of a single scattering density is used to calculate a
scattering curve 7 (0 , by the following application of Debye’s Law adapted to spheres 
(Glatter & Kratky, 1982; Perkins & Weiss, 1983):
g (Q )(n ' + 2 n 1Y JA 1 Eq 1.13
g(Q) = (3( sin QR - QR cos QR) f  /  Q6 R6 Eq 1.14
where g(Q) is the squared form factor for the sphere of radius R, n is the number of
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spheres filling the body, A j is the number of distances r} for that value of j ,  rj is the 
distance between the spheres, and m is the number of different distances rj. The single 
density scattering curve calculation is applicable to proteins, and to glycoproteins that 
have low carbohydrate contents provided that comparisons between the model scattering 
curves and the experimental data are consistent for the neutron and X-ray curves.
If a glycoprotein has a high carbohydrate content, differences between the scattering 
densities of its protein and carbohydrate moieties that may give rise to systematic 
deviations between the neutron and X-ray curves can be modelled using two-density 
sphere models. The relative scattering densities of the protein and carbohydrate spheres 
in an unhydrated sphere model are weighted by an approximation to the ratio of their 
calculated neutron matchpoints, compared to 100% 2H2 0 . Correspondingly, the relative 
scattering densities of the protein and carbohydrate spheres in a hydrated sphere model 
are weighted by an approximation to the ratio of their calculated electron densities 
compared to the electron density of bulk water. The different scattering densities of 
protein and carbohydrate are incorporated in two-density scattering curves calculated 
from (Glatter & Kratky, 1982):
1(0) 7 7 7 ^s  iiSinOr, , ™ sin Or,
~rr:=g(&[ niPt + mPi + Z P,Y,As + 2PzX Ai
!(° ) "  Qfj 7 i  Qr,
m sin Or
+ ^  P , P 2 X  A f — — 1 ] _  (n, p, + n 2 p 2 y 2 Eq 1.15
j=l
where g(Q) is the squared form factor for the sphere of radius R (Equation 1.14); the
model is constructed from n\ and nj spheres of different densities pi and p2 ; AjU, Aj22, 
10and Aj is the number of distances rj for that increment of j  between the spheres 1 and 1, 
2  and 2 , and 1 and 2  in that order; the summations Z  are performed for j  = 1 to m, where 
m is the number of different distances rj.
Synchrotron X-ray cameras utilise a pin-hole configuration that does not produce 
geometrical distortion of the beam, so a calculated X-ray curve does not have to be
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corrected in order for it to be compared to an experimental curve. Although neutron 
cameras such as those at the ILL and the RAL also use pin-hole geometries, their 
dimensions are larger than X-ray cameras and they also use longer wavelengths to 
maximise the available neutron flux, and these reasons necessitate that instrumental 
corrections are applied to the model neutron scattering curves. For the neutron 
scattering cameras D ll and D17 at the ILL in Grenoble, a Gaussian function based on a 
16% wavelength spread AAA (full-width-half-maximum) at A, of 1.0 or 1.1 nm and a 
beam divergence A6  of 0.016 radians as an empirical correction, has been applied to 
model neutron curves. The theoretical values of AAA are respectively 8 % and 10% for 
these two cameras, while that for A0 depends on both the beam aperture and the size of 
the detector cells and is approximately 0.01 radians. As part of this thesis, a re- 
evaluation of AAA for D17 data for serum amyloid P component gave 10% in good 
agreement with theory, although A0 was larger at 0.024 radians (Chapter 6 ; Ashton et 
al., 1997). The neutron fits deteriorate at large Q and this may indicate a small residual 
flat background that arises from incoherent scatter from the protons in the protein. The 
values used to correct model neutron curves for comparison to D17 data are also used 
for comparisons to D11 data. On LOQ, wavelengths in the range from 0.2 to 1.0 nm are 
used simultaneously (where time-of-flight techniques provide the necessary 
monochromatisation), and although this complicates the beam corrections, a Gaussian 
function as for D17 data has been applied to model neutron curves to obtain reasonable 
comparisons to the experimental data. Values of 16% for AAA for a putative A of 1.0 
nm and 0.016 radians for A0 were initially used (Mayans et al., 1995), but as part of this 
thesis a re-evaluation showed that values of 10% for AAA for a putative A of 0.6 nm and 
0.016 radians for A0 gave the best agreement between the model neutron curves and 
LOQ data (Chapter 6 ; Ashton et al., 1997).
The method of converting an atomic coordinate model into unhydrated and hydrated 
sphere models, followed by the calculation of neutron and X-ray scattering curves was 
initially tested using solution scattering data for two small proteins, p-trypsin and ai- 
antitrypsin, for which crystal structures were known (Smith et al., 1990; Perkins et al.,
1993). In this thesis, the methodology has been evaluated more rigorously here using
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the crystal structure for a significantly larger protein, namely pentameric serum amyloid 
P component (Chapter 6 ; Ashton et al., 1997).
1.4.1.4 Automated modelling using domain fold structures
The procedure for calculating scattering curves from an atomic coordinate model is 
implemented by a suite of FORTRAN computer programs (S. J. Perkins, unpublished 
software) and these have been incorporated into automatic strategies for the generation 
of atomic coordinate models (Figure 1.14; Mayans et al., 1995; Beavil et al., 1995; 
Perkins et al., 1998a). All solution scattering models are produced using INSIGHT II 
molecular graphics software and associated programs (Biosym/MSI, San Diego, USA). 
Typically, an initial model of the protein is generated from models of its constituent 
domain structures. After consideration of information relevant to the association of 
domains within the protein structure, moveable protein fragments are defined so as to 
consider the least flexible model. At its smallest, a moveable fragment could consist of 
a single domain fold, but if  domains are known to associate into well-defined structures, 
e.g. the association of serum amyloid P component domains into a pentameric ring 
structure (Chapter 6 ; Ashton et al., 1997), the moveable fragments may form a larger 
single entity. A set of axes is defined for each moveable fragment, and a Biosym 
Command Language macro is written to systematically move the fragments, either by 
translations or rotations, and thereby generate a series of models. Such automated 
solution scattering modelling searches have been performed on a Silicon Graphics 
INDY R4400SC Workstation with 64 Mb of memory and a 4 Gb hard disk, and their 
run times were up to several weeks.
1.4.1.5 C arbohydrate structures
If the protein being studied contains glycosylation sites, an average three-dimensional 
structure is determined for the N- and O-linked oligosaccharide chains using
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carbohydrate structural composition analyses in the literature. These structures are 
modelled by adapting suitable oligosaccharide structures from the PDB, and the 
structures are positioned at putative N- and O-linked glycosylation sites on the protein. 
The structures of N-linked carbohydrates on glycoprotein crystal structures can be 
divided into two broad types; those which extend away from the protein surface into 
solution, and those which lie against the protein surface in a compact conformation. An 
example of an extended N-linked carbohydrate is bound to Asnl59 on human leukocyte 
elastase (PDB code: lppg; Bode et al., 1989), while an example of a compact N-linked 
oligosaccharide is bound to Asn395 on Aspergillus awamori glucoamylase (PDB code: 
lagm; Aleshin et al., 1992 & 1994).
1.4.1.6 Model evaluation
Each model is evaluated using several criteria. The volume of each sphere model, 
indicated by the number of spheres generated from the coordinates during the grid 
transformation, is used to determine whether an automated modelling procedure has 
produced steric overlap of its domains. Each model is also evaluated by comparison of 
its calculated scattering curves to experimental data. Guinier fits are used to calculate 
Rg and Rxs values from each model scattering curve over the same Q ranges used for 
experimental measurements. An R-factor is calculated for a quantitative comparison of 
each model scattering curve / ( 0 Cai against experimental scattering data / ( 0 exP over the 
whole Q range, where /(0)cai is set as 1000:
= 11 - HQ )cd I x wo%  Eq 1.16
W ( Q ) ^ \
The use of R-factor values is analogous to that used for the refinement of 
crystallographic models, and it has been successfully applied to evaluation purposes for 
solution scattering modelling procedures (Smith et al., 1990; Beavil et al., 1995). Using 
these three criteria, it is possible to minimize the number of models that have to be 
considered from a large automated search. Models that do not conform to defined ranges 
of model volume, Rg and Rxs are rejected using filters, and then they are sorted in 
overall best fit using the R-factor.
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1.4.1.7 Hydrodynamic analyses
The theoretical sedimentation coefficient s°20,w of each hydrated sphere model can also 
be determined and its comparison to the experimental value offers a further criterion for 
validating solution scattering models (Figure 1.14). In order to determine the theoretical 
s°2o,w for a hydrated sphere model, the frictional coefficient /  of the model is calculated 
using the modified Oseen tensor procedure of Bloomfield (Garcia de la Torre & 
Bloomfield, 1977a, 1977b; Perkins, 1985). In this procedure, each sphere in a multi­
sphere model is assumed to be a point source of friction. The zth sphere has an 
associated frictional force Fj, which is calculated from its Stokes law frictional 
coefficient:
F -67C nri( u r v i) ( i - l ,n )  Eq 1.17
where T| is viscosity of the solvent; r, is the hydrodynamic radius of the 1th sphere; ux is 
the velocity of the Ith sphere; v* is the velocity the solvent would have at the same point 
if  the sphere was absent; and n is the number of spheres. The frictional coefficient of 
each sphere in a multi-sphere model is modulated by the hydrodynamic interactions of 
other spheres in the model, by what is referred to as a hydrodynamic interaction tensor. 
The hydrodynamic interaction tensor, 7y for spheres of finite sizes and of different 
hydrodynamic radii of n  and rj is given by:
T =— -— [ l+ J k J k +  ( r> +p )  (L  .  E l l k ) ]  Eq 1.18
SmjRif r I Rl 3 Rlj
where I  is the unit vector and Fy is the vector between spheres i and j . The 
hydrodynamic interaction tensor and the frictional force terms are related by:
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Eq 1.19
(excluding terms with i  =  j ) ,  where v-y is the unperturbed solvent velocity when the 
spheres are absent. The program GENDIA (Garcia de la Torre & Bloomfield, 1977a, 
1977b; Perkins, et al., 1993) is used to implement these equations, in which iterative 
procedures are used to calculate/ for an array of spheres. The theoretical sedimentation 
coefficient can then be calculated from /  using the Svedberg equation (Equation 1.11) 
and compared to the experimental value.
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CHAPTER 2
The Coagulation Pathway.
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2.1 Introduction.
The ability to stem the loss of blood in higher organisms is fundamental for survival. At 
the site of injury, platelets will aggregate and form a platelet plug capable of reducing, 
or temporarily stopping, the loss of blood. Platelets are cell fragments that originate in 
bone marrow and are present at a concentration of about 0.25 million per 1 mm of 
blood. When activated, platelets will release many proteins and small molecules that 
will not only serve to increase and accelerate platelet aggregation but will also initiate 
the process of tissue repair. During these reactions, negatively charged phospholipids 
such as phosphatidylserine appear on the surface of activated platelets or damaged cell 
membranes. These in turn set the stage for the coagulation cascade and the formation of 
an insoluble clot from fibrin that strengthens the platelet plug.
The importance of the coagulation cascade cannot be over emphasised. Only too 
frequently incidences and conditions that can blight or disable individual or even 
community life are identified. The whole process is a delicate balance between 
haemostasis and thrombosis. The formation of a blood clot that can ‘plug’, block and 
eventually facilitate repair of damaged vessel walls or tissue, is known as haemostasis. 
However, when clots grow too large or even break away from their site of origin they 
can cause the blockage of blood vessels or thrombosis.
The coagulation cascade can be subdivided into two overlapping processes, the extrinsic 
and intrinsic pathways. The intrinsic pathway plays an important role in the growth and 
maintenance of fibrin formation, but it is the extrinsic pathway that is critical in the 
initiation of fibrin formation. A fibrin clot is formed when several strands of the protein 
fibrin cross-link to form an insoluble mesh. Fibrin itself is formed from the plasma 
protein fibrinogen. The processes that lead to this fibrin mesh are outlined in Section 
2.2 .
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2.2 The coagulation cascade.
2.2.1 The extrinsic pathway.
All but one of the proteins needed for the extrinsic pathway are already in the blood 
stream, albeit in an inactive/precursor state. The one protein that is missing is the trigger 
-  membrane bound tissue factor. Tissue factor is only usually expressed by cells in the 
sub-endothelium, and therefore, is separated from the bloodstream. When tissue factor 
comes into contact with blood it forms a complex with blood coagulation factor VII or 
factor Vila (Figure 2.1, right side). Factor VII (FVII) is the serine protease zymogen and 
when complexed with the extracellular region of tissue factor (TF), and in the presence 
of Ca2+ and phospholipids, it readily converts to the active form, factor Vila (FVIIa). TF 
serves as a cofactor for FVIIa and will greatly enhance its protease activity towards its 
substrates, FVII, factor IX (FIX) and factor X (FX). FVIIa complexed with TF in the 
presence of phospholipids and Ca acts upon the inactive zymogens, FIX and FX, to 
form the active serine proteases factor EXa (FIXa) and factor Xa (FXa).
On the activation of FIXa and FXa the two pathways of the coagulation cascade merge 
(Figure 2.1). The newly formed FXa catalyses the formation of factor Va (FVa) from 
factor V. FXa then forms a complex with FVa and the FXa-FVa complex converts 
prothrombin to the serine protease thrombin. Thrombin will then act on the precursor 
fibrinogen to form fibrin. In the presence of fibrin and Ca2+ the conversion of factor XIII 
to factor XHIa (FXIIIa) by thrombin is accelerated. FXIIIa is an enzyme that forms 
cross-links between fibrin monomers and so forms the fibrin molecules into the fibrin 
mesh.
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Figure 2.1: Schematic representation of blood coagulation cascade. The coagulation 
cascade can be subdivided into two overlapping processes, the extrinsic (right hand 
side) and intrinsic (left hand side) pathways. The extrinsic pathway is initiated as a fast 
response to tissue damage whilst the intrinsic pathway is a slower more sustained 
response. The two pathways merge at the point where Factor IXa and Xa are formed.
59
2.2.2 The Intrinsic pathway.
The extrinsic pathway is quickly inhibited by several means and the primary route for 
continued fibrin growth is via the intrinsic pathway (Figure 2.1, left side). The fibrin clot 
itself is not a permanent clot and is in a continuous state of formation and degradation. 
This allows for the tissue surrounding the wound to heal correctly.
The appearance of thrombin initiates the intrinsic pathway by catalysing the conversion 
of Factor XI to the active enzyme Factor XIa in the presence of negatively charged 
phospholipids and Ca2+. Factor XIa will not only activate Factor XI in an autocatalytic 
manner but also catalyse, in the presence of Ca2+, the reaction of FIX to FIXa by 
cleavage of the same peptide bond as that cleaved by FVIIa.TF complex. The newly 
formed thrombin, along with FXa, will catalyse the reaction of Factor VIII to Factor 
Villa (FVIIIa). At this point, the extrinsic and intrinsic pathways both merge with the 
production of FXa (Figure 2.1).
2.3 Tissue factor.
As previously outlined, the extrinsic pathway of the coagulation cascade is initiated by 
the exposure of TF on membrane surfaces to the bloodstream. Human TF is a type I 
integral membrane glycoprotein with a molecular weight of Mr 45000 (Higashi & 
Iwanaga, 1998). The 263 amino acids form three distinct regions, the cytoplasmic (243- 
263), transmembrane (220-242) and extracellular region (1-219). The crystal structure 
and sequence similarities studies identified the 219 residues of the extracellular region 
as being in the cytokine/hematopoietic growth factor receptor family (Bazan, 1990; 
Harlos et al., 1994; Muller et al., 1994). The two domains are immunoglobulin-like 
(Fibronectin type III) domains and are orientated at an angle of 125° to each other 
(Figure 2.2).
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Figure 2.2: Ribbon cartoon diagram of the extracellular region of tissue factor. The 
figure shows the two fibronectin type III domains of the crystal structure of sTF (PDB 
code lboy; Harlos et al., 1994). Figure produced with MOLSCRIPT (Kraulis, 1991).
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TF’s role in the coagulation cascade is to act as a cofactor and to bind and allosterically 
regulate FVII/FVIIa (Eigenbrot & Kirchhofer, 2002). By binding the zymogen FVII it 
favourably orientates the trypsin type serine protease so that it undergoes proteolysis to 
its active form FVIIa. The way in which TF binds and orientates FVIIa is crucial in 
activating the coagulation cascade (Eigenbrot & Kirchhofer, 2002). The detailed 
structure of the extracellular region of tissue factor (known also as soluble tissue factor, 
sTF) was solved simultaneously by two groups (Harlos et al., 1994; PDB code lboy; 
Muller et al., 1994; PDB code lhft). The details of the similar structures are discussed 
elsewhere (e.g. Martin et al., 1995) but the three-dimensional cartoon diagram and the 
wiring diagram are shown in Figures 2.2 and 2.3. The extracellular region does have 
three N-glycosylation sites though these are not believed to play a part in complex 
formation (Martin et al, 1995).
Although it is only the extracellular region of TF that is directly involved with binding 
FVIIa, the transmembrane and cytoplasmic regions are essential in both anchoring the 
TF to the membrane and ensuring its correct orientation at the membrane surface. These 
two regions have been implicated in other possible biological roles for TF which are not 
discussed here (for recent reviews see: Riewald & Ruf, 2002; Peppelenbosch & 
Versteeg, 2001).
2.4 Factor VII.
Factor VII (FVII) has a four-domain structure similar to prothrombin, FX, FIX and 
protein C, all of which are vitamin K-dependent proteins. There is an amino terminal y- 
carboxyglutamic (Gla) domain (Section 2.4.1) followed by two epidermal growth factor 
(EGF1 and EGF2) like domains and a carboxy-terminal serine protease domain (SP). 
FVII is the zymogen precursor of the trypsin like serine protease factor Vila (FVIIa). To 
become FVIIa, the single chained FVII undergoes cleavage of a single peptide bond 
between Argl52 and lie 153. The cleavage occurs between the EGF2 and the SP
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1BOY: ACTIVE SITES_______________________________________________
▼ Site: 7A1 Core binding site for Factor Vila forming concavity between
‘finger’ and domain 1.
Active site residues: ARG135 PHE140 LEU133 LYS 20
THR60 ASP58 ILE22 GLU24
GLN110 VAL2 07
▼ Site: 7A2 Distal part of the binding site for Factor Vila on convex surface
domain 1 (extends to TYR78 in hydrophobic patch).
Active site residues: LYS48 LYS46 GLN37 ASP44
TRP45 TYR78
T Site: XA1 Site of interaction with macromolecular substrate Factor X which
may extend over 20 residues (154-174).
Active site residues: LYS 16 5 LYS 16 6
Figure 2.3: Secondary structure elements of the extracellular region of tissue factor. The 
crystal structure of the extracellular region of tissue factor (PDB code lboy; Harlos et al.,
1994) shows how the polypeptide chain folds into two immunoblobulin like domains. The 
T7A1, T7A2 and ▼ XA1 tags show the residues identified as being essential for 
binding both factor Vila and the substrate for Factor Vila, Factor X, as summarised below 
the figure (information from the header of the PDB file). Figure adapted from the WWW 
online database PDBSum (http://www.biochem.ucl.ac.ukTbsm/pdhsum/; Luscombe et al.,
1998).
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domains, but these two domains have many points of contact and are tightly associated 
by several salt bridges. The EGF1 and Gla domain in unbound FVII and FVIIa form a 
flexible tail region and have been difficult to study with high resolution techniques.
2.4.1 The Gla domain of FVII.
The N-terminal Gla domain of FVII or FVIIa consists of residues 1 to 44. Its name is 
derived from the fact that it is rich in y-carboxyglutamic residues (Gla), ten in all (Figure 
2.4). The first ten glutamic acid residues, all of which are in the Gla domain, are all 
carboxylated to Gla residues by a vitamin K-dependent enzyme system (Stryer, 1995). 
The Gla residues are essential in co-ordinating seven Ca2+ ions, which in turn are 
essential in stabilising the conformation of the Gla domain. The calcium ions are also 
essential in the Gla domain’s role in anchoring FVIIa or its zymogen to the phospholipid 
surface, thus facilitating the cascade reactions on the membrane surface.
The domain has been highly conserved between the trypsin like serine protease enzymes 
in the coagulation cascade and a similar structure and sequence is found in protein C, 
FIX, FX, and prothrombin. This emphasises the important role of the Gla domain in 
facilitating the coagulation cascade on the negatively charged phospholipids layer 
(Figure 2.4). Vitamin K antagonists such as dicoumarol and warfarin are effective 
anticoagulants (Stryer, 1995) and act by blocking the formation of Gla residues and 
subsequently the Gla domain, essential both for anchoring the coagulation factors to the 
membrane surface and in the case of FVIIa essential for complex formation with sTF 
which allosterically regulates FVIIa activity (reviewed in Eigenbrot & Kirchhofer, 
2002).
2.4.2 The first EGF domain of FVII.
The first epidermal growth factor like domain (EGF1) of FVII and FVIIa is attached to 
the Gla domain by a short linker region. This region forms an a-helix and contains a 
number of aromatic residues and is thus called the ‘hydrophobic stack’ (Higashi & 
Iwanaga, 1998). One feature of the EGF1 domain is the two O-linked glycosylation sites
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Figure 2.4: Details of the N-terminal Gla domain of Factor VII. Panel a) shows a baton 
representation of a y-carboxyglutamic acid residue after which the domain is named. 
The y-carboxyglutamic residues are post-translational modified glutamic acid residues. 
The ribbon cartoon figure of the human Gla domain is shown in panel b) (PDB code 
1 dan) and the seven co-ordinated Ca2+ atoms are shown in grey. The conservation of the 
secondary structure elements and positions of the y-carboxyglutamic acid residues of the 
Gla domains of human FVII and FIX and of pig FIXa can be clearly seen in c). The Gla 
residues are represented with a “C” with a symbol underneath. For a full domain 
structure of FVIIa the reader is referred to Figure 5.6 page 118. Panel a) and b) have 
been produced with MOLSCRIPT (Kraulis, 1991). Panel c) has been produced from the 
PDB coordinates as represented on the WWW database PDBSum 
(http://www.biochem.ucl.ac.uk/bsm/pdbsum).
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at Ser52 and Ser60 though their role in enzyme activity has been discounted (Bjoem et
^ I
al, 1991). EGF1 also has one Ca bound that is believed to be essential in correctly 
orientating it with the Gla domain.
2.4.3 The second EGF domain of FVII
The second EGF like domain of FVII (EGF2) is attached to EGF1 by an eight residue 
linker region. Unlike EGF1, EGF2 has a large area contacting the SP domain. This 
stabilises the orientation of the EGF2 domain and determines the orientation of the SP 
domain. There is also a disulphide bridge between Cysl35 and Cys262. EGF2 has not 
undergone the residue modification required for the glycosylation sites. The close 
association of the EGF2 domain with the SP domain has been conserved in the other 
trypsin-like coagulation factors. The region between the second EGF and SP domain is 
the site of enzymatic cleavage (Argl52-Ilel53) to separate the EGF2 domain from
the SP domain and is a prerequisite for activating the zymogen precursor to FVIIa.
2.4.4 The SP domain of FVII.
There are 254 residues that make up the carboxyl-terminal serine protease (SP) domain 
of FVII and FVIIa. The domain has two N-glycosylation sites at Asnl45 and Asn322. 
This catalytic domain shares a common core structure with other serine proteases of the 
thrombin/trypsin family (r.m.s.d. for 200 a-carbon pairs, 0.81 A to D-Phe-L-Pro-Arg 
chloromethyl ketone (PPACK)-thrombin (Bode et al, 1989; Banner & Hadvary, 1991; 
Banner et al, 1996). The residues involved in primary substrate recognition and 
catalysis are also highly conserved in both sequence similarity and spatial arrangement 
(Banner et al, 1996).
2.5 The TF. FVIIa complex.
Unbound FVIIa has little activity for its substrates FX and FIX until it forms a complex 
with sTF in the presence of Ca2+. The activity of the sTF.FVIIa complex is enhanced 
further in the presence of phospholipids (for a recent review see Butenas & Mann, 
2002). The total buried surface area on formation of the sTF.FVIIa complex is 1800 A2 
and involves a number of interactions, which are summarised below. For a detailed
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description the reader is referred to the reviews of Banner (1997); Higashi & Iwanaga 
(1998); Eigenbrot & Kirchhofer (2002).
2.5.1 The Gla domain and TF.
The Gla domain of FVII/FVIIa has been well established as an important part of binding 
FVII/FVIIa to TF to initiate the coagulation cascade. The interactions of the Gla domain 
with TF is mainly through the ‘hydrophobic stack’ (Banner et al„ 1996). The residues 
identified by the crystal structure of the FVIIa.TF complex as being important for 
binding the Gla domain are Trpl58, Val207 and the Cysl86-Cys209 disulphide bridge 
(Banner, 1997). This corresponds well with site directed mutagenesis work as reviewed 
by Martin et al, (1995) following the availability of the crystal structure of sTF.
2.5.2 The EGF1 domain and TF.
Mutational analysis has been most effective at showing the interaction between the two 
domains of TF and the EGF1 domain. These were reviewed by Higashi & Iwanaga 
(1998) and highlight the importance of the hinge region of TF and the hydrophobic stack 
between the Gla and EGF1 domains.
2.5.3 The EGF2 and SP domain and TF.
The functions of significant residues of the EGF2 and SP domains of FVII/FVIIa have 
been reviewed in detail elsewhere (Banner, 1997). One important property of the 
TF.FVIIa complex formation was not known until the recent availability of the crystal 
structure of the zymogen form of FVII (Eigenbrot et al, 2001). Previous structures of 
active site inhibited FVIIa (Banner et al, 1996; Kemball-Cook et al., 1999; Pike et al,
1999) advanced our knowledge of FVIIa structure and activation greatly but the 
structure of the zymogen form of FVII revealed a previously unseen conformational 
change in the SP domain of FVII, which completes FVIIa activation. In the zymogen 
structure, the second p-strand (B2) in the second P-barrel is in a different position 
relative to the neighbouring p-strand. The B2 strand has shifted towards the C-terminus 
by three amino acids. This is the final step and also explains TF’s role in converting 
“incompetent” FVIIa into “competent” fully active FVIIa (Eigenbrot & Kirchhofer, 
2002).
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2.6 The study of sTF and FVIIa with SAXS and SANS.
At the time of the study for this thesis, there was little evidence on the structural 
interactions between sTF and FVIIa. Site directed mutagenesis and associated 
techniques had revealed residues and residue regions important for the complex 
formation but little was known about the quaternary structure of the domains. This 
thesis developed the application of a new constrained modelling procedure based on 
solution scattering data, and critically assessed the utility of this approach. Using the 
available crystal structures from homologous domains for FVIIa and the crystal 
structures for sTF we were able to derive models for both complexed and uncomplexed 
FVIIa in solution. The subsequent availability of the crystal structure model (Banner et 
al., 1996) allowed us to verify our method and results. Details of the studies conducted 
on FVIIa, sTF and their complex in solution, using X-ray and neutron scattering data 
combined with this computer modelling technique, are described in Chapter 4 and 
Chapter 5 (Ashton et al., 1995; Ashton et al., 1998).
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CHAPTER 3 
Pentraxins
3.1 Introduction.
The pentraxins are an evolutionary ancient and stably conserved family of proteins, 
which consists of C-reactive protein (CRP) and serum amyloid P component (SAP). The 
family is a member of the ConA-like lectins/glucanases superfamily, which currently 
has 15 distinct families (SCOP online database, February 2004; Table 3.1). Other 
notable members of the superfamily are the legume lectins, galectin (animal S-lectin) 
and xylanase/endoglucanase 11/12. Similar structures to the pentraxins have been found 
in all vertebrates investigated (Pepys et al., 1997), and in some invertebrates e.g. 
Limulus polyphemus, the horseshoe crab.
The name ‘pentraxin’ itself comes from Greek words for five and berries (Osmand et 
al., 1977). This describes perfectly the quaternary structure of the five individual 
subunits as they associate with the same orientation to form a disk like configuration. 
The individual subunits are known as protamers and it is both the structural and ligand 
binding properties of these individual protamers that give the pentraxin family its 
characteristics.
The exact physiological role of the pentraxins has not been fully determined. However, 
the evolutionary conservation of the pentraxin structure and calcium-dependant specific 
binding to ligands, together with the failure to detect any polymorphism or deficiency of 
either CRP or SAP in man does suggest an important physiological role. The pentraxins 
are known to be implicated in several disease states and have therefore become the 
focus of recent research.
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Table 3.1: Summary of the ConA-like lectins/glucanases superfamily.
Superfamily: ConA-like lectins/glucanases (Class: All beta proteins Fold: ConA-like lectins/glucanases) 
Families:
1. Legume lectins (27) 
Concanavalin A
Lectin
Jack bean (Canavalia ensiformis) (45) , Brazilian jackbean (Canavalia brasiliensis) (1)
Garden pea (Pisum sativum) (6), Common lentil (Lens culinaris) (4), West-central african legume 
(Griffonia simplicifolia) (3), Griffonia simplicifolia, lectin I-b4 (2), Coral tree (Erythrina corallodendron) 
(7), Cockspur coral tree (Erythrina crista-galli) (2), Winged bean (Psophocarpus tetragonolobus), basic (2), 
Winged bean (Psophocarpus tetragonolobus), acidic (2), Lathyrus ochrus, isolectin I (7), Lathyrus ochrus, 
isolectin II (2), Peanut (Arachis hypogaea) (7), Soybean (Glycine max) (5), Field bean (Dolichos lab lab), 
Fril (1) , Horse gram (Dolichos biflorus), different isoforms (5), Mucana (Dioclea grandiflora) (1), Duke 
(Dioclea guianensis) (2), Furze (Ulex europaeus), UEA-I (2), Furze (Ulex europaeus), UEA-II (5),
Bloodwood tree (Pterocarpus angolensis) (3), Maackia amurensis, leukoagglutinin (1), Black locust 
(Robinia pseudoacacia) (2), Hairy vetch (Vicia villosa), isolectin b4 (1)
Phytohemagglutinin-L, PHA-L, also arcelin Kidney bean (Phaseolus vulgaris) (3), Kidney bean, G02771, arcelin-5a (1)
alpha-mylase inhibitor Kidney bean (Phaseolus vulgaris) (1)
2. Carbohydrate-recognition domain of P58/ERGIC-53 (1)
Carbohydrate-recognition domain of P58/ERGIC-53 Rat (Rattus norvegicus) (1)
Beta-glucanase-like
Bacillus licheniformis (1), Hybrid protein: residues 1-16 from Bacillus 
Amyloliquefaciens and Bacillus macerans (3), Bacillus macerans (6), 
Fibrobacter succinogenes (1)
Pseudoalteromonas carrageenovora (1)
Bacillus 1-3,1 -4-beta-glucanase
kappa-Carrageenase, catalytic
4. Galectin (animal S-lectin) (8)
S-lectin, different isoforms
Charcot-Leyden crystal (CLC) protein 
Galectin-3 CRD 
Congerin I 
Congerin II
5. Laminin G-like module (4)
Sex hormone-binding globulin 
Laminin alpha2 chain Mouse 
Ligand-binding domain of neurexin lbeta 
Growth-arrest-specific protein Gas6
6. Pentraxin (pentaxin) (2)
Serum amyloid P component (SAP)
C-reactive protein (CRP)
7. Calnexin/calreticulin (1)
Calnexin
8. vp4 sialic acid binding domain (1)
vp4 malic acid binding domain Rhesus rotavirus (2)
9. Clostridium neurotoxins, the second last domain (2)
Tetanus neurotoxin Clostridium tetani (8)
Botulinum neurotoxin Clostridium botulinum, serotype A (1), Clostridium botulinum, serotype B (7)
10. Exotoxin A, N-terminal domain (1)
Exotoxin A, N-terminal domain Pseudomonas aeruginosa (2)
11. Vibrio cholerae sialidase, N-terminal and insertion domains (1)
Vibrio cholerae sialidase, N-terminal and insertion domains
12. Leech intramolecular trans-sialidase, N-terminal domain (1)
Leech intramolecular trans-sialidase, N-terminal domain
13. Trypanosoma sialidase, C-terminal domain (1)
Trypanosoma rangeli sialidase, C-terminal domain Trypanosoma rangeli (6), Parasitic flagellate protozoan (Trypanosoma
cruzi) (8)
14. Glycosyl hydrolase family 7 catalytic core (5)
Cellobiohydrolase I  (cellulose)
Bovine (Bos taurus) (4), Human (Homo sapiens) (6), Chicken (Gallus gallus) 
(1), Toad (Bufo arenarum) (2)
Human (Homo sapiens) (4)
Human (Homo sapiens) (1)
Conger eel (Conger myriaster) (2)
Conger eel (Conger myriaster) (4)
Human (Homo sapiens) (9)
Mouse (Mus musculus) (1)
Rat (Rattus norvegicus) (1)
Human (Homo sapiens) (1)
Human (Homo sapiens) (3)
Human (Homo sapiens) (3)
Dog (Canis familiaris) (1)
Vibrio cholerae (1)
North american leech (Mactobdella decora) (5)
15. Xylanase/endoglucanase 11/12 (21) 
Xyianase 11
Endo-1,4-beta-glucanase (cellulose) catalytic 
domain
Trichoderma reesei, Cel7A (9), Trichoderma reesei, Endoglucanase I (1), 
Fusarium oxysporum (4), Humicola insolens Cel7B (3) , Phanerochaete 
chrysosporium, Cel7d (2)
Bacillus circulans (9), Bacillus subtilis (1), Bacillus agaradhaerens (4), 
Bacillus subtilis, B230 (1), Streptomyces sp. s38, xyll (1), Trichoderma 
harzianum (1), Trichoderma reesei, xynl (1), Trichoderma reesei, xynll (6), 
Thermomyces lanuginosus (1), Aspergillus niger (1), Aspergillus kawachii 
(1), Paecilomyces varioti bainier (1), Dictyoglomus thermophilum (1), 
Chaetomium thermophilum (1), Nonomuraea flexuosa (1)
Streptomyces lividans, CelB2 (2), Streptomyces sp. 1 lag8 (1), Rhodothermus 
marinus (1), Trichoderma reesei, Cell2A (2), Hypocrea schweinitzii (1) 
Aspergillus niger (2)
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3.2 What is known about physiological state of the pentraxins?
Both CRP and SAP are normal plasma proteins. Circulating levels of CRP will rise 
dramatically in response to tissue injury, infection and inflammation (for a recent review 
see Hirschfield and Pepys, 2003). The exact physiological role of CRP has not yet been 
determined. Recent advances such as the determination of the structure of the human 
CRP-phosphocholine (PC) complex (Thompson et al., 1998) has given us an insight to 
its possible role and mechanism in activating both the complement and coagulation 
pathways. Following tissue damage, infection, inflammation and neoplasia, continuing 
high levels of circulating CRP is believed to cause prolonged tissue damage by over 
activation of the body’s own defence mechanisms. Determining the detailed structure of 
CRP could yield potential molecular targets or drugs for reducing the scale of tissue 
damage.
Less still is known about the physiological role of SAP. SAP that has come out of 
solution, usually by binding to other proteins is known as amyloid P-component (AP) 
and is found in all amyloid plaques. An amyloid deposit is a starchy extracellular 
deposit consisting of a range of diverse precursor proteins forming amyloid fibrils, 
which in turn form the amyloid plaque. The composition of amyloid deposits in man 
vary depending on the form of the disease which include Alzheimer’s disease, 
transmissible spongiform encephalopathies, type 2 diabetes and cystic fibrosis (reviewed 
by Pepys, 1994). The result of the association of amyloid P-components (AP) with 
amyloid fibrils is to make the plaques resistant to degradation and clearing, as AP is 
itself resistant to proteolytic attack (Tennent et al., 1995).
Like CRP, SAP can undergo specific calcium-dependent interactions. SAP is also 
known to bind to several macromolecules including DNA and chromatin (Pepys and 
Butler, 1987; Butler et al., 1990), glycosaminoglycans (Hamazaki, 1987), agarose 
(Pepys et al., 1977), fibronectin and C4-binding protein (de Beer et al., 1981). There is 
also some evidence that SAP may act as a chaperone and it could be this role (or failure)
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in assisting protein molecules gain their biologically active conformations that may 
contribute to the pathogenesis of amyloidosis (Coker et al., 2000).
3.3 CRP pentamer structure.
CRP has been the source of intense clinical interest since it was observed that human C- 
reactive protein levels in plasma rise dramatically in response to infection or injury. 
Despite the detailed knowledge we now have on the physiological levels of CRP, little 
has yet been proven about its physiological role (reviewed in Hirschfield & Pepys, 
2003).
An understanding of a biological role for a protein is often facilitated by determining its 
3D structure. A structure for human CRP was first published by Shrive et al., 1996 
(PDB code lgnh). This structure showed the detailed folding pattern of the 206 amino 
acids, summarised in Figure 3.1 and Figure 3.2. Each protomer consisted of 14 
antiparallel P-strands, which form a P-sheet along with one a helix (for a detailed 
description and analysis of the CRP structure see Shrive et al., 1996). The structure also 
provided evidence for the calcium dependent binding of PE to CRP, and this was 
confirmed in the later structure of the CRP-PC complex (Thompson et al., 1998; PDB 
code lb09).
3.4 SAP pentamer structure.
Though the existence of CRP has been known far longer than SAP, it was the detailed 
structure of SAP that was first determined (Emsley et al., 1994; PDB code lsac). Indeed 
the structure of SAP was used to help determine that of CRP (Shrive et al., 1995; 
Thompson et al., 1998). The SAP structure gave us the first insight into how the 
calcium dependent binding of pentraxins to other biologically important ligands 
occurred.
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Figure 3.1: Schematic ‘wiring diagram’ of the secondary structure and motifs in the A 
chain of the human CRP structure (Shrive et al., 1996; PDB code lgnh), as represented 
on the WWW database PDBSum (http://www.biochem.ucl.ac.uk/bsm/pdbsum).
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Figure 3.2: The tertiary structure of the CRP pentamer. Figure 3.2a shows the topology 
of the A chain of CRP as represented by TOPS (http://www.tops.leeds.ac.uk/). Figure 
3.2b shows the ribbon cartoon diagram of CRP created using PyMOL (DeLano, W.L. 
The PyMOL Molecular Graphics System (2002) on World Wide Web 
http://www.pymol.org).
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The 204 amino acids that form a protomer for human SAP are expressed from a single 
copy of the gene located on chromosome 1 (Mantzouranis et al, 1985; Ohnishi et al, 
1986). A full description of the way in which these amino acids fold to form one SAP 
protamer is given elsewhere (Emsley et al., 1994) and summarised in Figure 3.3 and 
Figure 3.4. One significant difference between the crystal structures of CRP and SAP is 
that the five protomers of CRP have rotated inwards by 15° compared to those seen for 
SAP-5 (Emsley et a l , 1994; Shrive et a l , 1996). This rotation was unexpected, since 20 
residues involved in interprotomer contacts in SAP-5 were mostly conserved in the SAP 
and CRP sequences.
Each protomer is made up of a single chain containing one disulphide bridge between 
Cys36 and Cys95 and one N-glycosylation site at Asn32. The chain folds to create a ‘13- 
jelly roll’ fold with one a-helix on the same side as the glycosylation site (A-face). On
474-the opposite side to the glycosylation site every protomer has two Ca binding sites, 
which in turn regulate a single ligand binding site (B-face). The five protamers 
associates to form a ring structure with each protamer tightly, though not covalently, 
associating with its neighbour.
One structural feature missing from the SAP crystal structure is the structure of the 
carbohydrate. Although the overall percentage of the carbohydrate to protein is very 
small it is significant, as it is likely to dominate any interactions occurring on the A- 
face.
One significant interaction of the SAP pentamer is its association with a second SAP 
pentamer. Under certain conditions SAP is known to exist as a decamer and it is still 
unclear if  this is the state of SAP in human serum (see Pepys et al, 1997). The way SAP 
forms a decamer may have important implications in its physiological role. The crystal 
structure of a decamer complex of human SAP with bound dAMP has been determined 
(Hohenester et al, 1997), though this is not believed to be the physiological state (Pepys 
etal., 1997).
76
HTDLSGKVFVFPRESVTDHVNLITPLEKPLQNFTLCFRAYSDLSRAYSLFSYNTQGRDNE
L LVYKE RVG E YS LYIG R HKVT S KVIEK  F P APVHICVSWE SS SG I AE FWIHGT P LVKKG L R
QGYFVE AQPKIVLGQEQDSYGGKFDRSQSFVGEIGDLYMWDSVLP P ENT LS AYQGTP LP A
T3i ilo Us Uo Us S5 Us So i<5 r?o Us iS
NILDWQALNYEIRGYVI IKPLVWV
iis So i3s 36
A c tx a ta : -  ▼ CIA ▼ C2A Residoe Ihtetjctiohs- -
Figure 3.3: Schematic ‘wiring diagram’ of the secondary structure and motifs in the A 
chain of human SAP structure (Emsley et al., 1994; PDB code l sac), as represented on 
the WWW database PDBSum (http://www.biochem.ucl.ac.uk/bsm/pdbsum).
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Figure 3.4: The tertiary structure of the SAP pentamer. Figure 3.4a shows the topology 
of the A chain of SAP as represented by TOPS (http://www.tops.leeds.ac.uk/). Figure 
3.4b shows the ribbon cartoon diagram of SAP created using PyMOL (DeLano, W.L. 
The PyMOL Molecular Graphics System (2002) on World Wide Web 
http://www.pymol.org).
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3.5 The pentraxins and SAXS and SANS.
The aims of studying SAP and CRP using SAXS and SANS data for this thesis were 
twofold.
3.5.1 Biologically significant structures.
Prior to the start of this thesis study, little was known about the detailed molecular 
structures of either CRP or SAP. During the early part of this thesis study, significant 
breakthroughs were made with the publication of firstly the SAP structure (Emsley et 
al., 1994), followed shortly after by the CRP structure (Shrive et al., 1996). Previous 
SAXS and SANS studies had correctly predicted the dimensions of both CRP and SAP 
(Perkins and Pepys, 1986). The combination of the high-resolution structures with high 
quality SAXS and SANS data and a novel computer-modelling algorithm, could now be 
used to provide the first insights into pentraxin structures in solution. During these 
SAXS and SANS studies, a crystal structure of a decameric SAP complex with bound 
2'-deoxyadenosine-5-monophosphate (dAMP) also became available (Hohenester et al., 
1997). The significance of this structure is discussed later in Chapter 6 though it is 
worth noting here that each SAP pentamer only associates with its ligand, and not the 
other pentamer, to form the decamer. The scattering data was thus able to present a 
solution structure of the unliganded SAP decamer for the first time, and the orientation 
of the oligosacharides in the two forms of SAP, even though this could not be 
crystallised. The combination of crystallography and solution scattering approaches have 
lead to new insights on the SAP structure.
3.5.2 SAXS. SANS and computer-modelling.
The value of using high-resolution crystal structures along with high quality SAXS and 
SANS data to verify and predict the solution structures of both proteins and their 
complexes is well-recognised (for reviews, see Perkins et al., 1998; Svergun & Koch, 
2003). However, the conclusions of the scattering analysis cannot always be verified. 
This calls for calibration studies with proteins of known structure in a wide molecular 
weight range. Appropriate rigid protein structures that are larger than about 50 kDa are 
generally not available for calibration studies. The SAP pentamer however, is ideal for
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this purpose as its molecular weight is 123 kDa, close to many of the multidomain 
proteins for which obtaining detailed structural information using conventional 
techniques is difficult. Proteins with flexible domains would not be suitable for 
calibration studies as their domain orientation would vary in solution. The five domains 
of both SAP and CRP associate to form a stable ring structure, so their study and 
comparison with the known crystal structures can be used to verify the algorithms 
developed for constrained scattering modelling.
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CHAPTER 4
X-rav and Neutron Solution Scattering Data for 
Soluble Tissue Factor. Factor Vila and their Complex.
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4.1 Introduction
Blood coagulation has long been recognised as an important process essential for 
survival. Inappropriate coagulation obstructing blood vessels (or thrombosis) is 
responsible for much morbidity and mortality. Thrombotic disorders are often associated 
with cardiovascular, infectious and neoplastic disease. An understanding of the 
molecular basis of the procoagulant pathways will in the long term help to treat and 
even prevent many of these thrombotic disorders. Exposure of the membrane-bound 
receptor, tissue factor, to plasma initiates the coagulation pathways. Upon cell-surface 
expression of tissue factor, it forms a very stable catalytic enzyme-cofactor complex 
with the plasma serine protease coagulation factor Vila (FVIIa) with a IQ of binding 
estimated to be from 2 to 5 nM (O'Brien et al, 1993; Kelley et al, 1995; Martin et al, 
1995).
Both tissue factor and FVIIa are multidomain proteins. The crystal structure for the 
soluble extracellular region of tissue factor (sTF) (Harlos et a l , 1994; Muller et al., 
1994) shows that this contains two C2-type immunoglobulin fold domains, otherwise 
known as fibronectin type III domains. FVIIa contains four domains and at the time of 
this study no crystal structures for FVII were available. The serine protease (SP) and 
epidermal growth factor (EGF-2) domains in the crystal structure of human factor Xa 
(Padmanabhan et a l , 1993) are highly homologous in primary structure to those found 
in FVIIa. The NMR structures of the EGF-1 domain of human factors EX and X (Baron 
et al., 1992; Selander et a l , 1990) provide a close model for the EGF-1 domain in 
FVIIa. Finally the known crystal structure of the N-terminal Gla domain of prothrombin 
(Soriano-Garcia et al., 1992) may be used as a model for that in FVIIa. While an atomic 
model for FVIIa can be proposed, there is no information on the relative spatial 
arrangement of its domains in the unbound state of FVIIa. In addition, at the time this 
work was done no structure was available for the FVIIa-sTF complex.
Neutron and X-ray scattering studies provide the means, not only for determining the 
domain orientation of FVIIa, and verifying that for sTF, but also for determining a low 
resolution structure of the enzyme-cofactor complex (Perkins, 1988; Perkins, 1994). A 
complete set of neutron and X-ray data is reported which characterise the radius of
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gyration of the overall structure Rg and its cross-section Rxs, and the distance 
distribution function P(r). In this chapter it is shown that the FVIIa-sTF complex 
possesses a compact structure, a feature later confirmed by the crystal structure (Banner 
et al, 1996) and automated modelling analysis of the solution scattering data reported 
here (Chapter 5; Ashton et al, 1998). This offers an explanation for the high nanomolar 
affinity of the two proteins for each other in the complex in terms of the ability of many 
residues, identified from biochemical studies, to form specific intermolecular 
interactions in the complex.
4.2 Methods
4.2.1 Preparations of factor Vila, tissue factor and their complex.
I gratefully acknowledge the work and generosity of Professor E. G. D. Tuddenham, Dr 
G. Kemball-Cook and colleagues at the Hammersmith Hospital for the preparation work 
for all samples of FVIIa, sTF and their complex. Details of their preparation are 
included here for completeness.
Recombinant wild-type human FVII was expressed in Chinese Hamster Ovary (CHO) 
cells (Kemball-Cook et al, 1994) and purified to homogeneity by monoclonal antibody 
affinity chromatography (O’Brien et al, 1994) or with final purification carried out 
using a Resource Q ion-exchange column (Pharmacia, St Albans, UK). FVIIa was 
derived by autoactivation at 2-4 mg/ml in TBS-Ca buffer (50mM Tris/150mM 
NaCl/5mM CaC^ pH 7.4) at room temperature for 18 h, followed by rechromatography 
on Mono Q (Pharmacia) to isolate pure FVIIa. Shortly prior to data collection, FVIIa 
was subjected to gel-filtration on Superose 12 (Pharmacia) in TBS-Ca to remove trace 
aggregates, then reconcentrated using Centricon-30 devices (Amicon, Stonehouse, UK). 
In one experiment, purified non-activated FVII was prepared in TBS without prior 
autoactivation, and was found to be fully activated after data collection. Control 
experiments indicated that autoactivation is rapid in concentrated solutions of FVII.
Recombinant sTF (residues 1-219) was isolated from E.coli cell paste and purified as 
described previously (Boys et al, 1993), or alternatively by sequential ion-exchange
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chromatography on SP Sepharose High Performance and Resource Q columns 
(Pharmacia). The resulting protein was subjected to gel filtration as above before final 
reconcentration using Centricon-10 devices (Amicon) prior to data collection.
The complex was formed from FVIIa and sTF, which were purified as above, 
concentrated to volumes of 500 pi each, then mixed in TBS-Ca at 37°C for 5 min in a 
molar ratio of FVIIa:sTF of approximately 1:2 as determined by the absorbance at 280 
nm. The sTF-FVIIa complex was separated from excess sTF by gel filtration on 
Superose 12. Fractions from an elution peak corresponding to the complex were pooled 
and concentrated. sTF was eluted in a later peak as demonstrated by SDS-PAGE 
analysis (O’Brien et al, 1991). Concentrations c were calculated from absorbance 
measurements at 280 nm using absorption coefficients (1%, 1 cm) of 12.8, 15.6 and 
13.7 for FVIIa, sTF and their complex respectively calculated from their compositions 
(Perkins 1986). Sequences and carbohydrate contents were obtained from Hagen et al, 
(1986); Fisher et al, (1987); Thim et al, (1988); Harris and Spellman (1993); Bjoem et 
al, (1991).
Scattering data were obtained using TBS-Ca buffer in H2O buffers for X-ray work, 
while the neutron work involved dialysis at 6°C into the corresponding buffer in 2H2<3 
for at least 36 h with four buffer changes. SDS-PAGE under non-reducing conditions 
before and after scattering was used to verify the integrity of the samples. Samples were 
stored at 4-6°C until required. X-ray and neutron data collection was performed at 15°C 
using thermostatted sample holders.
4.2.2 X-rav and neutron data collection
X-ray curves were obtained in two beam sessions on cameras at Stations 2.1 and 8.2, 
both equipped with a quadrant detector, at the Synchrotron Radiation Source at 
Daresbury (Towns-Andrews et al, 1989). Sample-detector distances of 3.14 m and 3.46 
m were used, with beam currents of 136 mA to 203 mA and a storage ring energy of 2.0 
GeV. This setup resulted in an available Q range of between 0.06 to 2.38 nm'1 (Q = 4n 
sin 0/A,; scattering angle = 20 ; wavelength = A). Samples were measured in Teflon cells 
with 15-20 pm thick mica windows. Data were recorded using 10 time frames to
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monitor possible radiation damage effects. Other details of instrument calibration and 
data reduction are described elsewhere (e.g. in Chapter 1 and Beavil et al, 1995).
Neutron data were obtained during three beam sessions on the LOQ scattering 
instrument at the ISIS facility at the Rutherford Appleton Laboratory, Didcot, U.K. 
(Heenan et al, 1992). The pulsed neutron beam was derived from bombardment of a 
tantalum or depleted uranium target by 170-185 pA proton beam currents. A 3He 
ORDELA wire detector was employed at a sample-to-detector distance of 4.3 m, and 
yielded an available Q range of 0.05-2.2 n m 1. Samples were measured in 2 mm-thick 
rectangular quartz Hellma cells. Other details are described elsewhere (e.g. in Chapter 1, 
Beavil etal., 1995; Heenan et al, 1992; Mayans et al, 1995).
4.2.3 Guinier analyses of reduced scattering data.
In a given protein-buffer scattering contrast, the radius of gyration Rg is a measure of 
structural elongation provided the internal inhomogeneity of scattering densities within 
the glycoprotein can be neglected. Analyses of the I(Q) curves at small Q in Guinier 
plots give the Rg and the forward scattering at zero scattering angle 1(0) (Glatter & 
Kratky, 1982):
R g2Q 2
In I(Q) = In 1(0) - — Eq 4.1
The relative values of l(0)/c (c = sample concentration) gives relative molecular weights 
Mr of the proteins as a control of the data (Kratky, 1963). If the structure is sufficiently 
elongated, the averaged radius of gyration of the cross-sectional structure Rxs and the 
averaged cross-sectional intensity at zero angle [I(Q).Q]q_>o are obtained from (Glatter 
& Kratky, 1982; Hjelm, 1985):
In [I(Q).Q] = In [I(Q).Q]q^ o - Eq 4.2
The Rg and Rxs analyses lead to estimates of triaxial dimensions, where in particular the
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length of the longest axis (L) can be calculated using (Glatter & Kratky, 1982):
L =  ^12 (Rg2- f a s 2) Eq 4.3
or (Perkins et al., 1986):
[/(0.eu
7t.I{ 0)
Eq 4.4
X-ray and neutron Guinier analysis was carried out using the interactive programs 
SCTPL5 and SCTPL5g (A.S.Nealis, A.J.Beavil, and S.J.Perkins, unpublished software). 
Results were collated into spreadsheets in Microsoft Excel and curve fits were 
performed in Jandel Sigmaplot.
4.2.4 Distance distribution function analyses of reduced scattering data.
Indirect transformation of the full scattering data in reciprocal space I(Q) into that in real 
space P(r) was carried out using the GNOM program of Svergun et al., (1988).
P(r) corresponds to the distribution of distances r between any two volume elements 
within one particle. This offers an alternative calculation of Rg and 1(0), and gives the 
maximum dimension of the macromolecule L. To calculate the P(r) curves, the X-ray 
I(Q) curves contained 350-390 data points extending out to 2.2 nm'1 and the neutron 
I(Q) curves contained 69 data points extending out to 2.1 nm'1. Dmax was varied in 1 nm 
steps between 5-20 nm to test the stability of the P(r) transformation. L was determined 
from the value of r when P(r) became zero at large r; however errors in L can be 
significant for reason of the low intensity of P(r) in this region.
J  I(Q) Qr sin(Qr) dQ
Eq 4.5
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4,3 Results and Discussion.
4.3.1 Synchrotron X-rav data on factor Vila, extracellular tissue factor and their 
complex.
The full X-ray scattering curves I(Q) of FVIIa, sTF and their complex were analysed in 
two distinct Q ranges at low Q in order to obtain the radius of gyration Rg and the cross- 
sectional radius of gyration Rxs- Figures 4.1 and 4.2 show that the final Rg and Rxs data 
were obtained from linear plots in satisfactory QRg and QRxs ranges. For FVIIa, 
noticeable radiation damage effects were observed at low Q through apparent aggregate 
formation (see Figure 4.3). These were analysed using data collected in 10 consecutive 1 
min time frames. The Rg and 1(0) parameters were stable for the first minute of data 
collection, then increased linearly with time for the remaining period. X-ray data for 
FVIIa in Figures 4.1, 4.2 and 4.4 were analysed using only the first 1 min time-frame. 
Analyses of the dilution series between 0.6-2.5 mg FVIIa/ml showed no concentration 
dependence of the Rg or l(0)/c values (c: sample concentration). sTF was stable in the 
X-ray beam and the entire 10 minute data acquisition with 0.9 mg sTF/ml was used for 
Guinier analyses. The complex (3.9 mg/ml) exhibited slight radiation damage, and the 
first three time frames only were used for all data analyses.
The mean X-ray Rg value of FVIIa which defines its overall elongation is 3.24 ± 0.08 
nm (Table 4.1). The Rg/Ro ratio indicates the anisotropy or the degree of elongation of 
the structure, where Ro is the Rg of the sphere with the same hydrated volume as the 
protein in question. The Rg/Ro ratio is 1.53 ± 0.04 for FVIIa, which is slightly higher 
than the averaged value of 1.28 ± 0.10 for single-domain globular proteins (Perkins, 
1988). The overall solution structure of FVIIa is thus extended. Its mean Rxs value was 
1.53 ± 0.13 nm. Calculation of the length L of FVIIa by two methods from the Guinier 
analyses (Section 4.2.3) suggests a value of L between 9.9 nm to 11.4 nm. The mean X- 
ray Rg of sTF was determined to be 1.99 ± 0.05 nm, and resulted in an Rg/Ro ratio of 
1.19 ± 0.03. Its mean Rxs value is 0.52 nm, and its length L is 6.7 to 7.6 nm.
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Figure 4.1: X-ray and neutron Guinier Rq plots for factor Vila, extracellular tissue 
factor and their complex. Values of c for FVIIa were 1.9 and 3.9 mg/ml, those for sTF 
were 0.9 and 0.9 mg/ml, and those for the complex were 3.9 and 2.6 mg/ml, for X-rays 
and neutrons respectively. Filled circles between the Q.Rg ranges show the data points 
used to determine the Rg values (Table 4.1)
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Figure 4.2: X-ray and neutron Guinier Rxs plots for factor Vila, extracellular tissue 
factor and their complex. The scattering curves are the same as in Figure 4.1. The filled 
circles between the Q.Rxs ranges as arrowed show the data points used to determine the 
Rxs values (Table 4.1).
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Figure 4.3: Radiation damage effects on factor Vila and the complex formed between 
extracellular tissue factor and factor Vila during X-ray data collection. It should be 
noted that in the FVIIa data all three data collections gave identical results within the 
first time frame, but diverge after that. The 1(0) values result from Guinier analysis of 
the 10 individual time frames.
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Figure 4.4: Distance distribution functions P(r) for factor Vila, extracellular tissue 
factor and their complex. The scattering curves are the same as in Figure 4.1. The 
maximum of the P(r) curve is denoted M, the most frequently occurring distance within 
the protein (Table 4.1). The maximum dimension is denoted L.
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Table 4.1: Summary of solution scattering data for factor Vila, extracellular tissue 
factor and their complex
Guinier analysis' 
P(r) analysis
Q ranges used in Guinier fits (nm 1) 
Rg (nm) Rxs (nm)
Rg (nm)
L (nm ): Rg 
L (nm ): 1(0) 
L (nm) M (nm)
Factor Vila: 
X-ray (7)1
0.20 - 0.42 
3.24±0.08
3.37±0.05
0.6-1.4 
1.53±0.13 9.9±0.2 
11.4±0.5 
10 ±2 3.0±0.3
Neutron (3) 3.22±0.02
3.18±0.05
1.13±0.03 10.4±0.1 
10.0±1.0 
10 ±2 2.5±0.1
Tissue factor: 
X-ray (4)
0.18-0.60
1.99±0.05
2.12±0.12
0.7-1.4 
0.52±0.01 6.7±0.2
7.6±0.3
8.0±0.1 1.2±0.1
Neutron (1) 2.08±0.04
2.32±0.13
0.59±0.03 6.9±0.2
8.2±0.1
9.0 1.6
Complex: 
X-ray (2)
0.15-0.49
3.20±0.02
3.23±0.03
0.6-1.0 
1.56±0.02 9.7±0.1 
11.2±0.1 
10.2± 0.3 3.0
Neutron (1) 3.04±0.08
3.10±0.13
1.27±0.05 9.6±0.4
10.8±0.6
9.5 2.9
Footnotes:
1 Values are given as the mean ± standard deviation of a total of separate measurements 
as bracketed. For single runs, the standard deviation corresponds to that of the Guinier 
or P(r) fits. The X-ray and neutron Q ranges used for Guinier fits are shown above each 
set of Rg and Rxs values. The L values correspond to the longest dimension of the 
macromolecule calculated as defined above. The maximum of the P(r) curve is denoted 
M, the most frequently occurring distance within the protein (see Figure 4.4)
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The mean Rg of the complex was 3.20 ± 0.02 nm, its Rg/Ro ratio was 1.33 ± 0.01, its 
mean Rxs value was 1.56 ± 0.02 nm, and its length L was between 9.7 nm to 11.2 nm. 
The structural anisotropy of the complex was therefore intermediate between those of 
FVIIa and sTF. However sedimentation data have suggested that the frictional ratio f/f0 
of the complex is 1.52, which is larger than that for FVIIa of 1.39, and implies that the 
complex is more elongated than FVIIa (Waxman et al, 1993).
The distance distribution function P(r) allows the determination of the maximum 
dimension L (Section 4.2.4). The Rg and 1(0) parameters calculated from P(r) were all in 
good agreement with the Guinier analyses (Table 4.1). The X-ray P(r) curve for FVIIa 
reached a maximum at r = 3.0 nm to correspond to the most frequently occurring 
distance within FVIIa. The maxima for sTF and the complex were at 1.2 nm and 3.0 nm. 
L was determined to be 10 ± 2 nm for FVIIa, 8.0 ± 0.1 nm for sTF and 10.2 ± 0.3 nm for 
the complex. These were in agreement with the Guinier length calculations (Table 4.1). 
It is concluded that the length of the longest axis of the complex is similar to that of 
FVIIa. In other words, FVIIa and sTF form a side-by-side complex that leaves the 
overall length unchanged.
4.3.2 Neutron data on factor Vila, extracellular tissue factor and their complex.
Neutron scattering data were obtained for FVIIa, sTF and their complex in 100% H2O 
buffers. This corresponds to a negative solute-solvent contrast, compared to the positive 
contrast of the X-ray measurements (Perkins, 1988; Perkins 1994). The data served as a 
control of X-ray radiation damage (as no radiation effects occur with neutrons), and 
possible effects from large internal scattering density variations within FVIIa and the 
complex due to glycosylation. The Guinier analyses resulted in linear plots (Figures 4.1 
and 4.2). Values of c were 3.9-7.5 mg/ml for FVIIa, 0.9 mg/ml for sTF, and 2.6 mg/ml 
for the complex. No aggregation commonly observed with the use of 2H20 buffers was 
observed.
The corresponding sets of X-ray and neutron Guinier and P(r) data in Table 4.1 
generally showed good agreements with each other. This again demonstrated that the 
complex is intermediate in its structural anisotropy between those of FVIIa and sTF.
93
Two exceptions to this agreement were the Rxs values for FVIIa and the complex, 
which were significantly reduced by neutrons compared to the X-ray values. This is 
attributed to the high electron density of carbohydrate relative to protein, which will 
cause the observed X-ray Rxs value to increase, and the neutron Rxs to decrease. 
Surface carbohydrate can have a large effect on solution scattering curves. Use of the 
average of the X-ray and neutron values will approximately represent a structure at 
infinite contrast by analogy with the Stuhrmann relationship, in which this contrast 
effect is minimised (Perkins, 1988; Perkins 1994; Glatter & Kratky, 1982).
As the neutron intensities had been standardized using a deuterated polymer standard 
(Heenan & King, 1993), the Guinier l(0)/c values for FVIIa, sTF and their complex 
could be compared with l(0)/c values for other proteins of known molecular weights. 
The l(0)/c value for FVIIa and the complex were determined to be 0.051 and 0.072 
respectively. The ratio of l(0)/c values is 0.71: 1.00, which is close to the ratio of 0.67: 
1.00 expected from the Mr values of 51,400 and 76,200. No calculation was made for 
sTF as c was too low for an accurate l(0)/c value. Both l(0)/c values were consistent 
with values of 0.093 for recombinant human IgE-Fc (Mr of 75,300) (Beavil et a l, 1995) 
and 0.181 for bovine IgGl and IgG2 (Mr of 144,000) (Mayans et al, 1995). It is 
concluded that the complex was formed as expected.
4.4 Conclusions.
This work was performed before the crystal structure of the FVIIa-sTF complex was 
published (Banner et al, 1996). The solution scattering data show that FVIIa, sTF and 
their complex were monomeric, and that low resolution structural parameters can be 
derived from these. The X-ray and neutron data were self-consistent, and each data set 
served as a control of the other. Since the results can be averaged, the mean X-ray and 
neutron Rg values were computed from Table 4.1 to be 3.25 nm, 2.13 nm and 3.14 nm 
(±0.13 nm) for FVIIa, sTF and their complex respectively. The mean Rxs values were 
1.33 nm, 0.56 nm and 1.42 nm (± 0.13 nm), and the mean lengths L were 10.3 nm, 7.7 
nm and 10.2 nm respectively. Even though the molecular weights of FVIIa and sTF are 
comparable at 51,400 and 24,800, it is clearly seen that formation of the complex did
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not lead to significantly increased Rg or L values. These dimensions were very similar 
for FVIIa and the complex, indicating that the complex has a compact structure. This 
implies that many residues in both FVIIa and sTF will be in sufficiently close proximity 
to form intermolecular interactions to stabilise the complex. Both domains of sTF are 
expected to make many such contacts with FVIIa, in agreement with the biochemical 
data (Martin et al., 1995) and there will be much scope for the design of anticoagulants 
that will help regulate complex formation.
Figure 4.5 indicates a schematic outline of the structures of the two free proteins and 
their mode of association in the complex as suggested from the scattering data in the 
absence of detailed modelling (Chapter 5). The interface between the EGF-2 and SP 
domains in the crystal structure of Factor Xa is defined by many contacts (Padmanabhan 
et al., 1993), and is presumed to be similar in FVIIa. The N- and C-terminal a-carbon 
atoms of the FVIIa Gla, EGF-1 and EGF-2 domains were arranged to lie on one linear 
axis. On this basis, the length of FVIIa in Figure 4.5 is 10.2 nm, which agrees with the L 
values of Table 4.1, and suggests that the N-terminal domains of FVIIa are extended in 
solution. The length of sTF from the crystal structure is 8.3 nm, which also agrees with 
Table 4.1. The side-by-side model for the complex in Figure 4.5 is consistent with 
biochemical data which show that a fragment of FVIIa containing both the Gla and 
EGF-1 domains inhibit complex formation (Kazama et al., 1993). Since the Gla domain 
of blood coagulation proteases is thought to bind to cell membranes, and full length 
tissue factor is associated with cell membranes via a C-terminal transmembrane region, 
it can be presumed that the two domains of sTF are aligned with the C-domain next to 
the Gla domain in the complex (Figure 4.5).
Following the completion of these structural studies, a report was made of a crystal 
structure of active site-inhibited FVIIa and a subtilisin-cleaved extracellular region of 
tissue factor (Banner et al., 1996). Bazan (1996) recognised that the low resolution 
structure derived above was in good agreement with the subsequent crystal structure 
which showed that a compact complex is formed with FVIIa and tissue factor positioned 
side-by-side. Further analysis and the modelling of this data using homologous crystal 
structures are reported in Chapter 5.
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Factor Vila
Figure 4.5: Schematic diagram of the domains in human factor Vila and tissue factor 
and a possible association in their complex. Upper: sTF has two C2-type 
immunoglobulin fold domains (residues 1-101 and 108-219), joined by a six-residue 
linker region (Harlos et a l , 1994; Muller et al, 1994). N-glycosylation sites occur at 
A snll, Asnl24 and Asnl37, however the sTF used here was expressed in E.coli and 
hence was not glycosylated. Centre: Schematic ellipsoidal models to represent a possible 
association of sTF (shaded) and FVIIa to form a compact complex. Lower: FVIIa 
consists of an N-terminal (y-carboxylglutamic acid (Gla) domain (residues 1-45), 
followed by two epidermal growth factor (EGF-1 and EGF-2) domains (residues 49-82 
and 90-128) and a serine protease (SP) domain (residues 153-406). The Brookhaven 
codes are 2pfl, lixa and lhcg respectively. N-linked glycosylation sites occur at Asnl45 
and Asn322 in SP (Thim et al., 1988) and O-linked glycosylation sites occur at Ser52 
and Ser60 in EGF-1 (Harris and Spellman, 1993; Bjoem et al, 1991). It is stressed that 
the extended rotational orientation between the Gla, EGF-1 and EGF-2 domains in 
FVIIa is arbitrary.
C-Domain N-Domain
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CHAPTER 5
Modelling the Solution Scattering profiles of Factor Vila. 
Soluble Tissue Factor and their Complex.
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5.1 Introduction.
Inappropriate blood coagulation may result in thrombotic disorders often associated 
with cardiovascular, infectious and neoplastic disease. Such coagulation can be initiated 
by exposure of cell surface-expressed tissue factor to plasma. Similar to the full-length 
transmembrane receptor tissue factor, soluble tissue factor (sTF) forms a high affinity 
catalytic enzyme-cofactor complex with the plasma serine protease coagulation factor 
Vila (FVIIa), with a dissociation constant Kd estimated by surface plasmon resonance to 
be in the range of 2-5 nM (O'Brien et al., 1994; Kelley et al., 1995; Martin et al., 1995). 
Proteolysis of factor VII to its active form FVIIa proceeds via a cleavage between 
Argl52 and Ilel53. In the presence of Ca , this complex catalyses the conversion of 
both factor IX to factor IXa (FIXa) and factor X to factor Xa, both of which are active 
coagulation serine proteases. An understanding of the molecular basis of these initiating 
procoagulant reactions may in the long term help to treat and even prevent associated 
thrombotic disorders. Further background to FVIIa and sTF is given in Chapter 2 and in 
recent reviews (Morissey et al., 1997; Edgington et al., 1997; Banner, 1997; 0sterud, 
1997; Semeraro & Colucci, 1997).
This chapter focuses on the molecular modelling of sTF, FVIIa and their complex from 
scattering data. Both sTF and FVIIa are multidomain proteins (Figure 5.1). The crystal 
structure of sTF contains two fibronectin type III domains at an angle of 125° to each 
other to form an extended but rigid arrangement (Harlos et al., 1994; Muller et al., 
1994; Muller et al., 1996). The domains are identical in structure and topology to C2- 
type immunoglobulin folds, but exhibit distinct sequence differences (Williams & 
Barcley, 1988; Bork et al., 1994). FVIIa contains four domains: a serine protease 
domain (SP), two epidermal growth factor domains (EGF-1 and EGF-2), and a (y- 
carboxyglutamic acid-rich domain (Gla). The crystal structure of the complex between 
FVIIa and sTF revealed the location of all four FVIIa domains as well as those for sTF 
(Banner et al., 1996), but at the time of this study no crystal structure was available for 
free FVII or FVIIa. The FVIIa domains are structurally homologous to similar domain
98
FACTOR FVIIa Asn145
Asn
322
Gla IEGF1
44 145 
I
i
-831 |  91— 142 | 153‘
I I h  —
406
254
TISSUE FACTOR
COOH NH<
219- 1081101
Figure 5.1: Domain structures of human FVIIa and sTF. FVIIa contains an N-terminal 
Gla domain and two EGF domains in the light chain, and a SP domain in the heavy 
chain. As shown, the membrane-proximal C-terminal domain of sTF is close to the N- 
terminal Gla domain in FVIIa in the complex. Two O-linked glycosylation sites are 
found on EGF-1 at Ser52 and Ser60, and two N-linked glycosylation sites are found at 
Asnl45 and Asn322.
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structures in activated factors IX and X. Crystal structures of human factor Xa lacking 
the Gla domain showed the SP and EGF-2 domains, but the EGF-1 domain was not 
visible for reason of crystallographic disorder and occupied different positions in the 
two structures (Padmanabhan et al, 1993; Brandstetter et al, 1996). That for porcine 
FEXa showed the SP, EGF-2 and EGF-1 domains and most of the Gla domain 
(Brandstetter et al, 1995), but there is a striking bend in its domain arrangement in 
distinction to the linear one seen for FVIIa in its complex with sTF (Banner et al, 
1996). Structures for the EGF-1 domains of human factors IX and X and the Gla domain 
in bovine prothrombin are also available (Selander et al, 1990; Banner et al, 1992; 
Soriano-Garcia et al, 1992). Despite this abundance of homologous atomic structures, 
at the time of this study little information was available on the domain arrangement of 
FVII or FVIIa in solution, nor on that of its complex with sTF, nor on the disposition of 
two large N-linked oligosaccharide chains on FVIIa that were not visible in the crystal 
structure of the complex (Banner et al, 1996).
Solution scattering provides information on domain arrangements in multidomain 
proteins (Perkins, 1994; Perkins et al., 1998a). The usefulness of this technique has been 
much enhanced by the ability to use either intact crystal structures for scattering curve 
fitting (Smith et al., 1990; Perkins et al., 1993; Chapter 6; Ashton et al., 1997) or 
individual domain structures in an automated constrained curve-fit procedure (Mayans 
et al., 1995; Beavil et al., 1995; Boehm et al., 1996), both of which result in an 
improved understanding of the overall structure. Previous X-ray and neutron scattering 
data for FVIIa, sTF and their complex in solution, in the absence of the crystal structure 
correctly predicted the compact nature of the complex between FVIIa and sTF 
determined by crystallography (Chapter 4; Ashton et al., 1995; Bazan, 1996). The 
availability of coordinates for the crystal structures for the FVIIa-sTF complex and for 
the FVIIa-homologue FIXa now makes possible a quantitative analysis of the FVIIa 
domain structure in free solution from scattering data, and likewise that for the FVIIa- 
sTF complex. Knowledge of the domain arrangement of free FVIIa in solution is 
important for an appreciation of how membrane-bound TF is able to recognise FVIIa as 
a ligand. A verification of the domain arrangement in solution of the FVIIa-sTF 
complex provides important confirmation that the crystal structure of the complex is 
representative of the functional cofactor-enzyme complex. It is also possible to analyse
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the conformation of the two large N-linked oligosaccharide chains on FVIIa, which are 
not visible in the crystal structure.
Previous applications of constrained automated scattering curve-fit modelling have 
determined possible structures of multidomain proteins of unknown structure (Mayans 
et al, 1995; Beavil et al., 1995; Boehm et al, 1996) or of homodimeric and 
hbmotrimeric complexes (Ashton et al, 1997; Chamberlain et al, 1997). This approach 
is important in cases where it is not possible to derive even a low-resolution structural 
model for multidomain proteins or their complexes by other methods. The availability 
of the FVIIa-sTF crystal structure enables the extent to which such a procedure can be 
applied successfully to a heterodimeric protein-protein complex to be discussed.
5,2 Methods.
5.2.1 Crystal structures used for direct scattering curve comparisons.
Crystal coordinates for the complex between active site inhibited recombinant human 
FVIIa and subtilisin-cleaved sTF for use in this project were kindly provided by Dr D. 
W. Banner (PDB code 1 dan). The domain residue numbering is shown in Figures 5.1 
and 5.2 (Hagen et al, 1986). Two N-linked oligosaccharides at Asnl45 in the pre-SP 
linker and Asn322 in the SP domain (Figure 5.1) were added as these were not visible in 
the electron density map, using the modelling package INSIGHT II (Biosym/MSI, San 
Diego, USA) on Silicon Graphics INDY Workstations. These were constructed as the 
mean biantennary oligosaccharide structure
(NeuNAc.Gal.GlcNAc.Man)2Man.GlcNAc.GlcNAc(Fuc) in FVIIa (Thim et al., 1988), 
using as a template the nine-residue carbohydrate coordinates of Chain A in the Fc 
fragment of human IgGl KOL (lfcl) (Deisenhofer, 1981). The two O-linked structures 
in FVIIa were represented by Xyl.Glc at Ser52 and Fuc at Ser60, these being the mean 
of previously reported structures (Bjoem et al, 1991; Harris & Spellman, 1993). Both 
O-linked oligosaccharides were modelled from the library of fragments
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Figure 5.2: Alignment of the human FVII amino acid sequence with those in bovine 
prothrombin, porcine FIXa and human factor Xa to show the sequence identity with 
structurally homologous domains in the latter. The (y-carboxyglutamic residues in the 
Gla domain (residues 1-44) are denoted by g, the two N-linked oligosaccharide sites by 
C, and the catalytic triad (His-Asp-Ser) by #. Underlined sequences correspond to the 
homology models used for the linear starting model of FVIIa in Figure 5.5 below. The 
residue numbering refers to the mature amino acid sequence of human FVIIa.
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provided by INSIGHT II. Coordinates for the crystal structure of porcine FIXa (lpfx) 
were adapted to those of human FVIIa by adding two N-linked oligosaccharides at 
Thrl45 and Thr322 and two O-linked oligosaccharides at Pro52 and Leu60 (Figure 5.2; 
FVII sequence numbering) in order to replicate the FVIIa oligosaccharide structures. 
Three sets of human sTF crystal coordinates were used: an initial set for free sTF which 
was later replaced (lboy) (Harlos et al., 1994); a second independent set for free sTF 
(lhft, replaced after refinement by 2hft) (Muller et al, 1994; Muller et al., 1996); and 
those found in the complex with FVIIa (ldan). While three glycosylation sites occur at 
A snll, Asnl24 and Asnl37 in native sTF, these were not modelled here as the 
recombinant sTF used for scattering data was expressed in E. coli (Boys et al., 1993).
5.2.2 Automated scattering curve fit searches for FVIIa and its complex with sTF.
The automated curve fit procedure for the FVIIa domains was based on the 
reconstruction of these domains from available homologous structures which 
corresponds to the general method used for an unknown multidomain structure (Mayans 
et al., 1995; Beavil et al., 1995; Boehm et al., 1996; Ashton et al., 1995). The FVIIa 
residues 1-44 (Figures 5.1 and 5.2) were assigned to the Gla domain in prothrombin 
(code 2pfl) (Soriano-Garcia et al., 1992), residues 45-83 to the EGF-1 domain in factor 
IX (code lixa) (Selander et al., 1990; Baron et al., 1992), and residues 91-142 and 153- 
406 to the EGF-2 and SP domains in factor Xa (code lhcg) (Padmanabhan et al., 1993). 
This starting model included all 406 residues in FVIIa, except for 7 residues in the link 
between the two EGF domains and 10 between the EGF-2 and SP domains. The 
alignment of Figure 5.2 showed that N-linked oligosaccharide chains were positioned at 
Argl42 at the C-terminus of EGF-2 in factor Xa, and at Ile317 in the SP domain in 
factor Xa (FVII sequence numbering) to correspond to their locations in FVIIa.
Since the EGF-2 and SP domains form a fixed structure, the starting model for FVIIa 
curve fits with the X-axis, Y-axis and Z-axis rotations set as 0° (see Figure 5.5) was 
created by positioning the N- and C-terminal a-carbon atoms of the Gla, EGF-1 and 
EGF-2 domains on a long common linear X-axis with arbitrary separations of 0.5 nm 
between adjacent N- and C-terminal a-carbon atoms (see Figure 5.5 below). The origins 
for the rotational searches were defined as the C-terminal a-carbons of Tyr44 (Gla) and
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Leu83 (EGF-1). The three Y-axes were set to be parallel and were defined arbitrarily by 
the a-carbon atoms of Lys3 (Gla), Cys81 (EGF-1), and Gly93 (EGF-2). For automated 
curve-fitting (Mayans et al, 1995, Beavil et al, 1995; Boehm et al, 1996), rotations to 
create models were applied to this starting model using a Biosym Command Language 
(BCL) macro in conjunction with UNIX shell scripts. In this, each of the Gla and EGF-1 
domains were rotated relative to the EGF-2/SP domain pair into all X-, Y- and Z-axis 
orientations, while maintaining a fixed separation between N- and C-termini pairs 
between adjacent domains. The search utilised five 72° steps on each axis to give 56 or
15,625 models.
The curve fit searches for the complex between FVIIa and sTF used the linear starting 
model for FVIIa derived from homology modelling and the sTF crystal structure (Harlos 
et al, 1994). The long X-axis of sTF was defined using the N-terminal a-carbon of Thr3 
as origin, and the C-terminal a-carbon of Glu213. The Y-axis of sTF was defined 
arbitrarily by the a-carbon of Thr86. To initiate the search, the long axis of sTF was 
aligned parallel to the long axis of the Gla, EGF-1 and EGF-2 domains in the linear 
starting model for FVIIa. The starting FVIIa and sTF models were superimposed using 
the sTF and EGF-2 axes in which the common origin was set as the N-terminal a- 
carbon of sTF and the C-terminal a-carbon of EGF-2. Then, holding FVIIa fixed in 
position, sTF was translated from its initial position along the X-, Y- and Z-axes in 
order to generate structures. A total of four 90° reorientations of sTF about its long axis 
relative to FVIIa were examined in four separate searches in order to investigate the 
effect of the 125° angle between the two Fn-III domains in sTF on the outcome of the 
searches. In each search, after an initial translation of sTF of -5 nm on all three axes 
from the common origin, sTF was translated in 0.5 nm steps from -5 nm to +5 nm along 
all three axes to give a full range of 213 or 9,261 models for each of the four sTF 
orientations.
5.2.3 Experimental scattering and analytical ultracentrifugation data.
X-ray scattering data from Stations 2.1 and 8.2 at the Synchrotron Radiation Source, 
Daresbury, and neutron scattering data from the LOQ Instrument at the ISIS facility at 
the Rutherford Appleton Laboratory were obtained for active-site-inhibited FVIIa, sTF
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and the complex between them (Ashton et al, 1995; Chapter 4). The full 
characterization of these samples is described in Ashton et al, (1995), Chapter 4 and 
references cited therein. Solutions of FVIIa and the FVIIa-sTF complex at 0.2-0.8 
mg/ml, prepared as described in Ashton et a l, (1995) and Chapter 4, were analysed 
using a Beckman XLA analytical ultracentrifuge operated at 40,000 r.p.m. (An-Ti 60 
rotor) and equipped with scanning absorption optics at the National Centre for 
Macromolecular Hydrodynamics, Leicester. Traces were measured at 280 nm and 
analysed using a digitising pad to yield experimental s°2o,w values after correction for the 
density and viscosity of the buffer (Ralston, 1993).
5.2.4 Modelling of scattering and analytical ultracentrifugation data.
For the direct comparison of scattering curves with crystal structures (Figures 5.3 and
5.4 below), sphere models were created by placing each full atomic coordinate set in a 
three dimensional grid of cubes of side length 0.370 nm. By varying a cut-off such that a 
sphere was created at the centre of the cube if  a given number of atoms were present in 
the cube, the total volume of the resulting sphere model was set to be equal to the full 
volume calculated for the 433 and 219 amino acid and carbohydrate residues 
respectively in FVIIa and sTF (Perkins, 1986). This procedure corrected for any residues 
that were missing in the crystal structure or altered in homology models based on FIXa 
or on homologous domains. The FVIIa models contained about 1250 spheres (63.0 
nm3), and those for sTF contained about 630 spheres (31.5 nm3).
For the comparison of scattering curves from each of the structures calculated from the 
two automated searches based on homology models (Figures 5.5 and 5.6 below), the 
cube side was increased to 0.452 nm while retaining the same total volume. This 
reduced the computational resources required for each search. The consistent generation 
of the sphere models was achieved by fixing both the origin of the grid and the position 
of the FVIIa model within this grid. The FVIIa model contained 666 spheres and that for 
sTF contained 354 spheres.
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Figure 5.3: Comparison of the calculated and experimental wide-angle scattering curves 
I(Q) for FVIIa and its complex with sTF. The continuous lines represent the curves 
calculated from the crystal structure, while the points correspond to experimental data, 
(a, b) Curve fits for the X-ray and neutron data respectively, based on the FVIIa 
structure seen in the FVIIa-sTF complex, (c) Sphere model and a-carbon views of the 
FVIIa structure in the FVIIa-sTF complex, in which the full oligosaccharide structures 
are shown in bold. (d,e) Curve fits for the X-ray and neutron data respectively based on 
the FVIIa-sTF crystal structure, (f) a-Carbon and sphere model views of the FVIIa-sTF 
structure in the same orientation as that of (c), in which the FVIIa oligosaccharide 
structure is shown in bold outline in the former. The dashed lines shown in (b) and (e) 
correspond to the calculated curves depicted in (a) and (d) to show the effect of the
neutron instrumental corrections. The poor fit between the model curve fits and the 
neutron data at high Q is due to the incoherent scattering from the sample which was not 
modelled.
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Figure 5.4: Scattering curves calculated from the crystal structures of FVIIa and FIXa. 
(a) The scattering curves I(Q) calculated from the SP domain and the light chain in the 
FVIIa model of Figure 5.3(c) are compared with the calculated X-ray scattering curve of 
FVIIa taken from Figure 5.3(a). (b) The distance distribution functions P(r) are shown 
to correspond to the calculated scattering curves of FVIIa and FIXa, with the position of 
two peaks indicated by M.
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The X-ray and neutron scattering curves I(Q) were calculated from the sphere models by 
an application of Debye’s Law adapted to spheres of a single density (Chapter 1; Perkins 
et al, 1998a, Perkins & Weiss, 1983). In neutron curve fits, the hydration shell is not 
detectable and the dry sphere models obtained directly from the grid transformation 
were used for curve fitting. For X-ray curve fits, a hydration of 0.3 g FbO/g of 
glycoprotein and an electrostricted volume of 0.0245 nm /H2O molecule was used to 
readjust the sphere radius and coordinates to allow for the volume of the hydrated 
structure (Smith et al, 1990; Perkins et al, 1993; Ashton et al, 1997). For X-ray fits, no 
scattering curve corrections were applied for wavelength spread or beam divergence as 
these are thought to be negligible. For neutron fits, a 16% wavelength spread for a 
nominal A, of 1 nm and a beam divergence of 0.016 radians were used as an empirical 
correction for the calculated scattering curves (Mayans et al, 1995).
The curve fits were assessed by calculating the radius of gyration Rq and that of its 
cross-section Rxs from Guinier fits of the calculated curve in the same Q ranges used in 
the experimental data analyses (Ashton et al, 1995; Chapter 4). The R-factor goodness- 
of-fit parameter was defined by analogy with crystallography (Smith et al, 1990) for X- 
ray data in the Q range between 0.10 and 2.0 nm'1 and neutron data in the Q range 
between 0.15 and 2.0 nm'1 (denoted as R2 .0), and normalised using an 1(0) value of 
1000. Sedimentation coefficients (s°2o,w values) were calculated directly from the 
hydrated sphere models used for X-ray scattering curve fits using the program GENDLA 
(Perkins et al, 1993; Garcia de la Torre & Bloomfield, 1977a; Garcia de la Torre & 
Bloomfield, 1977b). In the automated searches, the comparison of the calculated and 
experimental curves was achieved by the use of filters to retain or reject models on the 
basis of less than 5% steric overlap between the domains, specified ranges for the 
calculated Rq and Rxs values and s°2o,w values, and low R-factor values (Perkins et al., 
1998a). For FVIIa and the complex, the Rg value of their models was required to be less 
than 3.21 nm and 3.4 nm respectively (Table 5.1).
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Table 5.1: Modelling analyses for factor Vila and the complex between factor Vila and 
soluble tissue factor
Models Rg (nm) Rxs (nm) R2.0 S 20.w
(%) (S)
(a) Factor Vila:
Mean experimental values 3.31 ± 0.08 1.53 ±0.13 - 3.3 ±0.1a
Calculated values using models from crystal structures
FVIIa from FVIIa-sTF (extended CHO) 1 3.46 1.43 7.6,7.9b 3.0
FVIIa from FVIIa-sTF (compact CHO) 1 3.31 1.55 5.7, 6.0b 3.2
FIXa-based (extended CHO) 1 3.21 1.37 6.5, 7.5b 3.3
FIXa-based (compact CHO) 1 3.06 1.49 4.8, 6.7b 3.5
Automated search using homology models (5 H 72° steps about X-, Y-, Z-axes)
Linear starting model 1 3.22 1.30 4.4, 6.8b 3.4
Bent model 1 2.58 1.61 19.3,14.7 3.8
Number of models 15625
Models with < 5% steric overlap 11955 2.90 ±0.19 1.40 ±0.12 5.4 ±2.0 3.6 ±0.12
Models with Rg > 3.15nm 1051 3.20 ±0.03 1.31 ±0.03 4.4 ±0.2 3.4 ±0.03
Models with RG>3.21nm 317 3.24 ±0.02 1.32 ±0.02 4.6 ± 0.2 3.4 ±0.02
(b) FVIIa-sTF Complex:
Mean experimental values 3.22 ± 0.03 1.56 ±0.02 4.4 ±0.3a
Calculated values using models from crystal structure
FVDa-sTF complex (extended CHO) 1 3.57 1.56 8.4, 7.7b 4.3
FVIIa-sTF complex (compact CHO) 1 3.47 1.60 6.5, 6.8b 4.5
Automated search using homology models (21 H 0.5 nm steps along X-, Y-, Z-axes; 4 orientations)
Total number of models 4 x 9261
Orientation 1 (models with 276 3.35 ± 0.04 1.72 ±0.08 6.5 ± 1.2 4.5 ±0.1
< 5% steric overlap; Rg < 3.4 nm)
Best model 1 3.24 1.64 3.8, 8.3b 4.7
a Experimentally determined values (Section 5.2.3).
b The first and second values correspond to the X-ray and neutron R2.0 values respectively
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5.3 Results and Discussion.
5.3.1 Comparison of the solution and crystal structures for FVIIa.
In the absence of a crystal structure for free FVIIa, the solution scattering data for free 
FVIIa in 5 mM Ca2+ were compared with the FVIIa structure found within the crystal 
structure of the FVIIa-sTF complex to determine the degree of agreement between them. 
This FVIIa structure in the sTF-FVIIa crystal complex showed an extended arrangement 
of the Gla, EGF-1 and EGF-2 domains with a tip-to-tip maximum dimension of 11.5 
nm. This is comparable with the length determination of 10.3 nm for FVIIa in solution 
by scattering (Ashton et al., 1995; Chapter 4). The FVIIa crystal structure showed that 
the EGF-2 and SP domains form many contacts with each other and may be considered 
as a rigid entity, and that the link between the Gla and EGF-1 domains is also well 
defined. One less well defined feature is the extended oligopeptide link HKDDQLI 
between the last disulphide bridge of EGF-1 and the first disulphide bridge of EGF-2 
domains (residues 84-90 in Figure 5.2). This forms a poorly defined helix in the crystal 
structure that may be flexible in solution (Figure 5.1). The two large N-linked 
oligosaccharide chains on opposite faces of the SP domain were not visible in the crystal 
structure of the complex, and constitute a second less well defined feature of the FVIIa 
structure. When the scattering curve was calculated for the FVIIa structure seen in the 
crystal structure of the complex with the addition of two extended oligosaccharide 
chains (see Figure 5.5), Rg and Rxs values of 3.46 nm and 1.43 nm respectively were 
obtained that were higher than the experimental values. The X-ray and neutron curve fits 
had goodness-of-fit R2.0 values of 7.6% and 7.9% respectively (Table 5.1). However, if 
the oligosaccharide chains were reorientated more closely to the protein surface of the 
SP domain in this FVIIa structure, Rq and Rxs values of 3.31 nm and 1.55 nm 
respectively were obtained that were in good agreement with the experimental values. 
The X-ray and neutron R2.0 values were better at 5.7% and 6.0% respectively (Table 
5.1a). It was concluded that a FVIIa structure with an extended EGF-l/EGF-2 link and 
compact N-linked oligosaccharides (Figure 5.3c) is consistent with the experimental 
data for free FVIIa in solution.
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Figure 5.5: a-carbon trace views of the sTF and FVIIa domain structures. The linear 
domain structure for FVIIa is the starting model with arbitrary domain orientations that 
was used for the automated searches. The oligosaccharides at Asnl45 and Asn322 are 
shown in extended conformations, in contrast to the more compact conformations 
shown in Figure 5.3. The C-terminal domain of sTF is positioned proximate to the N- 
terminal Gla domain in FVIIa in the complex. Distance constraints based on the 
positions of Lys20, Trp45, Asp58, Tyr94 and Phel40 in sTF are indicated by dotted 
lines that represent the perpendiculars from these a-carbon atoms to the long X-axis of 
the FVIIa model. The mean of the five perpendicular distances is denoted as D in the 
text. The a-carbon positions of the three N-linked oligosaccharides on sTF are indicated 
by • symbols (see text). The X- and Z-axes are as indicated; the Y-axis is perpendicular 
to the page.
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As FVIIa is 90% protein and 10% carbohydrate by weight, scattering inhomogeneity 
effects may be important. The X-ray data correspond to a high positive solute-solvent 
contrast, while the neutron data in 100% H2 O correspond to a high negative solute- 
solvent contrast that inverts the relative contributions of high and low macromolecular 
scattering densities to the observed scattering curve. The similarity of the R2.0 values for 
both the X-ray curve fit (Figure 5.3a) and the neutron curve fit (Figure 5.3b) after 
correction for instrumental effects (see dotted lines in Figure 5.3b) showed that these 
inhomogeneity effects were unimportant.
The four domains of FVIIa are homologous to those found in FIXa. In the crystal 
structure of free porcine FIXa, three of its four domains were clearly visualised. The 
fourth (Gla) domain was partially resolved but could be successfully modelled using the 
prothrombin Gla domain structure (Brandstetter et al, 1995). The FIXa crystal structure 
exhibits a sharp 110° bend between the long axes of the EGF-1 and EGF-2 domains in 
the light chain that is stabilised by a salt bridge unique to FIXa between Glu78 and 
Arg97 in the numbering of Figure 5.2. The oligopeptide linker between EGF-1 and 
EGF-2 in FIXa is four residues shorter than that seen in FVIIa (Figure 5.2). The 
maximum linear dimension of the four FIXa domains is accordingly shorter at 10.5 nm 
than that of 11.5 nm for FVIIa. To test whether this shorter, bent FIXa domain 
arrangement could represent the domain structure of free FVIIa in solution, a scattering 
curve was calculated from this FIXa crystal structure (Section 5.2) for comparison with 
the experimental FVIIa scattering data. If extended oligosaccharide structures were used 
in this model, the resulting Rq and Rxs values of 3.21 nm and 1.37 nm respectively were 
close to the experimental values, and X-ray and neutron R2.0 values of 6.5% and 7.5% 
respectively were obtained (Table 5.1a). When compact oligosaccharide structures were 
used, the resulting Rg value of 3.06 nm was in poorer agreement with the experimental 
value, but better R2.0 values of 4.8% and 6.7% were obtained. The inconsistency of these 
two outcomes, together with visual inspection of the two curve fits (not shown), did not 
favour a bent FEXa-like domain arrangement as a model for the FVIIa domain 
arrangement in solution (Table 5.1a).
Comparative calculations of the scattering curve I(Q) and its distance distribution 
function P(r) from the crystal structures of complexed FVIIa and free FEXa (Figure 5.4)
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showed more clearly that FVIIa in solution contains an extended light chain domain 
arrangement and not a bent one. The experimental X-ray I(Q) for free FVIIa in Figure 
5.3(a) showed a slight inflexion at Q = 0.9 nm'1, which suggested that structurally 
distinct and separated "head" and "tail" moieties existed in free FVIIa. Even though the 
whole FVIIa structure contributes to all parts of the FVIIa I(Q) curve, the calculation of 
I(Q) for the SP domain alone gave a good match to the FVIIa curve between Q of 0.6-
1.3 nm*1 in Figure 5.4(a), while that for the light chain alone in FVIIa gave a good match 
to the FVIIa curve below Q of 0.35 nm*1 in the Q range where the SP curve is relatively 
flat in Figure 5.4(a). This provided an explanation of the inflexion in I(Q) at 
Q = 0.9 nm'1. Similar calculations using the FIXa crystal structure gave neither of these 
matches (not shown), which is attributable to the closer spatial proximity of the SP 
domain to the light chain in this bent structure. More significantly, the P(r) curves from 
the crystal structures of complexed FVIIa and free FIXa showed a large difference 
(Figure 5.4b). That for FVIIa contains a main peak at M of 3.0 nm and a subpeak at 7.0 
nm. That at 3.0 nm is assigned to interatomic distances mostly within the SP domain, 
while that at 7.0 nm is assigned to interatomic distances mostly within an extended light 
chain structure, the second of which has 31% of the height of the main peak. The 
calculated curve was in excellent agreement with the experimental P(r) curve of free 
FVIIa which shows two peaks at 3.0 and 7.0 nm, the second of which has a peak height 
of 32% of the first (see Figure 4.3 in Chapter 4). In contrast, the P(r) curve for FIXa 
contained only a main peak at 3.0 nm (Figure 5.4b). This is attributable to the proximity 
of the SP domain and light chain in the bent FIXa structure. Thus, the difference 
between the two P(r) curves rule out a significantly bent light chain domain structure for 
free FVIIa in solution.
5.3.2 Automated modelling curve fitting for the FVIIa domains.
Solution scattering does not yield unique structures but only compatible ones. Since the 
above results for FVIIa were based on comparisons with only two crystal structures, 
supplementary curve fits were needed in order to establish a more general structural 
description for FVIIa. Thus an automated curve fit analysis was performed to assess all 
possible domain arrangements (Section 5.2.2). A linear starting model that corresponded
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to the most extended domain arrangement positioned the long axes of the Gla, EGF-1 
and EGF-2 domains on a common long axis, included a short linker between the EGF-1 
and EGF-2 domains, and possessed extended oligosaccharide structures. Since the 
FVIIa-sTF crystal structure was unavailable at the time the search was performed, this 
starting model was constructed from homologous domains found in prothrombin, FIXa 
and factor Xa (Section 5.2.2; Figure 5.5). This model had a length of 11.0 nm, and gave 
an acceptable curve fit to the experimental X-ray data. The Rg and Rxs values were low 
at 3.22 nm and 1.30 nm, but good X-ray and neutron goodness-of-fit R2.0 values of 4.4% 
and 6.8% were obtained. In contrast, a bent domain model in which the EGF-1 and Gla 
domains were both rotated by 72° about the Y-axis in the X-Z plane of Figure 5.5 gave 
very poor curve fits with R2.0 values of 19.3% and 14.7%.
This linear starting FVIIa model was used for an automated curve-fit search based on
15,625 possible domain arrangements, which were evaluated using fits to the 
experimental X-ray curve. The application of a steric overlap filter left 11,955 models 
(Table 5.1a). Of these models, only 1,051 had Rg values greater that 3.15 nm, and 317 
had Rg values greater than 3.21 nm. These 317 models (which included the starting 
linear model) had individual X-, Y- and Z-axis rotations that were distributed over all 
values without preference for specific ranges, and gave good agreement with the 
experimental X-ray data. In conclusion, the search showed that only the most extended 
domain arrangements in free FVIIa were compatible with the experimental X-ray curve. 
These correspond not only to the extended FVIIa structure seen in the FVIIa-sTF crystal 
structure, but also to other structures that may be in equilibrium with this, provided that 
all these other structures are extended. In addition, this search did not rule out the 
presence of a short linker structure between EGF-1 and EGF-2 in free FVIIa, which 
becomes more elongated after forming a complex with sTF to give the FVIIa structure 
seen in the FVIIa-sTF complex.
5.3.3 Comparison of the crystal and solution structures for the FVIIa-sTF complex
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In order to see whether the crystal structure of inhibited FVIIa and subtilisin-cleaved 
sTF (Banner et al, 1996) is compatible with the solution structure of the FVIIa-sTF 
complex, the scattering curve calculated from the crystal structure was compared with 
the experimental scattering curves for the complex formed between intact sTF and 
inhibited FVIIa in Figures 5.3(d) and 5.3(e). The same extended and compact N-linked 
oligosaccharide structures used above for free FVIIa were used in order to permit direct 
comparison with the FVIIa curve fits. Small curve fit differences for the complex were 
seen between the two oligosaccharide conformations, and the compact one again gave a 
better curve fit (Figure 5.3f). The experimental Rg values of free FVIIa and the FVIIa- 
sTF complex are similar within experimental error (Table 5.1), and this was attributed to 
the compact nature of the interaction made between FVIIa and sTF in their complex 
(Ashton et al, 1995; Chapter 4). In the present modelling, the calculated Rg value for 
the complex was larger by 0.25 nm than the experimental value, however satisfactory X- 
ray and neutron R2 .0 values of 6.5-6.8% were obtained, and this supported the similarity 
of the crystal and solution structures of the complex (Table 5.1b). The difference in Rg 
values may be attributed to the less extensive data collection for the complex compared 
to FVIIa in Ashton et al, (1995) and Chapter 4. It was concluded that the curve fits of 
Figures 5.3(d) and 5.3(e) ruled out the possibility of a major domain rearrangement 
between the crystal and solution states.
5.3.4 Automated modelling curve fitting for the FVIIa-sTF complex.
The feasibility of an automated curve-fit search to determine candidate models for a 
multidomain heterodimeric protein complex is important for the study of other such 
systems. This was therefore examined using the FVIIa-sTF complex as a model system, 
since these candidate models can be compared with the recently solved crystal structure 
for this complex. Such a search assumes that major structural rearrangements in the two 
associating multidomain structures between the free and bound states are absent. For 
sTF, supporting evidence for this was obtained by the comparison of scattering curves 
calculated for free and complexed sTF crystal structures, which gave good R2.0 values of 
2.3-3.5%. Comparisons of the calculated Rg values of 2.34-2.49 nm with the
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experimental value of 2.06 ±0.12 nm (Ashton et al., 1995; Chapter 4) showed that these 
were larger by 0.28-0.43 nm. This Rg difference is attributed to the small size of sTF 
and the less extensive data collection for sTF compared to FVIIa in the earlier study 
(Ashton et al., 1995; Chapter 4), and is not considered significant in the present context. 
For FVIIa, only extended domain arrangements in the free and complexed forms were 
determined from the above analyses, and the extended linear FVIIa structure of Figure
5.5 was therefore reused here.
A comprehensive search for all sterically allowed structures of sTF relative to FVIIa in 
the complex would involve six rotational and translational parameters. Their full 
treatment would result in too many models to analyse with present computational 
resources. Previously, automated curve-fit searches for two homo-oligomeric complexes 
were constrained by symmetry and this significantly reduced the number of models to be 
tested (Perkins et al, 1998a; Ashton et al., 1997; Chamberlain et al., 1997). As 
symmetry constraints were not available for a heterodimeric complex, a biochemical 
constraint was used instead. It is known that the C-terminal domain of sTF is close to 
the Gla domain of FVIIa, since the EGF-1 and Gla domains interact with sTF (Kazama 
et al., 1993), and both the C-terminal domain of sTF and the Ca2+-rich Gla domain are 
proximal to the negatively-charged cell membrane in the membrane-bound complex. 
This constraint fixed the position of sTF so that the C-terminus of sTF was close to the 
Gla domain (shown in Figures 5.1 and 5.5). Accordingly only translational searches of 
sTF in this orientation relative to FVIIa were performed and this restricted the number 
of models to be tested to 9,261. Three further searches were also made with the sTF 
structure rotated in 90° steps about its longest axis.
Analysis of the conformational searches identified 276 possible structures for the 
complex in the search based on the sTF orientation shown in Figure 5.5, where 97% of 
the 9,261 possible models had been eliminated by the use of steric overlap and Rg 
filters. The two filters eliminated models that were too compact or too elongated 
respectively. The 276 structures included those related to the known crystal structure of 
the complex. At this point, further biochemical constraints were found to be useful. This 
is detailed as follows:
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(i) Projection views of these 276 models (Figure 5.6) showed that a sufficiently large 
translational range had been scanned. Both the Rg and Rxs values of the 276 models 
agreed with experiment, and gave low R2 .0 values between 3.8%-9.4%. Similar results 
were obtained in the other three searches using the different sTF orientations about its 
long axis (not shown). The 276 locations of sTF relative to FVIIa in the ZX (and YX) 
projection covered a large area on the longest X-axis of FVIIa. The ZY projection shows 
that the 276 locations correspond to an annulus that surround the three small Gla and 
EGF domains or the large SP domain. Analysis of all four 90° orientations of sTF about 
its longest axis (not shown) showed that the greatest uncertainty in the position of these 
filtered models was along the X-axis (range of 5 nm), followed by the Z-axis (range of 4 
nm), then the Y-axis translation (range of 2 nm).
(ii) Surface plasmon resonance analyses of mutants has shown that the sTF residues 
Lys20, Trp45, Asp58, Tyr94 and Phel40 (Figure 5.5) are important for binding to the 
Gla and EGF domains in FVIIa (Kelley et al., 1995; Martin et al., 1995). The 
biochemical constraint based on this was used to divide the 276 models into two sets. 
The mean value D of the perpendicular distances between these five a-carbon atoms in 
sTF and the X-axis of FVIIa (Figure 5.5) was 3.0 ± 1.1 nm for all 276 models. The 92 
models with D less than 2.5 nm (highlighted as • in Figure 5.6) correspond to an 
annulus of sTF locations surrounding the Gla and EGF domains in the ZY projection. 
The ZX projection showed that the 92 highlighted locations covered the long axis of the 
EGF and Gla domains.
(iii) The best X-ray fit model (A) had X-, Y- and Z-translations of sTF by 2.0 nm, 1.5 
nm and 0.5 nm respectively from the origin, with a separation between the centres of 
mass of 2.6 nm (Table 5.1b; Figure 5.6), and gave an R2 .0 value of 3.8%. This model 
and others were located in the +Z/+Y quadrant in the ZY projection. This quadrant 
corresponds to the large space contained between the SP domain and the light chain.
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Figure 5.6: Two projection views of the outcome of the automated search for the FVIIa- 
sTF complex. The ZX and ZY projection views summarise the distribution of 276 sTF 
structures relative to the FVIIa model after the exclusion of models with large steric 
overlap or large Rg values. The ZX projection is shown also in Figure 5.5. Below each 
grid, outlines of the FVIIa and sTF domains are shown in the same scale to show the 
best-fit structure for the complex, denoted by the A symbol in the grid. The + symbol on 
FVIIa denotes the origin of the grid, and the + symbol on sTF (dotted outline) denotes 
its N-terminus. Note that the separation between the two + symbols matches the 
separation of the origin of the grid and the A symbol in the grid. The O and • symbols 
in the grid denote the position of the N-terminus of sTF in the 276 models of the 
complex. O denotes 184 complex models with D values greater than 2.5 nm, while • 
denotes 92 complex models with D less than 2.5 nm that satisfy the biochemical 
constraint of Figure 5.5 (see text). The V symbol denotes the worst fit model from the 
276 models. Also shown is an a-carbon view of the crystal structure of the FVIIa-sTF 
complex in the same orientation and scale as the domain outline, with sTF shown in 
bold.
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Comparison of the domain outlines in Figure 5.6 with molecular graphic views of the 
crystal structure of the complex provided a striking confirmation of the layout of FVIIa 
and sTF in this best fit structure (Figure 5.6). The rotational orientations of the FVIIa 
domains and sTF about their long axes were however distinctly different in the crystal 
structure compared to Figure 5.5, and could not be identified in this search. The worst 
X-ray fit model (V) and others were located in the -Z/-Y quadrant in the ZY projection, 
in which sTF is now on the opposite face of FVIIa.
(iv) Two final checks were performed on the best-fit model from the search (Figure 5.6). 
The occupancy of the three Asn glycosylation sites in native tissue factor would hinder 
protein-protein interactions with FVIIa, and their location acts as a biochemical 
constraint that defined disallowed models. In Figure 5.5, Asnl24 and Asnl37 are on the 
right side of sTF, while Asnl 1 is on the left, and define possible surface areas of sTF 
that do not interact with FVIIa. This was sterically consistent with the best-fit model 
from the search shown in Figure 5.5. This best fit model was supported also by the 276 
corresponding neutron curve fits, where the best model had R2 .0  = 8.3% and the worst 
one had R2 .0 = 10.3%.
5.3.5 Sedimentation coefficient analyses for FVIIa and its complex with sTF.
The modelling of sedimentation coefficient data from analytical ultracentrifugation 
provides an alternative determination of the dimensions of FVIIa and the FVIIa-sTF 
complex. Previously, using models based on hydrodynamic ellipsoids, the Perrin 
equations resulted in molecular dimensions for FVIIa of 20.4 nm x 2.8 nm x 2.8 nm at 
one limit and 12.6 nm x 9.8 nm x 1.4 nm at the other (Waxman et al, 1993). Those for 
the FVIIa-sTF complex were 25.4 nm x 2.6 nm x 2.6 nm at one limit, and 18.6 nm x 7.8 
nm x 1.2 nm at the other. Since X-ray and neutron scattering showed that both FVIIa 
and the FVIIa-sTF complex had lengths of 10.2-10.3 nm, and the crystal structure for 
the FVIIa-sTF complex is 11.5 nm long with a diameter of 4.0-5.0 nm, the lengths from 
scattering are seen to be in better agreement with the FVIIa-sTF crystal structure than 
those from the Perrin equations. This discrepancy is now explored.
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Hydrodynamic modelling was performed to assess the use of sedimentation coefficients 
s°2o,w to analyse these structures. Firstly, remeasurement of the experimental s°2o,w values 
for FVIIa and the FVIIa-sTF complex gave values of 3.3 ± 0.1 S and 4.4 ± 0.3 S 
respectively from sedimentation velocity runs using a Beckman XLA ultracentrifuge 
(Section 5.2.3). While the first value is in good agreement with that of 3.4 ± 0.1 S 
reported previously using a Beckman Model E ultracentrifuge (Waxman et al, 1993), 
the second value is higher than that of 3.9 ± 0.1 S determined previously. Secondly, 
using small spheres, the theoretical s°2o,w values were calculated from the 
crystallographic models and the automated search models for comparison with 
experiment (Table 5.1). In agreement with the scattering modelling, the s°2o,w calculation 
for the FVIIa model derived from the crystal structure of the complex was in better 
agreement with experiment if  the oligosaccharides were in a compact conformation 
(Table 5.1a). Likewise the 317 best-fit FVIIa scattering models from the automated 
search gave good agreement with experiment (Table 5.1a). These showed that the use of 
small spheres was successful in accounting for the experimental s°2o,w value of 3.3 ± 0.1 
S. However, unlike the scattering analyses, the s°2o,w calculation could not exclude the 
bent FVIIa model derived from FIXa (Table 5.1a). In the case of the FVIIa-sTF 
complex, good agreement was also found with the crystal structure which gave 
calculated s°2o,w values of 4.3-4.5 S in good agreement with the experimental value of
4.4 ± 0.3 S (Table 5.1b). The 276 best-fit scattering models gave a calculated mean 
value of 4.5 ±0.1 S. It is concluded that the scattering and hydrodynamic calculations 
were consistent with each other, and that the earlier measurement of s°2o)W for the 
complex had been underestimated.
5.4 Conclusions.
5.4.1 Structures of FVIIa and FVIIa-sTF.
Solution scattering has provided new information on the domain arrangements in FVIIa 
and the FVIIa-sTF complex that usefully extends the interpretation of recent crystal 
structures for coagulation factors, both when free and when complexed. Multidomain 
structures cannot be solved unambiguously by scattering analyses, but the knowledge of
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these crystal structures now places limits on the scattering analyses and makes them 
more powerful in the analysis of unknown multidomain structures (Perkins et al, 1998).
In application to FVIIa, previous scattering studies had indicated that the FVIIa domains 
were extended (Ashton et a l, 1995; Chapter 4). Here, the direct comparison of 
scattering data for free FVIIa in solution with the extended FVIIa structure in the recent 
crystal structure of the FVIIa-sTF complex shows that they are consistent. In addition, 
several new curve fit analyses rule out a bent light chain structure for FVIIa such as seen 
in the crystal structure of the homologous coagulation factor FIXa. In FIXa, the bend in 
this structure occurs at the short EGF-1/EGF-2 link and is attributed to a Glu-Arg 
interdomain salt bridge that is conserved in FEXa but not in either FVIIa or factor Xa. In 
FVIIa, this link is longer and is seen as a short poorly formed helix in the FVIIa-sTF 
crystal structure to suggest that this may be somewhat flexible and extended in solution, 
which would be consistent with the new curve fits presented here. Fluorescence 
experiments with labelled FVIIa have suggested that free FVIIa is more flexible than in 
the complex with sTF (Waxman et a l, 1993). This link is also likely to be flexible in 
factor Xa as this link is longer than that of FIXa, and EGF-2 but not EGF-1 was 
observed in the crystal structure of des-Gla factor Xa (Paddmanaban et al., 1993). In a 
second crystal form of des-Gla factor Xa, the EGF-1 domain is in a different location 
relative to the SP and EGF-2 domains (Brandstetter et al, 1996). In addition, the NMR 
structure of the Gla/EGF-1 domain pair in factor X suggests that there is flexibility 
between these two domains as well (Sunnerhagen et al, 1995). These observations 
imply that multiple related FVIIa conformations of similar energies may coexist in 
solution. The significance of the present automated FVIIa curve fit analyses is to show 
that all these extended structures will be similar in overall length, and ideal for the 
recognition of tissue factor. There would be no significant energy price to be paid in 
terms of domain reorientation during complex formation, and this together with the 
extensive dispersion of contact residues across the four FVIIa domains would account 
for the low nanomolar Kd reported for the interaction.
Subsequent to the study reported here, a number of uncomplexed FVII and active site 
inhibited FVIIa crystal structures have become available (Table 5.2; Kemball-Cook et 
al, 1999; Pike et al, 1999; Eigenbrot et al, 2001). Despite these significant advances in
121
the structural studies of FVIIa and its zymogen precursor these structural studies have 
not been able to produce a complete model of unbound FVII or FVIIa either with or 
without the oligosaccharides (Table 5.2; Kemball-Cook et al, 1999; Pike et al, 1999; 
Eigenbrot et al, 2001). This further substantiates the findings from these solution 
scattering studies that both the EGF1 and Gla domains are flexible regions and are likely 
to take many conformations whilst in solution. The recent structure of the zymogen FVII 
(Eigenbrot et al, 2001) has shown how a small conformational difference between the 
SP domain of FVII and that of FVIIa could contribute to the activation of FVIIa on 
complexing with sTF (for a recent review see Eigenbrot & Kirchhofer, 2002). Such a 
small realignment of the p-sheets would not have been seen in SAXS and SANS studies.
In application to the FVIIa-sTF complex, the scattering data showed that a compact 
complex of FVIIa with sTF was formed (Ashton et al, 1995; Chapter 4). The present 
scattering analysis was important to verify the similarity of its domain structure in 
solution with that in the crystal structure, despite the removal of the sTF residues 85-89 
in the crystal structure and the existence of packing contacts in the crystal state. It is 
generally thought that the tight interaction of the Gla, EGF-1, EGF-2 and SP domains in 
FVIIa with the domain pair in sTF locks the flexible FVIIa structure into a more rigid 
conformation. This would stabilise an active conformation and/or a reorientation of the 
enzymatic SP domain in FVIIa that would lead to its activation and the initiation of 
blood coagulation (Martin et al, 1995; Bazan, 1996). Data from a fluorescence energy 
transfer study suggest that this may well be the case (McCallum et al, 1996).
Solution scattering also provided information on the two N-linked oligosaccharide 
structures of FVIIa not seen in any other available structure (Table 5.2). Since these lie 
on the outer periphery of FVIIa, scattering data are sensitive to their conformation. The 
FVIIa curve fits suggest that these oligosaccharides are not as extended as found in 
several other glycoproteins by similar scattering analyses (Ashton et al, 1997; Boehm et 
al, 1996), and the same result was obtained with the FVIIa-sTF curve fits. Their 
conformations shown in Figures 5.3(c) and 5.5 suggest that two sides of the SP domain 
are masked, while leaving accessible the catalytic triad at Hisl93-Asp242-Ser344 at the
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Table 5.2: Summary of the known FVII and FVIIa structures.
FVIIa
(from complex)
FVIIa solution
model
FVIIa
FVIIa
FVII
Author
Banner etal., 1996
A sh tons al., 1998
Kemball-Cook et al, 1999 
Pike et al, 1999 
Eigenbrot et al, 2001
Completeness of FVII/FVIIa 
SP-EGF2-EGF1 -Gla
SP-EGF2-EGFl-Gla +
Oligosaccharides
SP-EGF2
SP-EGF2-EGF1
SP-EGF2
PDB code 
1DAN
N/A
1CVW
1QFK
1JBU
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top of the structure as viewed in Figure 5.3(f), as well as its contact region with sTF 
between the SP domain and the FVIIa light chain. The O-linked oligosaccharides on the 
EGF-1 domain likewise do not mask the contact surface of FVIIa. Inspection of the sTF 
structure in its complex shows that the N-linked oligosaccharides of sTF also do not 
hinder the contact region of sTF with FVIIa.
5.4,2 Automated modelling of heterodimeric complexes bv scattering and 
ultracentrifugation.
The novelty of the present curve-fit modelling lies in its application to a heterodimeric 
complex formed between two multidomain proteins (Perkins et al, 1998a). The joint 
use of both X-ray and neutron scattering curve fits together with analytical 
ultracentrifugation data serves as controls for reproducibility and possible solute-solvent 
contrast effects. Previous curve-fit applications have described its calibration for 
proteins of known crystal structures and molecular weights between 23,000-125,000 
(Smith et al, 1990; Perkins et al, 1993; Ashton et al, 1997), and its application to 
single multidomain proteins and homodimeric and homotrimeric complexes (Mayans et 
al, 1995; Beavil et al, 1995; Boehm et al, 1996; Ashton et al, 1995). In the present 
application, as in those previous ones, suitable homologous atomic structures are 
essential to constrain the curve fit analyses. These may be available either directly by 
high sequence similarity with known atomic structures (homology modelling), or 
indirectly by protein fold recognition methods and analogy modelling (Bazan, 1990; 
Edwards & Perkins, 1996). For single multidomain proteins, further constraints are 
imposed by use of the correct stereochemical connections between the domains, in order 
that the curve fits are directed towards determination of the domain arrangement. For 
homo-oligomeric complexes, further constraints are imposed through known symmetry 
relationships, in order that the curve fits can assess the arrangement of the monomers 
within the oligomer. The present analysis of a heterodimeric complex however lacks 
symmetry constraints. After constraining the search based on the inferred relative 
orientation of the two proteins in the complex, the use of steric overlap and Rq filters 
still left many allowed structures. However, in the search based on Figure 5.5, the use of 
further biochemical constraints based on identified contact residues between the two 
proteins (together with the known location of glycosylation sites which would be
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excluded from the protein-protein interface) permitted the location of sTF in the space 
between the SP domain and the light chain, in agreement with the crystal structure of the 
complex. This approach usefully narrowed the range of possible structures for the 
complex. Thus, in the absence of a crystal structure, it is envisaged that the automated 
modelling technique with the application of biochemical constraints, together with the 
use of electrostatic and surface docking methods, will result in improvements in 
structure determinations for other heterodimeric complexes such as ligand-receptor 
pairs.
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CHAPTER 6
Pentameric and Decameric Structures in Solution of 
Serum Amyloid P Component by X-rav and Neutron Scattering 
and Molecular Modelling Analyses.
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6,1 Introduction
Human serum amyloid P component (SAP) is a plasma glycoprotein composed of 
identical subunits that are non-covalently associated in a disc-like pentameric 
configuration with cyclic symmetry (Pepys et a l,  1997; Chapter 3; Figure 6.1). In the 
presence of Ca2+, SAP rapidly aggregates and precipitates, but in the absence of Ca2+ or 
in the presence of EDTA it forms a very stable decameric structure composed of two 
pentameric discs interacting face-to-face. The closely related molecule C-reactive 
protein (CRP) (Figure 3.2; Figure 6.2), the other member of the human pentraxin family, 
is composed of a single pentameric ring that is stable in Ca2+ and does not form 
decamers. SAP binds to all forms of amyloid fibril in vitro (Pepys et a l , 1979) and is 
universally present in amyloid deposits including the cerebral amyloid of Alzheimer's 
disease (Coria et a l , 1988). The binding of SAP to amyloid fibrils in vitro protects them 
from proteolysis (Tennent et a l , 1995). SAP binds also to sulphated 
glycosaminoglycans and is the major DNA- and chromatin-binding protein in plasma. 
Closely associated pairs of SAP molecules bind to fibronectin and C4-binding protein. 
Calcium is required for these binding interactions to take place (Pepys et a l , 1997). In 
addition SAP is a calcium-dependent lectin, and its interaction with methyl 4 ,6-0(1- 
carboxyethylidene)-p-D-galactopyranoside (MOpDG) is well characterized (Hind et a l , 
1984).
Neutron scattering showed that the use of a crystallisation buffer at pH 5.5 in the 
presence of calcium unexpectedly yielded a pentameric structure for SAP (SAP-5) 
(Wood et a l , 1988). The atomic structure showed that each SAP subunit has a tertiary 
structure with two antiparallel P-sheets that is similar to the legume lectins such as 
concanavalin A and pea lectin, together with two a-helices (Emsley et a l , 1994). An 
oligosaccharide chain is located at Asn32 on the a-helix face (A-face for "a-helix") of 
the SAP pentamer opposite to the face containing the calcium binding residues in SAP 
(B-face for "binding", see Figure 6.1). The oligosaccharide is homogeneous and is of the 
biantennary complex-type class (Hamazaki, 1990; Pepys et a l , 1994). There is little
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Ca2+
Figure 6.1: Diagrammatic representations of 
SAP pentameric structure.
^  I
Top: each pentamer has two Ca bound to the 
B face and shown as two white spheres. 
Middle: a side view of the pentamer.
Bottom: The main a-helix of the A face is 
clearly visible in orange.
Figure produced with MOLSCRIPT (Kraulis, 
1991).
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Figure 6.2: Sequence alignment of SAP (PDB code lsac) and CRP (PDB code lgnh). 
Residues inserted relative to SAP e.g. serine and threonine in CRP between residues 44 
and 45 are identified as Ser44A and Thr44B (Srinivasan et al. 1994).
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precedent among glycoproteins for the single invariant glycoform of SAP, and its 
existence may be important for function. Since SAP-10 displays maximal calcium- 
dependent ligand binding and is susceptible to proteolysis in the absence of calcium 
(Pepys & Baltz, 1983; Kinoshita et al., 1992), it is likely that the A-face forms the 
pentamer-pentamer interaction in SAP-10. However, the crystal structure of a dAMP 
nucleotide complex with SAP shows a decameric structure in which the dAMP ligand is 
enclosed between two B-faces (Hohenester et al., 1997). Further evidence for the A-to- 
A face interaction in the decamer is therefore required. In addition, while the 
oligosaccharide chains are positioned on the outer edge of the A-face of SAP, there is 
little information on their conformation in SAP.
X-ray and neutron solution scattering is a powerful means of investigating domain 
structures in multidomain proteins (Perkins, 1988, 1994). Typically such proteins are 
too glycosylated or flexible to be crystallised intact, however atomic structures are often 
available for individual domains within the protein. Scattering curve modelling 
constrained by these known atomic structures and their connection provides a method to 
determine the overall domain structure and its possible functional significance. This 
requires protocols for scattering curve calculations starting from atomic co-ordinates. 
Previous tests based on (3-trypsin and 0 Ci-antitrypsin corresponded to structures with 
molecular weights of 23,000 and 52,000 (Smith et al., 1990; Perkins et a l, 1993). 
However many interesting multidomain proteins have higher molecular weights from
100,000 upwards. Since the rigid ring structure of SAP-5 removes the motional freedom 
between its subunits, SAP provides a good opportunity to test curve-fitting protocols. 
Here, using experimental X-ray and neutron data, we show that our previously-described 
procedure is able to account for the scattering curve of SAP-5 calculated from its crystal 
structure. This protocol was then used to analyse the solution structure of SAP-10 for 
which no crystal structure is yet available. It is shown here that the scattering analyses 
favour a SAP decameric structure formed by the interaction of the two A-faces.
Solution scattering is also able to investigate carbohydrate structures in glycoproteins 
(Perkins, 1988; Perkins 1994). In general, X-ray scattering in high positive solute- 
solvent contrasts is more sensitive to the carbohydrate structure relative to that of 
protein, while neutron scattering in high negative solute-solvent contrasts using H2 O
130
buffers is less sensitive to carbohydrate and acts as a control of the X-ray data. Thus 
extended or compact carbohydrate conformations could be identified in oti-acid 
glycoprotein (44% carbohydrate), Cl inhibitor of complement (26% carbohydrate) and 
carcinoembryonic antigen (50% carbohydrate) (Perkins et al., 1985,1990; Boehm et a l , 
1996). Even though SAP is only 9% carbohydrate by weight, the location of five 
glycosylation sites on the outer circumference of SAP will have a maximal effect on its 
scattering curves, and we present an analysis of carbohydrate conformations in SAP.
6.2 Methods
6.2.1 Purification of SAP for solution scattering
All SAP and CRP samples for these experiments were kindly provided by Professor 
M.B.Pepys and his colleagues. A description of their preparation is included here for 
completeness.
SAP was isolated by Ca2+-dependent phosphoethanolamine Sepharose affinity 
chromatography from the serum of healthy blood donors contributing to the National 
Blood Transfusion Service or from human pooled ascites and pleural effusion fluids 
(Pontet et a l , 1978; De Beer & Pepys, 1982; Hawkins et al., 1991). SAP was 
concentrated in an Amicon pressure cell and purified by gel filtration as a single peak to 
give concentrations of up to 15 mg/ml. The best-determined absorption coefficient of 
SAP (1%, 1 cm, 280 nm) is 17.1 and was used throughout this study (Nelson et al., 
1991). This value is slightly reduced compared to a value of 17.8 calculated from the 
204 amino acid and 11 carbohydrate residues per subunit (sequence accession codes 
SAMP_HUMAN, P02743; Pepys et a l , 1994; Perkins, 1986) or to the occasionally- 
accepted value of 18.2 (Haupt et a l, 1972). SAP samples were stored at 4°C and used 
within a few days for scattering experiments. For X-ray scattering and neutron scattering 
in H2 O buffers and neutron scattering in 2H20 buffers, samples were dialysed for 36 h 
with four buffer changes at 4°C. SAP-10 in the decameric conformation studied here 
was obtained by dialysis into seven buffers as summarised in Table 6.1(a). Pentameric 
SAP-5 was obtained by dialysis into six buffers as summarised in Table 6.1(b).
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Table 6.1: Buffer concentrations for SAP-10 and SAP-5 scattering experiments.
a) Buffer concentrations for SAP decamer scattering experiments.
Buffer Na, K phosphate 
(mM)
EDTA
(mM)
NaCl
(mM)
Tris
(mM)
NaN3 Na acetate 
(mM)
PH
A 20 10 130 - 6
B 20 10 130 - - - 7
C - 10 140 10 0.1 % - 8
D - 10 250 - - 20 5.5
E - 10 500 - - 20 5.5
F - 10 750 - - 20 5.5
G - - 64 - 0.1% 230 5.5
b) Buffer concentrations for SAP pentamer scattering experiments.
Buffer MopDG1
(mM)
EDTA
(mM)
NaCl
(mM)
Tris
(mM)
NaN3
(mM)
Na acetate 
(mM)
Ca acetate 
(mM)
CaCl2
(mM)
pH
H2 - 4.5 64 4.5 6.8 250 45 - 5.5
I - - 500 - - 20 - 20 5.5
J - - 750 - - 20 - 20 5.5
K 1.3 - - 100 0.1 % 140 - 60 6
L 1.3 - - 100 0.1 % 140 - 60 7
M 1.3 - - 100 0.1 % 140 - 60 8
Footnotes:
1 methyl 4,6-0-(l-carboxyethylidene)- (3-D-galactopyranoside
2 Crystallisation Buffer (Wood et al., 1988)
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6.2.2 X-rav and neutron scattering data collection for SAP
X-ray scattering curves were obtained in two beam sessions using a camera with a linear 
detector at Station 7.3 at the Synchrotron Radiation Source, Daresbury (Nave et a l, 
1986). Sample-detector distances of 2.21 m or 2.69 m resulted in usable Q ranges of 
0.07 to 1.30 nm'1 and 0.09-0.85 nm'1 (Q = 4tc sin 0/A,; scattering angle = 20; wavelength 
= X). Data acquisition times for samples of thickness 1 mm enclosed in mica windows 
were 10 min, obtained as a single time-frame, with samples and buffers measured in 
alternation to minimise background subtraction errors. The detector was calibrated using 
fresh, wet rat tail collagen. Sample temperatures were 10°C. Two further X-ray beam 
sessions utilised a camera with a quadrant detector at Station 2.1 (Towns-Andrews et 
a l , 1989; Worgan et a l , 1990). Sample-detector distances of 3.14m or 3.17m resulted 
in a usable Q range of 0.10 to 2.0 nm'1. Data acquisition times were also 10 min, now 
obtained as 10 time frames of 1 min each to confirm the absence of radiation damage 
effects by their comparison. Sample temperatures were 15°C. Curves were normalised 
based on an ion chamber positioned between the sample and the detector, and detector 
responses were measured using a uniform 55Fe radioactive source. Buffer curves were 
subtracted from sample curves using the SWANAL (Station 7.3) or OTOKO (Station 
2.1) software packages, and normalised using the detector response (Nave et al., 1986; 
Boulin etal., 1986).
Neutron scattering data were obtained in four sessions on Instrument D17 at the Institut 
Laue-Langevin, Grenoble, which is analogous in construction to Instrument D ll. 
Sample-detector distances of 1.40 m and 3.46 m with a main beam-detector angle of 0° 
and 20° were used. The wavelength X was usually set as 1.10 nm, but sometimes was
1.00 nm, 1.20 nm or 1.39 nm. The three detector settings resulted in three subcurves 
with a maximally usable Q range of 0.08 to 3.3 nm'1. Data acquisition times were 
typically 10 min in 2H20 buffers and 60 min in H2O buffers. Samples were measured at 
20°C in rectangular quartz cells of thickness 2 mm for 2H20 samples and 1 mm for H2O 
samples. Absorbances at 280 nm to determine SAP concentrations were measured using 
these cells. The increased flux on Instrument D ll (Lindley et al., 1992) was better 
suited for data collection in H2O buffers, and D ll used sample-detector distances of
2.00 m and 5.00 m with the collimation set at 2.5 m and 5.5 m respectively. The
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wavelength X of 1.00 nm gave a usable Q range of 0.06 to 1.1 nm'1. Data acquisition 
times were 5-10 min in 2H20 buffers and 30-45 min in H2O buffers at 15°C. Data were 
processed using RNILS, SPOLLY, RGUIM and RPLOT (Ghosh, 1989). The D17 and 
D ll data were corrected for a cadmium background, then the buffer curve was 
subtracted from the sample curve, and the result was normalized using the incoherent 
scattering from a 1 mm H2 O sample after correction using an empty cell background.
Neutron scattering data were also obtained in one session on the LOQ instrument at the 
pulsed neutron source ISIS at the Rutherford Appleton Laboratory, Didcot, U.K. 
(Heenan & King, 1993), using a neutron beam from a tantalum target (proton current 
170 pA). The fixed sample-detector distance of 4.3 m gave a usable Q range of 0.07 to 
1.9 nm'1. Samples and buffers were measured for 1 h for 4 x 106 monitor counts in 2 
mm thick cells at 15°C. Intensities were normalised relative to a partially deuterated 
polystyrene standard (Wignall & Bates, 1987). Data were reduced using COLETTE 
(Heenan et al., 1989) where the intensities were binned based on wavelengths of 0.22-
1.00 nm, and corrected for a linear wavelength dependence of the transmission. The Q 
range was calculated in 0.04% logarithmic increments which were optimal for both the 
Guinier analyses at low Q values, and better signal-to-noise ratios at large Q.
6.2.3 G uinier and distance distribution function analyses of reduced scattering 
data
In a given solute-solvent contrast, the radius of gyration Rg is a measure of structural 
elongation if the internal inhomogeneity of scattering densities has no effect. Guinier 
analyses at low Q give the Rg and the forward scattering at zero angle 1(0) (Glatter & 
Kratky, 1982):
In I(Q) = In 1(0) - Ro2 Q2/3 Eq 6.1
This expression is valid in a Q.Rg range up to 1.3. The relative l(0)/c values (c = sample 
concentration) for samples measured in the same buffer during a data session gives the 
relative molecular weights Mr of the proteins when referenced against a suitable 
standard (Kratky, 1963; Jacrot & Zaccai, 1981; Wignall & Bates, 1987). Data analyses
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employed an interactive graphics program SCTPL5 (A. S. Nealis, A. J. Beavil & S. J. 
Perkins, unpublished software) on a Silicon Graphics 4D35S Workstation.
Indirect transformation of the scattering data in reciprocal space I(Q) into that in real 
space P(r) was carried out using GNOM (Svergun et al., 1988; Semenyuk & Svergun, 
1991; Svergun, 1992).
P(r) =  —  ? l(Q) Qr sin(Qr) dQ Eq6.2
2 k  o
P(r) corresponds to the distribution of distances r between volume elements. This offers 
an alternative calculation of Rg and 1(0) which is now based on the full scattering curve, 
and also gives the maximum macromolecular dimension L. GNOM employs a 
regularisation procedure with an automatic choice of the transformation parameter a  to 
stabilise the P(r) calculation (Svergun, 1992). A range of maximum assumed 
dimensions Dmax was tested, and the final choice of Dmax was based on three criteria:
(i) P(r) should exhibit positive values
(ii) the Rg from GNOM should agree with the Rg from Guinier analyses
(iii) the P(r) curve should be stable as Dmax was increased beyond the estimated 
macromolecular length.
6.2.4 Debve sphere modelling of the SAP and  C RP scattering curves
The X-ray and neutron scattering curves were modelled using small single-density 
spheres to represent the SAP structure. The X-ray and neutron scattering curve I(Q) 
were calculated by an application of Debye's Law adapted to spheres of a single density 
(Perkins & Weiss, 1983):
^  = 8(0) (n + 2ri2 X  Aj ^ )  E q 6.3
1(0) J-> Qrj
g(Q) = (3 (sin  QR - QR cos Q R)/ /  Q6 R6 Eq6.4
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where g(Q) is the squared form factor for the sphere of radius R, n is the number of 
spheres filling the body, Aj is the number of distances q for that value of j, q is the 
distance between the spheres, and m is the number of different distances q. The 
calculation method (Smith et al., 1990; Perkins et al., 1993) in application to SAP is 
summarised as follows:
The pentameric SAP coordinates at 0.2 nm resolution with all 1020 amino acid residues 
(PDB code: lsac) were used for all calculations. Since carbohydrate was not visible in 
the crystal structure, the oligosaccharide structure at Asn32 was modelled using the co­
ordinates of oligosaccharide Chain A in the crystal structure of human IgGl KOL Fc 
(code lfcl; Deisenhofer, 1981), to which two additional residues were added to generate 
the full biantennary structure (NeuNAc.Gal.GlcNAc.Man)2 .Man.GlcNAc.GlcNAc 
(Pepys et al., 1994; Figure 6.3) The co-ordinates were converted to spheres by placing 
all the atoms within a three-dimensional grid of cubes of side 0.425 nm. A cube was 
included in the sphere model if  it contained sufficient atoms above a specified cut-off 
such that the total volume of the resulting 2118 cubes equalled that of the dry 
glycoprotein of 162.6 nm3 calculated from the sequence (Perkins, 1986). Neutron curve 
fits were based on spheres of radius 0.264 nm placed at the centre of each cube, each 
sphere having the same volume as each cube. X-ray curve fits were based on a hydrated 
model, whose volume of 214.5 nm3 is the sum of the dry model and that of a hydration 
shell of 0.3 g t^O /g SAP (Perkins, 1986). A program HYPRO (A.W. Ashton & S. J. 
Perkins unpublished software) was written in which an adjustable total of up to 26 cubes 
was added to surround each of the 2118 cubes in the dry model in order to represent a 
hydration layer. Duplicate cubes in the resulting model were removed by a reapplication 
of the grid transformation with an adjustable cut-off set to result in the correct hydrated 
volume of 214.5 nm3 which was achieved with 2719 spheres. The sphere sizes are much 
less than the nominal resolution of 27t/Qmax of the scattering curves. No corrections were 
applied for X-ray wavelength spread or beam divergence as these are negligible, while 
those for neutron data were applied as described in Perkins & Weiss (1983) and Mayans 
e ta l  (1995).
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NeuNac -  -  GlcNAc -  Man
^ ^ M a n  -  GlcNAc - GlcNAc 
NeuNac -  -  GlcNAc -  Man (Fuc)
Figure 6.3: The carbohydrate structure of SAP. Inset shows the initial co-ordinates of 
oligosacharide Chain A from the crystal structure of human IgGl KOL Fc (PDB code 
lfcl; Deisenhofer et al., 1981). The main figure shows the biantennary structure of the 
oligosacharide chain of SAP (Pepys et al., 1994), as shown schematically below with 
the residue colouring in the structure corresponding to those in the schematic diagram. 
The figure was created using PyMOL (DeLano, W.L. The PyMOL Molecular Graphics 
System (2002) on World Wide Web http://www.pymol.org).
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The pentameric CRP coordinates at 0.3 nm resolution (PDB code: lgnh) contained two 
independent molecules, in which all 206 residues per protomer were present. Cubes of 
side 0.425 nm were again used. The two dry models contained 1840 and 1860 spheres to 
correspond to the protein volume of 148.7 nm3 calculated from the sequence. The 
hydrated model of volume 195.6 nm3 was based on 2454 spheres.
In application to curve fitting for SAP-10, INSIGHT II 95.0 (Biosym/MSI, San Diego, 
USA) and Biosym Command Language macros were used. SAP-10 was assumed to be 
formed from two SAP-5 structures which are unchanged in conformation and possess a 
common central five-fold axis of symmetry. The starting SAP-10 model was formed by 
the superimposition of two SAP-5 structures, and then one SAP-5 was turned by 180° to 
reverse the orientation of its A- and B-faces. The pentamers were either in direct 
alignment with each other, or were rotated by 36° about the five-fold axis of symmetry. 
The two pentamers were separated by 4.0 nm, and eighty co-ordinate models were 
generated by translating one pentamer relative to the other for 8.0 nm along the central 
five-fold axis in 0.1 nm steps (see Figure 6.4). In order to automate the appraisal of 
these SAP-10 models, one pentamer passed completely through the other pentamer 
without regard for steric overlap, and this generated both the BAAB and ABBA face-to- 
face orientations. Each SAP-10 model was converted into spheres for calculation of the 
scattering curve. Models were then assessed using:
(1) The total number of spheres, which demonstrates the absence of steric overlap 
between the two pentamers, for which at least 95% of the expected total of spheres 
was required.
(2) The Rg value, which was calculated from the Guinier fit of the calculated scattering 
curve in the same Q range used for experimental data analysis;
(3) The R-factor of agreement, defined by analogy with crystallography, for which the 
observed and calculated curves were compared in the Q range between 0.10 and 2.0 
nm-1 (Smith et al., 1990; Beavil et al., 1995).
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Figure 6.4: Schematic representation of a typical modelling search for a SAP decamer. 
The search would start with one SAP pentamer, represented by the left hand structure 
marked “1”, being moved in 0.1 nm steps through the central stationary structure, marked 
“2”, to the position of the right hand structure (“1” in dotted outline) along the axis passing 
through the centre of the SAP structures as shown. This search would then be repeated 
once the structure marked “1” had been rotated by 36° around its central axis.
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6.3 Results and Discussion
6.3.1 Synchrotron X-rav scattering of SAP-10 and SAP-5
X-ray scattering data for SAP-10 in Buffer C (with Tris and EDTA) were obtained in 
the concentration range between 2-12 mg/ml. Those for SAP-5 in Buffer H (the 
crystallisation buffer with Ca2+) were obtained in the concentration range between 2-5 
mg/ml. The upper panels of Figure 6.5 show that linear Guinier plots in satisfactory 
Q.Rg ranges were obtained using a Q range of 0.1-0.35 nm'1 for fits. Analyses of the 10 
time-ffames used during data acquisition on Station 2.1 indicated the absence of 
radiation damage effects that are commonly seen with other proteins. No concentration 
effects were observed which would indicate either association or dissociation 
phenomena, or the presence of interparticle interference effects.
The X-ray Guinier analyses from four independent data sessions showed that the mean 
Rg value of SAP-10 is 4.23 ±0.12 nm (22 values), and that for SAP-5 is 3.99 ± 0.11 nm 
(5 values). In two data sessions on Station 2.1 where the relative l(0)/c values were 
available for both SAP-5 and SAP-10, the ratio of these for SAP-10: SAP-5 gave values 
of 1.64 and 1.74 (± 0.12). These ratios are slightly less than the expected molecular 
weight ratio of 2.00.
The full scattering curves I(Q) for SAP-10 and SAP-5 in the upper panels of Figure 6.5 
show that the two forms are readily distinguished. The quadrant detector on Station 2.1 
gave improved signal-to-noise ratios and more extensive data in the Q range above 1 
nm*1 compared to the use of the linear detector on Station 7.3. A minimum is visible in 
the full curve at Qmm of 0.88 nm*1 for SAP-10 (arrowed as A in Figure 6.5) which is less 
prominent in the SAP-5 X-ray curve. Knowledge of the scattering properties of a ring­
like structure shows that this minimum corresponds to a mean ring diameter of 27c/Qniin 
= 7.1 nm (Perkins & Pepys, 1986). The calculation of the distance distribution function 
P(r) of SAP-10 and SAP-5 yielded a narrower profile for SAP-10 compared to that for
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Figure 6.5: Comparison of the experimental scattering curves I(Q) for SAP-10 and SAP- 
5. The SAP-10 X-ray curves were obtained on Stations 2.1 and 7.3 at concentrations of
2.4 and 6.6 mg/ml respectively. The SAP-5 X-ray curve was obtained on Station 2.1 at a 
concentration of 2.5 mg/ml. The SAP-10 neutron curves correspond to SAP-10 in 0% 
2H20  buffer (Instrument D11 at 5.6 mg/ml) and in 100% 2H20  buffer (Instrument D11 at 
5.8 mg/ml; Instrument D17 at 5.4 mg/ml; Instrument LOQ at 8.6 mg/ml). The SAP-5 
neutron curves correspond to SAP-5 in 0% 2H20  buffer (Instrument D ll at 8.5 mg/ml) 
and in 100% 2H20  buffer (Instrument D ll at 6.3 mg/ml; Instrument D17 at 6.6 mg/ml; 
Instrument LOQ at 8.6 mg/ml).
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SAP-5 (see Figure 6.10). The maximum macromolecular dimension L was determined 
as 11.1 ± 0.6 nm for SAP-10 and 10.9 ± 0.3 nm for SAP-5. The maximum M in the P(r) 
curve is the most frequently occurring distance within SAP. As M was 5.8 ±0.1 nm for 
SAP-10 and slightly reduced at 5.4 ±0 .1  nm for SAP-5, M is not sensitive to the 
presence of pentameric or decameric SAP structures.
6,3.2 Neutron scattering of SAP-10 and SAP-5
Neutron scattering for SAP in both H2O and 2H20 buffers provided molecular weight 
determinations as well as acting as a control for the absence of X-ray radiation damage 
effects and internal scattering density inhomogeneity effects in different solvents. SAP 
is visualised in high positive and negative solute-solvent contrasts in H2O and 2H2 0  
buffers respectively, and this can be compared with the high positive solute-solvent 
contrast seen by X-rays.
In neutron Guinier analyses, linear Rg plots were again obtained for SAP-10 and SAP-5 
in both solvents using Instrument D17 (lower panels of Figure 6.6) as well as 
Instruments D ll and LOQ. All three instruments gave similar Guinier analyses. Nine 
dilution series of SAP-10 and seven for SAP-5 were measured between 1-12 mg/ml, and 
showed no concentration dependence (Figure 6.7). Decamers were obtained with seven 
buffers (Table 6.1) that covered the pH range between 5.5 to 8.0, all in the absence of 
Ca2+, and all but one in the presence of EDTA. Pentamers were obtained using six 
buffers that covered the pH range 5.5 to 8.0, all in the presence of Ca2+ and some in the 
presence of MO(3DG. No pH-dependent conformational changes could be detected from 
Guinier analyses. At lower pH values of 4 and 5, associative phenomena were observed 
(Wood et al., 1988). The lack of change in the pH range between 5.5 to 8.0 for the SAP- 
10 structure implies that the four His residues per protomer (pK values close to 6-7) do 
not influence decamer formation. Side-chain solvent accessibilities in the SAP crystal 
structure were calculated by the Lee & Richards (1971) method in the COMPARER 
program using a probe radius of 1.4 A (Sali & Blundell, 1990). Of these four His
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Figure 6.6: X-ray and neutron Guinier Rg plots for SAP-10 and SAP-5. The X-ray data 
for SAP-10 were obtained at concentrations of 9.5, 7.2, 4.8 and 2.4 mg/ml from one 
session at Station 2.1 at the SRS, together with X-ray data for SAP-5 at a concentration of
2.5 mg/ml in the same session. The neutron data for SAP-10 in 100% 2H20 buffers were 
obtained at concentrations of 9.7, 7.3, 4.6 and 3.7 mg/ml on Instrument D17. The neutron 
data for SAP-5 in 100% 2H20 buffers were obtained at 9.7, 7.5, 6.1 and 4.1 mg/ml on 
Instrument D17. Filled circles between the Q.Rg ranges show the data points used to 
determine the Rg values (Table 4.1 and 6.2 and 6.3). Statistical error bars are shown 
when large enough to be visible.
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Figure 6.7: Calculated Rg measurements plotted against sample concentration for SAP- 
5 and SAP-10 in both X-ray and neutron scattering experiments. The plots clearly show 
that there is no concentration dependence of the Rg values and hence the scattering 
experiments.
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residues, the sidechain of Hisl is 80% surface-exposed on the outer periphery of the 
SAP ring, while those of His 19 and His78 are 15-60% surface-exposed at the B-face, 
and that of His93 is buried (Figure 6.8 and 6.9). Decamer formation by the association 
of the two A-faces would account for the observed lack of effect of pH, in contrast to 
the association of the two B-faces which would bring 20 His residues into proximity 
with each other. In addition, the SAP ring itself is stabilised by three salt bridges 
between Asp42, Glul53 and Lysl99 in one protomer and Lysll7, Lysll6 and Glu99 
respectively in the adjacent protomer. None of these ionic interactions will be affected 
in the pH range between 5.5 to 8.0.
In the pH range 5.5 to 8.0, the mean Rg value for SAP-10 in 2H20 buffer was 4.09 ± 
0.14 nm (28 values), and that for SAP-10 in H2 O buffer was 3.90 ± 0.10 nm (5 values). 
The corresponding Rg values for SAP-5 were smaller at 3.69 ± 0.12 nm (28 values) and 
3.53 ± 0.07 nm (1 value) respectively. The neutron Rg values were unchanged between 
H2O and H2O, and this is attributable to the surface location of hydrophilic amino 
acids inside and outside the SAP ring. For globular glycoproteins, the Rg values are 
generally higher in H2 O solvents than in 2H2 0  solvents, because hydrophilic amino 
acids and carbohydrate residues occur at the surface, and hydrophobic amino acids occur 
in the inner core, and the former have a higher scattering density than the latter (Perkins, 
1986, 1988). This lack of change in the neutron Rg with contrast for SAP is unique and 
is attributable to its ring structure. The larger Rg values seen by X-rays (Table 6.2) are 
therefore predominantly the result of hydration effects in SAP which are not detectable 
by neutron scattering.
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His93
Figure 6.8: The solvent/protein contact surface of the SAP A face with the Histidine 
(His) residues highlighted. The His residues are highlighted in blue and Hisl is clearly 
visible whilst His96 is only partially visible on the surface of the hole (see Section 
6.3.2). The figure was created using PyMOL (DeLano, W.L. The PyMOL Molecular 
Graphics System (2002) on World Wide Web http://www.pymol.org). Using the surface 
display mode, PyMOL does not show the solvent accessible surfaces; rather it shows the 
solvent/protein contact surface (PyMOL online manual).
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Hisl9
His78
Figure 6.9: The solvent/protein contact surface of the SAP B face with the Histidine 
(His) residues highlighted. The His residues are highlighted in blue and His 19 and 
His78 are clearly visible (see Section 6.3.2). The figure was created using PyMOL 
(DeLano, W.L. The PyMOL Molecular Graphics System (2002) on World Wide Web 
http://www.pymol.org). Using the surface display mode, PyMOL does not show the 
solvent accessible surfaces; rather it shows the solvent/protein contact surface (PyMOL 
online manual).
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Table 6.2: Modelling analyses for the structure of SAP-5
X-ray modelling
Experimental X-ray Rg value 3.99 ±0.11 nm (5)
Modelling analysis Rg (nm) R-factor (%)
SAP with carbohydrate (model X) 3.97 3.7
SAP with carbohydrate (model Y) 3.87 5.1
SAP with carbohydrate (model Z) 3.74 8.0
SAP without carbohydrate (lsac) 3.60 15.9
CRP without carbohydrate (lgnh: mean) 3.64 14.1
Neutron modelling
Experimental neutron Rg (0% 2H20) 3.53 ± 0.07 nm (1)
Experimental neutron Rg (100% 2H20) 3.69 ± 0.12 nm (28)
Modelling analysis Rg (nm) R-factor (%)
D17 LOQ
SAP with carbohydrate (model X) 3.80 4.0 4.7
SAP with carbohydrate (model Y) 3.73 4.2 4.2
SAP with carbohydrate (model Z) 3.62 6.0 5.1
SAP without carbohydrate (lsac) 3.50 8.9 7.0
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Two sets of Mr calculations were performed from the neutron Guinier l(0)/c values:
(a) From the D11 data, l(0)/c for SAP-10 and SAP-5 in H2 O buffer was determined to 
be 0.105 and 0.059 (± 0.002) relative to the incoherent scattering of H2O at a 
wavelength of 1.00 nm. These gave an Mr ratio of 1.78 ± 0.06. The l(0)/c values in 
2H20  buffer were 0.850 =fc 0.004 and 0.503 ± 0.004 for SAP-10 and SAP-5 
respectively, and gave a Mr ratio of 1.69 ± 0.04. Based on mean neutron 
transmissions of 0.445 for the H2O sample and 0.824 for the 2H20 sample and the 
sample thicknesses (Section 6.2.2), the neutron matchpoint was determined as 
40.0% 2H20  for SAP-10 and SAP-5. This is in good agreement with the value of 
40.8% 2H20  calculated from the composition on the standard assumption of 10% 
nonexchange of exchangeable protons within SAP (Perkins, 1986). This matchpoint 
corresponds to a partial specific volume of 0.771 ml/g for the dry glycoprotein. The 
hydrated glycoprotein would have one of 0.735 ml/g that corresponds to the value 
used in X-ray scattering or ultracentrifugation analyses.
(b) From the LOQ data, the mean l(0)/c value of 0.247 ± 0.009 observed for SAP-10 
and 0.146 ± 0.004 for SAP-5 gave a Mr ratio of 1.69 ±0.12. When standardised with 
l(0)/c values determined for six proteins of known Mr between 27,000-144,000 
using LOQ, all referenced to a known polymer standard (Mayans et al., 1995; 
Ashton et al. 1995; Beavil et al., 1995), these l(0)/c values resulted in Mr values of
230,000 ± 10,000 and 136,000 ± 7,000 for SAP-10 and SAP-5 respectively, which 
are close to the sequence-derived values o f254,000 and 127,000 respectively.
The scattering curves I(Q) for SAP-10 and SAP-5 in Figure 6.5 show again that the two 
forms are easily identified. LOQ gave the most extensive available Q range when 
compared to D ll and D17 for which two or three detector positions were required to 
yield a similar Q range. The minimum in the full curve of SAP-10 is again observed at 
Qmin of 0.88 nm'1 for SAP-10 as for X-ray scattering, showing that this is unaffected by 
hydration. The distance distribution function P(r) of SAP-10 and SAP-5 yielded a 
narrower profile for SAP-10 compared to SAP-5. The maximum dimension L was 
determined as 11.0 ± 0.7 nm and 10.5 ± 0.5 nm for SAP-10 and SAP-5 respectively. M 
was determined to be 5.6 ±0.1 nm for SAP-10 and 5.2 ±0.1 nm for SAP-5. The three
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neutron instruments all resulted in similar P(r) curves in Figure 6.10. In particular, the 
D ll P(r) curves measured in H2 O and H2 O solvents showed no significant difference 
from each other, in support of the lack of change in the Rg values seen between these 
two solvents (above).
6.3,3 Absorbance and fluorescence properties of SAP-5 and SAP-10
The above molecular weight calculations for SAP-5 and SAP-10 cannot be rationalised 
on the basis of the same absorption coefficient for both forms, since 5 determinations of 
the l(0)/c ratio for SAP-10: SAP-5 show that this ratio is consistently slightly less than 
the expected value of 2. The absolute Mr calculation from l(0)/c showed that the Mr 
value for SAP-10 is 9% less than expected while that for SAP-5 is at the limit of 
experimental error. If the absorption coefficient of SAP-10 is postulated to be 18 and 
that for SAP-5 is 16, this would result in a predicted ratio of l(0)/c values of 1.78 as 
observed. The crystal structure of the SAP pentamer accounts for these findings. The 
calculation of side-chain solvent accessibilities (Sali & Blundell, 1990) showed that, 
while Trp98 is buried within the SAP ring, Trpl08, Trpl60, Trpl85 and Trp203 are all 
located at the A-face of the SAP protomer with accessibilities of 12%, 5%, 0% and 10% 
respectively (Figure 6.11). Localised changes in solvent exposure upon decamer 
formation between the two A-faces may alter the local environment of what will be a 
total of 40 Trp residues in proximity to each other, and change the absorption coefficient 
and fluorescence properties of SAP.
Difference absorption measurements were accordingly performed using SAP-10 in a 
buffer containing 10 mM Tris, 0.1% NaN3 , 140 mM NaCl at pH 7.4 (Figure 6.12a). The 
(SAP-10 - SAP-10) and (buffer - buffer) difference spectra gave baselines of zero. The 
addition of 10 mM MOpDG and 2 mM Ca2+ resulted in an absorbance increase of 0.028 
at 280 nm in the ([buffer + MOpDG] - buffer) difference spectrum. The same addition 
of ligands to SAP-10 caused its dissociation into SAP-5, and the difference spectrum of 
(SAP-5 - SAP-10) resulted in an absorbance increase of 0.012 at 280 nm, and the 
observation of distinct subpeaks in the difference spectrum (Figure 6.12a). The 
reduction of 0.016 absorbance units from the starting optical density of 0.39 corresponds
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Figure 6.10: Distance distribution functions P(r) for SAP-10 and SAP-5. The P(r) 
curves were calculated from the I(Q) curves of Figure 6.5. The dotted X-ray P(r) curve 
corresponds to data from Station 7.3. The dotted neutron P(r) curve corresponds to data 
obtained using H2O buffer. The maximum of the P(r) curve is denoted M, the most 
frequently occurring distance within SAP, and the maximum dimension is denoted L. 
The negligible P(r) intensity at r values beyond that indicated by L for SAP-5 by X-rays 
corresponds to a trace amount of aggregate.
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Trpl08
Trpl60
Trpl85
Trp203
Figure 6.11: The solvent/protein contact surface of the SAP A face with the Typtophan 
(Trp) residues highlighted and the B face inset. The Trp residues are highlighted in red 
and Trp 108, Trp 160, Trp 185 and Trp203 are clearly visible whilst Trp98 is buried 
within the ring (see Section 6.3.3). There are no Trp residues visible on the B face (top 
right inset). The figure was created using PyMOL (DeLano, W.L. The PyMOL 
Molecular Graphics System (2002) on World Wide Web http://www.pymol.org). Using 
the surface display mode, PyMOL does not show the solvent accessible surfaces; rather 
it shows the solvent/protein contact surface (PyMOL online manual).
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Figure 6.12: Difference absorbance and fluorescence spectra of SAP-10 and SAP-5. In 
(a), the two bottom traces correspond to the (buffer - buffer) and (SAP-10 - SAP-10) 
background runs. The MOpDG and (SAP-5 - SAP-10) traces correspond to the addition 
of 10 mM MOpDG and 2 mM Ca2+ to the buffer and SAP-10 samples respectively. The 
absorbance of SAP-10 is 0.39 (2.3 mg/ml) in a path thickness of 1 cm, and the scans 
were recorded on 0.2 nm steps of 1 sec each. In (b), the fluorescence emission spectra 
are shown for SAP-10 at 0.023 mg/ml and again on the addition of 10 mM MOpDG and 
2 mM Ca2+ to give SAP-5. Sample temperature = 20°C. We thank Dr A. J. Beavil for his 
assistance with these measurements.
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to the dissociation of 2.3 mg/ml SAP-10 into SAP-5 if  the absorption coefficient of 
SAP-10 is 17.5 and that of SAP-5 is 16.5. Fluorescence emission spectra between 300- 
500 nm using an excitation frequency of 280 nm were recorded for the same SAP-10 
sample in a 100-fold dilution. After subtraction of the buffer baseline to correct for the 
water Raman peak and background scattering, Figure 6.12b showed that a 44% increase 
in Trp fluorescence at 340 nm occurred on the dissociation of SAP-10 into SAP-5. 
These results are compatible with the association of the A-faces at the interface between 
the two pentamers in the decamer.
6.4 Modelling
6.4.1 Scattering curve modelling for the SAP-5 pentamer
In order to correlate the scattering curve of SAP-5 with its crystal structure, the latter 
was converted into a small-sphere model for curve calculations (Section 6.2.4). This 
required the prior addition of five sets of oligosaccharide co-ordinates to Asn32 on the 
outer circumference of the A-face of SAP-5. For the reasons discussed in Boehm et al. 
(1996), the latter were generated from the structure found in the Fc fragment of IgG 
(Figure 6.3). The five extended chains in the plane of the SAP ring were positioned in 
either one of two orientations displaced by 90° (models X and Y), while a third one 
placed all five chains perpendicular to the plane of the ring (model Z) (Figure 6.13). 
Single-density models were used for reason of the observed lack of dependence of the 
neutron curve on the contrast. The averaged nuclear densities of protein and 
carbohydrate relative to solvent correspond to 40 and 56 in H2O and 60 and 44 in 2H20 
(giving scattering density ratios of 1.40 and 0.73 respectively), while the corresponding 
electron densities are 434 and 489 e/nm3 relative to that of H2 O at 334 e/nm3 (a density 
ratio of 1.55) (Perkins, 1986). As carbohydrate is only 8.7% by weight in SAP, this 
together with the ring structure of SAP accounts for the lack of observable contrast 
dependence.
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Figure 6.13: Orthogonal views of pentameric SAP structures with three alternative 
oligosaccharide conformations. Models X and Y correspond to an in-plane arrangement 
of five oligosaccharide chains attached to Asn32 relative to the SAP-5 ring in two 
rotational orientations that differ by 90°. Model Z corresponds to a perpendicular 
arrangement of the five oligosaccharide chains. The oligosaccharide face with Asn32 
and the calcium-binding face are denoted as A-face and B-face respectively. The 
diameters of the SAP ring with and without carbohydrate and the thickness of the SAP 
ring are indicated.
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The calculated X-ray curve is dependent on hydration, in which a monolayer of 
electrostricted water molecules is hydrogen bonded to the surface of SAP (Perkins, 
1986; Smith et a l, 1990; Perkins et a l , 1993). The previous modelling of X-ray 
scattering curves from hydrated models used an algorithm that performed a linear three- 
dimensional expansion of the sphere model until its volume equalled that of the 
hydrated protein. This is inappropriate for SAP as the void space at the centre of SAP 
would become bigger and not smaller, and this was confirmed by poor curve fits. A new 
algorithm HYPRO (A. W. Ashton & S. J. Perkins unpublished software) was written to 
add a surface layer of 676 spheres to the starting model (Section 6.2.4). The SAP 
models X and Y gave curves whose Rg values of 3.97 nm and 3.87 nm agreed well with 
the experimental value of 3.99 nm (Table 6.2). Good curve fits were obtained with R- 
factors of 3.7% and 4.3% respectively (Figure 6.14a). Hydrations of 0.0 g and 0.6 g 
H20/g SAP gave worsened curve fits, where the R-factors increased to 6.8-8.6% and 
3.9-6.0% respectively (Figure 6.14a). Slightly worsened curve fits were obtained with 
SAP-5 model Z, which had a slightly reduced Rg value and an increased R-factor of 
5.3%. Much worsened curve fits were obtained with a SAP-5 or CRP model without 
carbohydrate, where the Rg value was decreased to 3.60-3.64 nm and the R-factor was 
increased to 14.1-15.9%. These fits show that the hydrated crystal structure of SAP-5 
accounts for the X-ray scattering curve, with a preference for Model X or Y and 
extended oligosaccharide structures.
The calculated neutron curve is based on the unhydrated structure, but is dependent on 
corrections for instrumental effects. Unlike previous calibrations with trypsinogen and 
ai-antitrypsin (Smith et a l , 1990; Perkins et al., 1993), H2 O and 2H20 solute-solvent 
contrast effects for SAP were negligible, and this meant that single-density models 
could be used. The predicted Rg values of 3.62-3.80 nm for the SAP-5 models X, Y and 
Z agreed with the observed value of 3.69 nm (Table 6.2). The removal of carbohydrate 
reduced the predicted Rg value to 3.50 nm. Based on an optimised 10% wavelength 
spread for a wavelength of 1.10 nm and a beam divergence of 0.024 radians for D17 
(Perkins & Weiss, 1983), models X, Y and Z gave similar good fits to the neutron data 
in the Q range out to 0.9 nm'1 with R-factors of 4.0-6.0% (Figure 6.14b). Model X
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Figure 6.14: X-ray and neutron curve fits for a pentameric SAP structure. The sphere 
models used for the calculated curve fit are shown as insets, where SAP-5 is viewed at 
its B-face.
(a) The continuous line corresponds to the calculated curve for the hydrated SAP-5 
model X (inset), which is compared with the X-ray scattering curve from Figure 6.5. 
The effect of removing oligosaccharide is indicated by the dashed line. The upper and 
lower dotted lines indicate the curves from models with hydrations of 0.0 g and 0.6 g 
H2 O/ g SAP respectively.
(b) The continuous line corresponds to the calculated curve for the unhydrated SAP-5 
model X, which is compared with neutron scattering curves from D17 and LOQ (Figure 
6.5). The upper and lower dotted lines indicate the curves from models with hydrations
of 0.3 g and 0.6 g H2O/ g SAP respectively. The poor fit between the model curve fits 
and the neutron data at high Q is due to the incoherent scattering from the sample which 
was not modelled.
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gave worsened R-factors of 5.1% and 8.8% when hydrations of 0.3 and 0.6 g F^O/g 
SAP respectively were used. For LOQ, after similar optimisation, the curve fits had R- 
factors that ranged between 4.2-5.1% using a wavelength spread of 10% for a putative 
wavelength of 0.6 nm and a beam divergence of 0.016 radians (Figure 6.14b). Model X 
also gave worsened R-factors of 6.0% and 9.0% with hydrations of 0.3 and 0.6 g F^O/g 
SAP respectively. These fits confirmed the modelling procedure for neutron curves 
based on dry structures, and supported the presence of extended oligosaccharide 
conformations.
6.4.2 Comparison of the scattering curves of SAP-5 and CRP
The neutron scattering curve for CRP in Figure 3 of Perkins & Pepys (1986) is distinct 
from that for SAP-5 in Figure 6.5. The CRP curve exhibited a better-formed minimum 
at Q close to 0.9 nm'1 than SAP-5. The crystal structure of CRP at 0.3 nm resolution 
showed that the five protomers had rotated inwards by 15° compared to those seen for 
SAP-5 (Emsley et al., 1994; Shrive et a l , 1996). This rotation was unexpected, since 20 
residues involved in interprotomer contacts in SAP-5 were mostly conserved in the SAP 
and CRP sequences (Srinivasan et al., 1994; Figure 6.2). The calculation of the 
scattering curves of CRP and SAP-5 showed a clear difference only if  carbohydrate is 
present on SAP-5. The R-factor between the calculated curves for CRP and 
carbohydrate-free SAP-5 was 1.2-2.0% by X-ray modelling, and 1.1-1.2% by neutron 
modelling. The two deglycosylated structures can only be distinguished by accurate 
scattering experiments.
6.4.3 Scattering curve modelling for SAP-10
The association of two SAP-5 pentamers based on models X, Y and Z and carbohydrate- 
free SAP together with the X-ray scattering curve was used to determine a structure for 
the SAP-10 decamer (Section 6.2.4, Figure 6.4). The 640 decamer models generated 
from 8 translational searches were first evaluated using R-factors (Figure 6.15). Each 
search resulted in two minima that corresponded to the BAAB and ABBA face-to-face
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Figure 6.15: Survey of 80 models for the SAP-10 decamer. A SAP-5 pentamer (Model 
Y) was translated along the five-fold axis common to both pentamers, after reorientation 
by 36°. The centre of the fixed model is at 4 nm. 4236 spheres are expected in the 
starting models, and dashed lines indicate where the two pentamers exhibit 5% and 10% 
steric overlap in the decamer. The Rq of each model is shown in comparison with a 
dashed line indicating the experimental X-ray Rg value of 4.23 nm. The R-factor of 
agreement between the X-ray and calculated curves is shown in comparison with a 
minimum at 3.3%. The two vertical lines correspond to the two best fit structures for the 
SAP decamers, in which either the A-faces or the B-faces are in contact with each other 
(the BAAB and ABBA models respectively).
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decamers. The R-factors were 3.1-3.5% for models X and Y, 3.7-3.9% for model Z, and 
4.3-4.6% for carbohydrate-free SAP (Table 6.3), and favoured models X and Y. At the 
BAAB minimum, models X and Y had Rq values of 4.23-4.29 nm that agreed well with 
the experimental value of 4.23 nm. At the ABBA minimum, models X and Y exhibited 
slightly larger Rg values, and model Z and carbohydrate-free SAP showed slightly 
reduced values (Table 6.3), and these discrepancies favoured the BAAB minimum. At 
the minima, the dry BAAB decamer models contained 97-99% of the expected total of 
4236 spheres, while the dry ABBA decamer models contained 95-100% of this expected 
total. At the minima, the separation of the centres of mass of the two pentamers was 2.7- 
2.8 nm for Model X, 3.0-3.3 nm for Model Y, 3.3-3.5 nm for Model Z, and 3.5-3.8 nm 
for carbohydrate-free SAP (Table 6.3). These separations therefore showed some 
dependence on the oligosaccharide structure. As side-views of the SAP decamer models 
showed that the pentamer surfaces were in good contact with each other at a centre-to- 
centre separation of 3.3 nm. Given that the full thickness of the SAP ring is 3.6 nm, 
models in which the two pentamers were rotated by 36° and not 0° offered better surface 
contacts between the pentamers at a separation of 3.3 nm (Figure 6.15). These 
considerations showed that the decamer model X is too compact, while the decamer 
model Y in its BAAB configuration with a 36° rotation was the most satisfactory (Table 
6.3; Figures 6.15 and 6.16a). The curve fits for this best-fit model worsened to R-factors 
of 3.6% and 8.9% on the use of hydrations of 0.0 g and 0.6 g f^O/g SAP respectively.
As a control of the decamer X-ray curve fits, the 12 best-fit X-ray models from Table
6.3 were used for neutron curve fits. The Rg value of 4.13 nm for the final unhydrated 
SAP-10 model Y in its BAAB and 36° configuration was within error of the observed 
value of 4.09 nm (Table 6.3). Based on the above instrumental parameters for D17, the 
final SAP-10 model gave good curve fits with the neutron data in 2H20 buffers in a Q 
range out to 0.9 nm-1 with an R-factor of 4.7% (Figure 6.16b). The R-factors worsened 
to 5.3% and 7.8% on the use of hydrations of 0.3 g and 0.6 g t^O /g glycoprotein 
respectively (Figure 6.16b). Likewise for LOQ, a good fit was obtained with an R-factor 
in the Q range up to 1.9 nm'1 was 6.7%. The R-factors worsened to 7.1% and 9.1% on
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Table 6.3: Modelling analysis for the structure of SAP-10 
X-ray modelling
Experimental X-ray Rq value 4.23 ± 0.12 nm (22)
Modelling analysis Rg (nm) R-factor (%) Separation (nm)
BAAB ABBA BAAB ABBA BAAB ABBA
SAP (model X - 0°) 4.29 4.36 3.5 3.5 2.8 2.7
SAP (model X - 36°) 4.28 4.36 3.5 3.5 2.7 2.7
SAP (model Y - 0°) 4.24 4.30 3.4 3.1 3.0 3.1
SAP (model Y - 36°) 4.23 4.32 3.4 3.2 3.3 3.3
SAP (model Z - 0°) 4.171 4.17 3.91 3.7 3.51 3.3
SAP (model Z - 36°) 4.151 4.17 3.81 3.7 3.41 3.3
SAP (lsac - 0°) 4.14 4.13 4.6 4.5 3.7 3.5
SAP (lsac - 36°) 4.16 4.14 4.5 4.3 3.8 3.5
Neutron modelling
Experimental neutron Rg (0% 2H20) 3.90 ± 0.10 nm (5)
Experimental neutron Rq (100% 2H20) 4.09 ± 0.14 nm (28)
Modelling analysis Rg (nm) R-factor (%: D17) R-factor (%: LOQ)
BAAB ABBA BAAB ABBA BAAB ABBA
SAP (model Y - 36°) 4.13 4.17 4.7 5.1 6.7 7.2
1 Steric effects from the oligosaccharides result in a greater separation of the A-faces in 
this curve fit.
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Figure 6.16: X-ray and neutron curve fits for a decameric SAP structure. The sphere 
models used for the calculated curve fit are shown as insets.
(a) The continuous line corresponds to the modelled curve for the hydrated SAP-10 
model Y in the BAAB best-fit structure in which the pentamers are rotated 36° 
relative to each other and the centre-to-centre separation is 3.2 nm between the two 
pentamers. This is compared with the X-ray scattering curve from Station 2.1 
(Figure 6.5). The upper and lower dotted lines indicate the curves calculated using 
0.0 g and 0.6 g H2O/ g SAP respectively.
(b) The continuous line corresponds to the same SAP-10 model Y, which is compared 
with the neutron scattering curves from D17 and LOQ. The dotted lines indicate the 
effect of changing the hydration of the model from 0.0 g to 0.3 g and 0.6 g H2O/ 
glycoprotein. The poor fit between the model curve fits and the neutron data at high 
Q is due to the incoherent scattering from the sample which was not modelled.
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the use of hydrations of 0.3 g and 0.6 g F^O/g glycoprotein respectively (Figure 6.16b). 
The 11 other Rg values for Models X, Y and Z (Table 6.2; data not shown) all ranged 
between 4.04-4.16 nm and were not able to discriminate between the SAP models, 
although use of the R-factors of the curve fits was more successful in this regard. These 
fits again confirmed the modelling procedure for neutron curves based on dry structures.
6.5 Conclusions
6.5.1 Solution structures of SAP-5 and SAP-10
In relation to the solution structures of SAP-5 and SAP-10, the scattering data and their 
modelling have provided key insights that complement the atomic detail revealed by the 
recent SAP-5 and CRP crystal structures. In particular, four lines of evidence (a-d) from 
scattering and other experiments show that SAP-10 decamers are formed by the 
association of two SAP-5 pentamers at their A-faces:
(a) The structure of the SAP-10 decamer was maintained unchanged in the pH range 
between 5.5 to 8.0. As His residues are prevalent on the B-face and not the A-face of 
SAP-5, decamer formation by the association of the two A-faces and not the B-faces 
will account for the lack of observed effect of pH on the scattering curves of the 
decamer.
(b) The molecular weight calculations for SAP-5 and SAP-10 showed consistently that 
SAP-10 has a slightly higher absorption coefficient than SAP-5. Difference 
absorbance and fluorescence spectroscopy extended this result by indicating 
significant perturbations in the Trp residues upon dissociation of SAP-10 into SAP- 
5. Since the crystal structure of SAP showed that four Trp residues per protomer are 
close to the A-face of SAP-5, the proximity of 40 Trp residues between the A-faces 
in the decamer would account for these observations.
(c) After calibration of the modelling procedure using SAP-5, the scattering curve 
modelling for SAP-10 favoured the BAAB structure and not the ABBA structure, 
and this result is independent of the oligosaccharide conformation. This is most 
clearly seen in the different Rq values for the BAAB and ABBA structures obtained
163
after each of these two structures were optimised for steric contact between 
pentamers and a minimum in the R-factor (Figure 6.15).
(d) Formation of a BAAB structure is consistent with biochemical data on the cleavage 
of SAP decamers at the centre of the B-face adjacent to the Ca2+ site by
^ I
chymotrypsin in the absence of Ca ions. This means that the cleavage sites have to 
be readily accessible to chymotrypsin in the decamer (Kinoshita et a l, 1992). 
Pentamers are formed in the presence of Ca2+ and MOpDG which bind at the B-face 
of SAP pentamers (Emsley et al., 1994), while decamers are formed in the absence 
of Ca2+.
Solution scattering provides an unambiguous means of distinguishing between SAP 
pentamers and decamers (Figure 6.5). As discussed by several groups (Pepys et a l , 
1997), it should not be assumed that biochemical or structural investigations of SAP 
always correspond to the decameric form. Gel filtration experiments offer one means of 
distinguishing SAP pentamers and decamers, but the results can be misinterpreted as 
careful attention is required to many variables (W. L. Hutchinson & M. B. Pepys, 
unpublished data; Pepys et a l , 1997). Fluorescence experiments offer a third means of 
distinguishing between the two forms (Figure 6.5), and we are currently investigating 
this.
X-ray scattering modelling suggests that the uniquely uniform oligosaccharide structure 
of SAP has an extended conformation relative to the SAP ring, although it is not 
possible to choose between Model X and Y (Figure 6.13). Model Z would lead to steric 
overlap of carbohydrate between the two pentamers. Such an extended oligosaccharide 
conformation in SAP-5 is expected from other scattering studies of glycoproteins such 
as Cl inhibitor and carcinoembryonic antigen (Perkins et al., 1990; Boehm et a l , 1996). 
It is of interest that, in the best-fit SAP-10 model, a 36° rotation between the two 
pentamers will bring opposite pairs of Asn32 oligosaccharide sites into proximity. The 
uniform glycosylation of SAP may reflect the existence of specific carbohydrate 
interactions between the two pentamers. A laser-photoexcited dye study of SAP showed 
that the accessibility of some Trp, Tyr and His residues changes when SAP is 
desialylated (Siebert et a l , 1995). Alterations in the glycosylation of different 
recombinant forms of SAP leads either to pentamers or decamers (unpublished results in
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Pepys et a l , 1997), however the degree to which SAP glycosylation contributes to the 
formation of BAAB decamers is presently unclear. The carbohydrate-carbohydrate 
interactions between two SAP pentamers rotated by 36° resemble those between the two 
oligosaccharide chains at Asn297 at the centre of the Fc fragment of IgG (Deisenhofer, 
1981) in three respects:
• the distance between the two a-carbon atoms at Asn32 in opposite pentamers is 
3.1-3.6 nm in the best-fit SAP-10 model, which is similar to that of 3.3 nm 
between the two a-carbon atoms at Asn297 in IgG-Fc;
• the two protein surfaces in question oppose each other in both SAP-10 and IgG- 
Fc;
• the two oligosaccharide chains are aligned parallel to each other in both SAP-10 
and IgG-Fc.
6.5.2 Calibration of modelling protocols for scattering and hydrodynam ic data
The reliable modelling of scattering curves from crystal structures is important to show 
that multidomain protein structures and the complexes formed between them can be 
analysed by scattering (Mayans et al., 1995; Beavil et al., 1995; Boehm et al., 1996, 
1997; Chamberlain et al., 1997). In such automated curve fitting analyses, known 
atomic structures in a multidomain protein are positioned with the correct domain 
connectivities, and a sufficient number of structures (and scattering curves) is generated 
to include all sterically allowed conformations. The rejection of calculated scattering 
curves using the experimental curve as a filter retains a small fraction of good curve fit 
models, which then constitutes the structure determination. The present study with SAP- 
5 shows that the X-ray and neutron modelling procedure previously tested with two 
other proteins of reduced Mr values of 23,000 and 51,500 (Smith et al., 1990; Perkins et 
al., 1993) is also applicable to a glycoprotein of Mr 127,000. This analysis is not a trivial 
exercise. For example, it was not known beforehand if  the assumptions in relation to 
protein hydration required modification before being applied to larger glycoproteins.
Key stages in the scattering curve modelling procedure are summarised and justified. 
The hydration shell surrounding the protein structure is important for X-ray scattering
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calculations. This is well-represented by a monolayer of water molecules hydrogen 
bonded to the protein surface, which amounts to 0.3 g H^O/g glycoprotein (Perkins, 
1986). As the water molecules are fixed to the protein surface and do not form open 
hydrogen bonding networks as found in bulk water, the volume of each molecule is 
smaller (0.0245 nm3) compared to that in bulk water (0.0299 nm3) (Perkins, 1986). The 
hydration shell is readily modelled by increasing the volume of the atomic structure to 
match the sum of the volumes of the dry protein and its hydration shell. Either the 
dimensions of the dry sphere model can be expanded to match the hydrated volume, or 
additional spheres are added to the surface of the sphere model so that the total of 
spheres matches the hydrated volume. The first procedure will distort the 
macromolecular structure if this has a ring-like structure as for SAP, while the second 
procedure provides a more accurate structure but is computationally more complex. No 
instrumental corrections are required as synchrotron cameras utilise a pin-hole 
configuration without geometrical distortions of the beam.
Neutron curve modelling is based on the dry structure, when the hydration shell 
surrounding the protein is not visible (Perkins, 1986). Neutron contrast variation 
experiments of proteins using mixtures of H2 O and 2H2 0 , combined with estimates of 
the non-exchanged exchangeable proton content by *H NMR, give matchpoints that 
correspond to protein partial specific volumes that are higher compared to those 
determined by densitometry. The difference between these two values corresponds well 
with a hydration shell (Perkins, 1986). Curve fitting exercises for (3-trypsin, <Xi- 
antitrypsin, SAP-5 and SAP-10 show that improved curve fits were obtained with 
unhydrated structures when compared to hydrated structures (Smith et al., 1990; Perkins 
et a l , 1993; Figures 6.14 and 6.16). The particular merit of the neutron data for SAP-5 
and SAP-10 is that, unusually, solute-solvent contrast effects were unimportant and do 
not affect this conclusion. The X-ray Rg values of SAP-5 and SAP-10 were detectably 
larger than the neutron Rg values, even though the difference is small (Table 6.1 and 
6.2), and this is attributable to a hydration shell. Neutron curve modelling requires 
allowance for instrumental effects in terms of wavelength spread and beam divergence 
corrections. Empirical parameters for these based on a 10% wavelength spread and a 
beam divergence of 0.024 radians were found satisfactory for D17 scattering curves for 
both SAP-5 and SAP-10. While agreement is good with the theoretical 10% wavelength
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spread for D17, the theoretical beam divergence is estimated as 0.01 radians and less 
than that observed. This difference may result from the effect of a small residual flat 
background that may arise from incoherent scatter from the proton content in the SAP 
samples and will influence the calculated curve at large Q where the intensities are 
smaller (Figures 6.14b and 6.16b). The pulsed wavelength range of 0.2-1.0 nm used 
simultaneously for LOQ data collection complicates curve-fit analyses, and the effect of 
this may account for the slightly worse curve fits for the LOQ data. However a 10% 
wavelength spread and a beam divergence of 0.016 radians for a putative wavelength of 
0.6 nm was a workable compromise for LOQ that gave curve fits equivalent to those for 
D17.
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CHAPTER 7
Conclusions
7.1 Factor Vila and its complex with extracellular tissue factor.
Solution scattering provided new information on the domain arrangements in FVIIa and 
the FVIIa-sTF complex prior to their crystal structure determinations, and subsequently 
extended the interpretation of recent crystal structures for FVII, FVIIa and sTF, both 
when free and when complexed. Multidomain structures cannot be solved 
unambiguously by scattering analyses, but the comparison of the scattering data with 
these crystal structures now places limits on both the scattering and crystallographic 
analyses and this combination makes them more powerful in the analysis of unknown 
multidomain structures (Perkins et al., 1998a).
In application to FVIIa, sTF and the complex, initial scattering studies had indicated that 
the FVIIa domains were extended with the mean X-ray and neutron Rg values were 
computed to be 3.25 nm, 2.13 nm and 3.14 nm (± 0.13 nm) for FVIIa, sTF and their 
complex respectively. The mean Rxs values were 1.33 nm, 0.56 nm and 1.42 nm (±0.13 
nm), and the mean lengths L were 10.3 nm, 7.7 nm and 10.2 nm respectively (Ashton et 
al., 1995; Chapter 4). Looking at FVIIa alone, the direct comparison of scattering data 
for free FVIIa in solution with the extended FVIIa structure in the crystal structure of the 
FVIIa-sTF complex shows that they are consistent. With the automated FVIIa curve fit 
analyses, we were able to show that the extended structures were similar in overall 
length, and provided an ideal template for the recognition of tissue factor. There would 
be no significant energy price to be paid in terms of domain reorientation during 
complex formation, and this together with the extensive dispersion of contact residues 
across the four FVIIa domains would account for the low nanomolar Kd reported for the 
interaction. The scattering data also showed conclusively that in solution, a compact 
complex of FVIIa intertwined with sTF was formed (Ashton et al., 1995; Chapter 4).
Subsequent to the study reported here, a number of uncomplexed FVII and active site 
inhibited FVIIa crystal structures have become available (Table 5.2; Kemball-Cook et 
al., 1999; Pike et al., 1999; Eigenbrot et al., 2001). Despite these significant advances in 
the structural studies of FVIIa and its zymogen precursor these structural studies have 
not been able to produce a complete domain model of unbound FVII or FVIIa either 
with or without the oligosaccharides (Kemball-Cook et al., 1999; Pike et al., 1999;
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Eigenbrot et al, 2001). These newer crystal structures further substantiate findings of 
this study that both the EGF1 and Gla domains are flexible regions and are likely to take 
many conformations whilst in solution.
Solution scattering also provided information on the two N-linked oligosaccharide 
structures of FVIIa not seen in any other available structure. Since these lie on the outer 
periphery of FVIIa, scattering data are sensitive to their conformation. The FVIIa curve 
fits suggested that these oligosaccharides are not as extended as found in several other 
glycoproteins by similar scattering analyses (Ashton et al, 1997; Boehm et al, 1996), 
and the same result was obtained with the FVIIa-sTF curve fits. The models suggest that 
two sides of the SP domain are masked by the oligosaccharides, while leaving 
accessible the catalytic triad at Hisl93-Asp242-Ser344 at the top of the structure, as 
well as its contact region with sTF between the SP domain and the FVIIa light chain. 
The O-linked oligosaccharides on the EGF-1 domain likewise do not mask the contact 
surface of FVIIa. Inspection of the sTF structure in its complex shows that the N-linked 
oligosaccharides of sTF also do not hinder the contact region of sTF with FVIIa.
7.2 Pentraxins.
In relation to the solution structures of SAP-5 and SAP-10, the scattering data and their 
modelling have provided new insights that complement the atomic detail revealed by the 
SAP-5 and CRP crystal structures. In particular, four lines of evidence (a-d) from 
scattering and other experiments show that the SAP-10 decamers that are usually 
purified in the biochemistry laboratory are formed by the association of two SAP-5 
pentamers at their A-faces:
(a) The structure of the SAP-10 decamer was maintained unchanged in the pH range 
between 5.5 to 8.0. As His residues are prevalent on the B-face and not the A-face of 
SAP-5, decamer formation by the association of the two A-faces and not the B-faces 
will account for the lack of observed effect of pH on the scattering curves of the 
decamer.
(b) The molecular weight calculations for SAP-5 and SAP-10 showed consistently that 
SAP-10 has a slightly higher absorption coefficient than SAP-5. Difference 
absorbance and fluorescence spectroscopy extended this result by indicating
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significant perturbations in the Trp residues upon dissociation of SAP-10 into SAP- 
5. Since the crystal structure of SAP showed that four Trp residues per protomer are 
close to the A-face of SAP-5, the proximity of 40 Trp residues between the A-faces 
in the decamer would account for these observations.
(c) After calibration of the modelling procedure using SAP-5, the scattering curve 
modelling for SAP-10 favoured the BAAB structure and not the ABBA structure, 
and this result is independent of the oligosaccharide conformation. This is most 
clearly seen in the different Rg values for the BAAB and ABBA structures obtained 
after each of these two structures were optimised for steric contact between 
pentamers and a minimum in the R-factor (Figure 6.15).
(d) Formation of a BAAB structure is consistent with biochemical data on the cleavage
04-of SAP decamers at the centre of the B-face adjacent to the Ca site by
04-chymotrypsin in the absence of Ca ions. This means that the cleavage sites have to 
be readily accessible to chymotrypsin in the decamer (Kinoshita et al., 1992). 
Pentamers are formed in the presence of Ca2+ and MO(3DG which bind at the B-face 
of SAP pentamers (Emsley et al., 1994), while decamers are formed in the absence 
of Ca2+.
Using X-ray scattering modelling suggested that the uniquely uniform oligosaccharide 
structure of SAP has an extended conformation relative to the SAP ring, although it is 
not possible to determine unambiguously the exact conformation. Such an extended 
oligosaccharide conformation in SAP-5 is expected from other scattering studies of 
glycoproteins such as Cl inhibitor and carcinoembryonic antigen (Perkins et a l , 1990; 
Boehm et al., 1996). The uniform glycosylation of SAP may reflect the existence of 
specific carbohydrate interactions between the two pentamers. Alterations in the 
glycosylation of different recombinant forms of SAP leads either to pentamers or 
decamers (unpublished results in Pepys et al., 1997), however the degree to which SAP 
glycosylation contributes to the formation of BAAB decamers is presently unclear.
Crystallography studies of the SAP-10 decamer in the complex with dAMP (Hohenester 
et al., 1997) showed that this formed an association at their B-faces with dAMP 
sandwiched at their centre. It is clear that the modes of SAP association are complex.
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7.3 Calibration of modelling protocols for scattering and
hydrodynamic data.
The study with SAP-5 shows that the X-ray and neutron modelling procedure previously 
tested with two other proteins of reduced Mr values of 23,000 and 51,500 (Smith et a l , 
1990; Perkins et a l , 1993) is also applicable to a glycoprotein of Mr 127,000.
The hydration shell surrounding the protein structure is important for X-ray scattering 
calculations. This is well-represented by a monolayer of water molecules hydrogen 
bonded to the protein surface, which amounts to 0.3 g E^O/g glycoprotein (Perkins, 
1986). As the water molecules are fixed to the protein surface and do not form open 
hydrogen bonding networks as found in bulk water, the volume of each molecule is 
smaller (0.0245 nm3) compared to that in bulk water (0.0299 nm3) (Perkins, 1986). The 
hydration shell is readily modelled by increasing the volume of the atomic structure to 
match the sum of the volumes of the dry protein and its hydration shell. Either the 
dimensions of the dry sphere model can be expanded to match the hydrated volume, or 
additional spheres are added to the surface of the sphere model so that the total of 
spheres matches the hydrated volume. The first procedure will distort the 
macromolecular structure if this has a ring-like structure as for SAP, as the central pore 
becomes wider and not narrower, while the second procedure provides a more accurate 
structure but is computationally more complex.
Neutron curve modelling was based on the dry structure, when the hydration shell 
surrounding the protein is not visible (Perkins, 1986). Neutron contrast variation 
experiments of proteins using mixtures of H2O and 2H2 0 , combined with estimates of 
the non-exchanged exchangeable proton content by lH NMR, give matchpoints that 
correspond to protein partial specific volumes that are higher compared to those 
determined by densitometry. The difference between these two values corresponds well 
with a hydration shell (Perkins, 1986). Curve fitting exercises for p-trypsin, (Xi- 
antitrypsin, SAP-5 and SAP-10 show that improved curve fits were obtained with 
unhydrated structures when compared to hydrated structures (Smith et a l , 1990; Perkins 
et al., 1993; Ashton et a l, 1997). The particular merit of the neutron data for SAP-5 and 
SAP-10 is that, unusually, solute-solvent contrast effects were unimportant and did not
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affect this conclusion. The X-ray Rg values of SAP-5 and SAP-10 were detectably 
larger than the neutron Rg values, even though the difference was small, and this is 
attributable to a hydration shell. Neutron curve modelling requires allowance for 
instrumental effects in terms of wavelength spread and beam divergence corrections. 
Empirical parameters for these based on a 10% wavelength spread and a beam 
divergence of 0.024 radians were found satisfactory for D17 scattering curves for both 
SAP-5 and SAP-10. While agreement is good with the theoretical 10% wavelength 
spread for D17, the theoretical beam divergence is estimated as 0.01 radians and less 
than that observed. This difference may result from the effect of a small residual flat 
background that may arise from incoherent scatter from the proton content in the SAP 
samples and will influence the calculated curve at large Q where the intensities are 
smaller. The pulsed wavelength range of 0.2-1.0 nm used simultaneously for LOQ data 
collection complicates curve-fit analyses, and the effect of this may account for the 
slightly worse curve fits for the LOQ data. However a 10% wavelength spread and a 
beam divergence of 0.016 radians for a putative wavelength of 0.6 nm was a workable 
compromise for LOQ that gave curve fits equivalent to those for D17.
7.4 Automated model fitting of SAXS and SANS data.
The novelty of the curve-fit modelling reported in Chapter 5 for the FVIIa-sTF complex 
lies in its application to a heterodimeric complex formed between two multidomain 
proteins (Perkins et al, 1998a). The joint use of both X-ray and neutron scattering 
curve fits together with analytical ultracentrifugation data served as controls for 
reproducibility and possible solute-solvent contrast effects. Previous curve-fit 
applications have described its calibration for proteins of known crystal structures and 
molecular weights between 23,000-125,000 (Smith et al., 1990; Perkins et al, 1993; 
Ashton et al, 1997), and its application to single multidomain proteins and 
homodimeric and homotrimeric complexes (Mayans et al, 1995; Beavil et al, 1995; 
Boehm et al, 1996; Ashton et al., 1995). In these studies, as in previous ones, suitable 
homologous atomic structures are essential to constrain the curve fit analyses. These 
may be available either directly by high sequence similarity with known atomic 
structures, or indirectly by protein fold recognition methods and analogy modelling 
(Bazan, 1990; Edwards & Perkins, 1996). For single multidomain proteins, further 
constraints are imposed by use of the correct stereochemical connections between the
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domains, in order that the curve fits are directed towards determination of the domain 
arrangement. For homo-oligomeric complexes, further constraints are imposed through 
known symmetry relationships, in order that the curve fits can assess the arrangement of 
the monomers within the oligomer. The analysis of the FVIIa-sTF heterodimeric 
complex lacked symmetry constraints. After constraining the search based on the 
inferred relative orientation of the two proteins in the complex, the use of steric overlap 
and Rg filters still left many allowed structures. However, in the search the use of 
further biochemical constraints based on identified contact residues between the two 
proteins (together with the known location of glycosylation sites which would be 
excluded from the protein-protein interface) permitted the location of sTF in the space 
between the SP domain and the light chain, in agreement with the crystal structure of the 
complex. This approach usefully narrowed the range of possible structures for the 
complex. Thus, in the absence of a crystal structure, it is envisaged that the automated 
modelling technique with the application of biochemical constraints, together with the 
use of electrostatic and surface docking methods, can result in improvements in 
structure determinations for other heterodimeric complexes.
7.5 Closing observations.
This thesis has advanced the method of scattering analysis of biological assemblies in 
solution. The ease of modelling solution scattering data makes it a valuable technique 
which is now becoming a routine procedure in structural and functional analysis of 
proteins in solution.
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APPENDIX A 
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abstract: Factor V ila (FVIIa) is a soluble four-domain plasma serine protease coagulation factor that 
forms a tight complex with the two extracellular domains o f the transmembrane protein tissue factor in 
the initiating step o f blood coagulation. To date, there is no crystal structure for free FVIIa. X-ray and 
neutron scattering data in solution for free FVIIa and the complex between FVIIa and soluble tissue 
factor (sTF) had been obtained for comparison with crystal structures o f the FVIIa—sTF complex and of 
free factor IXa (FIXa). The solution structure o f free FVIIa as derived from scattering data is consistent 
with the extended domain arrangement o f FVIIa seen in the crystal structure o f its complex with sTF, but 
is incompatible with the bent, less extended domain conformation seen in the FIXa crystal structure. The 
FVIIa scattering curve is also compatible with a subset o f 317 possible extended structures derived from 
a constrained automated conformational search o f 15 625 FVIIa domain models. Thus, the scattering 
data support extended domain models for FVIIa free in solution. Similar analyses showed that the solution 
scattering derived and crystal structures of the FVIIa—sTF complex were in good agreement. An automated 
constrained search for allowed structures for the complex in solution based on scattering curves showed 
that only a small family of compact models gave good agreement, namely those in which FVIIa and sTF 
interact closely over a large surface area. The general utility o f this approach for structural analysis o f 
heterodimeric complexes in solution is discussed. Analytical ultracentrifugation data and the modeling 
o f these data were consistent with the scattering results. It is concluded that in solution FVIIa has an 
extended or elongated domain structure, which allows rapid interaction with sTF over a large surface 
area to form a high-affrnity complex.
Inappropriate blood coagulation may result in thrombotic 
disorders often associated with cardiovascular, infectious, and 
neoplastic disease. Such coagulation can be initiated by 
exposure of cell surface expressed tissue factor to plasma. 
Similar to the full-length transmembrane receptor tissue 
factor, soluble tissue factor (sTF)1 forms a high-affrnity 
catalytic enzyme—cofactor complex with the plasma serine 
protease coagulation factor Vila (FVIIa), with a dissociation 
constant KD estimated by surface plasmon resonance to be 
in the range 2—5 nM (1—3). Proteolysis of factor VII to its 
active form FVIIa proceeds via a cleavage between Argl52 
and Ilel53. In the presence of Ca2+, this complex catalyzes 
the conversion of both factor IX to factor IXa (FIXa) and 
factor X to factor Xa, both of which are active coagulation
* To whom correspondence and requests for reprints should be 
addressed.
* Royal Free Hospital School of Medicine.
s Imperial College Medical School.
1 Abbreviations: FVIIa, factor Vila; FIXa, factor IXa; sTF, soluble 
extracellular tissue factor (residues 1 -219); SP, serine protease domain; 
EGF, epidermal growth factor domain; Gla, y-carboxyglutamic acid- 
rich domain; Rg, radius of gyration; Rxs, radius of gyration of cross 
section; R2.0 , R factor of agreement.
serine proteases. An understanding of the molecular basis 
of these initiating procoagulant reactions may in the long 
term help to treat and even prevent associated thrombotic 
disorders. Recent reviews give further background to FVIIa 
and sTF (4 -8 ) .
Both sTF and FVIIa are multidomain proteins (Figure 1). 
The crystal structure of sTF contains two fibronectin type 
III domains at an angle of 125° to each other to form an 
extended but rigid arrangement (9—11). The domains are 
identical in structure and topology to C2-type immunoglo­
bulin folds, but exhibit distinct sequence differences (12,13). 
FVIIa contains four domains: a serine protease domain (SP), 
two epidermal growth factor domains (EGF-1 and EGF-2), 
and a y-carboxyglutamic acid-rich domain (Gla). The crystal 
structure of the complex between FVIIa and sTF revealed 
the location of all four FVIIa domains as well as those for 
sTF (14), but no crystal structure is presently available for 
free FVIIa. The FVIIa domains are structurally homologous 
to similar domain structures in activated factors IX and X. 
Crystal structures of human factor Xa lacking the Gla domain 
showed the SP and EGF-2 domains, but the EGF-1 domain 
was not visible for reason of crystallographic disorder and
© 1998 American Chemical SocietyS0006-2960(97)02574-9 CCC: $15.00
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occupied different positions in the two structures (75, 16). 
That for porcine FIXa showed the SP, EGF-2, and EGF-1 
domains and most of the Gla domain (77), but there is a 
striking bend in its domain arrangement in distinction to the 
linear one seen for FVIIa in its complex with sTF (14). 
Structures for the EGF-1 domains of human factors IX and 
X and the Gla domain in bovine prothrombin are also 
available (18—20). Despite this abundance of homologous 
atomic structures, little information is available on the domain 
arrangement free in solution of FVIIa, nor on that of its 
complex with sTF, nor on the disposition of two large 
N-linked oligosaccharide chains on FVIIa that were not 
visible in the crystal structure of the complex (14).
Solution scattering provides information on domain ar­
rangements in multidomain proteins (21, 22). Recently the 
usefulness of this technique has been much enhanced by the 
ability to use either intact crystal structures for scattering 
curve fitting (23—25) or individual domain structures in an 
automated constrained curve-fit procedure (26—28), both of 
which result in an improved understanding of the overall 
structure. Previous X-ray and neutron scattering data for 
FVIIa, sTF, and their complex in solution correctly predicted 
the compact nature of the complex between FVIIa and sTF 
determined by crystallography (29, 30). The availability of 
coordinates for the crystal structures for the FVIIa—sTF 
complex and for the FVIIa-homologue FIXa now makes 
possible a quantitative analysis of the FVIIa domain structure 
in free solution from scattering data, and likewise that for 
the FVIIa—sTF complex. Knowledge of the domain ar­
rangement of free FVIIa in solution is important for an 
appreciation of how membrane-bound TF is able to recognize 
FVIIa as a ligand. A verification of the domain arrangement 
in solution of the FVIIa—sTF complex provides important 
confirmation that the crystal structure of the complex is 
representative of the functional cofactor—enzyme complex. 
It is also possible to analyze the conformation of the two 
large N-linked oligosaccharide chains on FVIIa, which are 
not visible in the crystal structure.
Previous applications of constrained automated scattering 
curve-fit modeling have determined possible structures of 
multidomain proteins of unknown structure (26—28) or of 
homodimeric and homotrimeric complexes (25, 31). This 
approach is important in cases where it is not possible to 
derive even a low-resolution structural model for multido­
main proteins or their complexes by other methods. The 
availability of the FVIIa-sTF crystal structure enables the 
extent to which such a procedure can be applied successfully 
to a heterodimeric protein—protein complex to be discussed.
METHODS
(a) Crystal Structures Used fo r  Direct Scattering Curve 
Comparisons. Crystal coordinates for the complex between 
active-site-inhibited recombinant human FVIIa and subtilisin- 
cleaved sTF were kindly provided by Dr. D. W. Banner 
(Brookhaven code ldan). The domain residue numbering 
is shown in Figures 1 and 2 (32). Two N-linked oligosac­
charides at Asnl45 in the pre-SP linker and Asn322 in the 
SP domain (Figure 1) were added as these were not visible 
in the electron density map, using the modeling package 
INSIGHT II (Biosym/MSI, San Diego, USA) on Silicon 
Graphics INDY Workstations. These were constructed as
Biochemistry, Vol. 37, No. 22, 1998 8209
FACTOR Vila «r
COOHNHj-i Gla IEGF1 SPEGF2
TISSUE FACTOR
F ig u r e  1: Domain structures o f human FVIIa and sTF. FVIIa 
contains an N-terminal Gla domain and two EGF domains in the 
light chain and a SP domain in the heavy chain. As shown, the 
membrane-proximal C-terminal domain of sTF is close to the 
N-terminal Gla domain in FVIIa in the complex. Two O-linked 
glycosylation sites are found on EGF-1 at SerS2 and Ser60, and 
two N-linked glycosylation sites are found at Asnl45 and Asn322.
the mean biantennary oligosaccharide structure (NeuNAc*- 
Gal*GlcNAc*Man)2Man*GlcNAc*GlcNAc(Fuc) in FVIIa (33), 
using as a template the nine-residue carbohydrate coordinates 
of Chain A in the Fc fragment of human IgGl KOL (lfcl)
(34). The two O-linked structures in FVIIa were represented 
by Xyl*Glc at Ser52 and Fuc at Ser60, these being the mean 
of previously reported structures (35, 36). Both O-linked 
oligosaccharides were modeled from the library of fragments 
provided by INSIGHT II. Coordinates for the crystal 
structure of porcine FIXa (lpfx) were adapted to those of 
human FVIIa by adding two N-linked oligosaccharides at 
Thrl45 and Thr322 and two O-linked oligosaccharides at 
Pro52 and Leu60 (Figure 2; FVII sequence numbering) in 
order to replicate the FVIIa oligosaccharide structures. Three 
sets o f human sTF crystal coordinates were used: an initial 
set for free sTF which was later replaced (lboy) (9); a second 
independent set for free sTF (lhft, replaced after refinement 
by 2hft) (10, 11); and those found in the complex with FVIIa 
(ldan). While three glycosylation sites occur at A snll, 
Asnl24, and Asnl37 in native sTF, these were not modeled 
here as the recombinant sTF used for scattering data was 
expressed in Escherichia coli (37).
(b) Automated Scattering Curve-Fit Searches fo r  FVIIa 
and Its Complex with sTF. The automated curve-fit proce­
dure for the FVIIa domains was based on the reconstruction 
of these domains from available homologous structures which 
corresponds to the general method used for an unknown 
multidomain structure (26-29). The FVIIa residues 1-44 
(Figures 1 and 2) were assigned to the Gla domain in 
prothrombin (code 2pfl) (20), residues 45—83 to the EGF-1 
domain in factor IX (code lixa) (18, 19), and residues 91 — 
142 and 153—406 to the EGF-2 and SP domains in factor 
Xa (code lhcg) (15). This starting model included all 406 
residues in FVIIa, except for 7 residues in the link between 
the two EGF domains and 10 between the EGF-2 and SP 
domains. The alignment of Figure 2 showed that N-linked 
oligosaccharide chains were positioned at Argl42 at the C 
terminus of EGF-2 in factor Xa, and at Ile317 in the SP 
domain in factor Xa (FVII sequence numbering) to cor­
respond to their locations in FVIIa.
Since the EGF-2 and SP domains form a fixed structure, 
the starting model for FVIIa curve fits with the jc-axis, y-axis,
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F ig u r e  2 : Alignment of the human FVII amino acid sequence with 
those in bovine prothrombin, porcine FIXa, and human factor Xa 
to show the sequence identity with structurally homologous domains 
in the latter. The y-carboxyglutamic residues in the Gla domain 
(residues 1 —44) are denoted by g, the two N-linked oligosaccharide 
sites by C, and the catalytic triad (His-Asp-Ser) by #. Underlined 
sequences correspond to the homology models used for the linear 
starting model of FVIIa in Figure 5 below. The residue numbering 
refers to the mature amino acid sequence of human FVIIa.
and z-axis rotations set as 0° (see Figure 4 in ref 29) was 
created by positioning the N- and C-terminal a-carbon atoms 
of the Gla, EGF-1, and EGF-2 domains on a long common 
linear x  axis with arbitrary separations of 0.5 nm between 
adjacent N- and C-terminal a-carbon atoms (see Figure 5 
below). The origins for the rotational searches were defined 
as the C-terminal a  carbons of Tyr44 (Gla) and Leu83 (EGF-
1). The three y axes were set to be parallel and were defined 
arbitrarily by the a-carbon atoms of Lys3 (Gla), Cys81 
(EGF-1), and Gly93 (EGF-2). For automated curve fitting 
(26—28), rotations to create models were applied to this 
starting model using a Biosym Command Language (BCL) 
macro in conjunction with Unix shell scripts. In this, each 
of the Gla and EGF-1 domains was rotated relative to the 
EGF-2/SP domain pair into all x-, y- and z-axis orientations, 
while maintaining a fixed separation between N- and 
C-termini pairs between adjacent domains. The search 
utilized five 72° steps on each axis to give 56 or 15 625 
models.
The curve-fit searches for the complex between FVIIa and 
sTF used the linear starting model for FVIIa derived from 
homology modeling and the sTF crystal structure (9). The
long x  axis of sTF was defined using the N-terminal a carbon 
of Thr3 as origin, and the C-terminal a carbon of Glu213. 
They axis of sTF was defined arbitrarily by the a carbon of 
Thr86. To initiate the search, the long axis of sTF was 
aligned parallel to the long axis of the Gla, EGF-1, and 
EGF-2 domains in the linear starting model for FVIIa. The 
starting FVIIa and sTF models were superimposed using the 
sTF and EGF-2 axes in which the common origin was set 
as the N-terminal a carbon of sTF and the C-terminal a  
carbon of EGF-2. Then, holding FVIIa fixed in position, 
sTF was translated from its initial position along the x, y, 
and z axes in order to generate structures. A total of four 
90° reorientations of sTF about its long axis relative to FVIIa 
were examined in four separate searches in order to 
investigate the effect of the 125° angle between the two Fn- 
III domains in sTF on the outcome of the searches. In each 
search, after an initial translation of sTF of —5 nm on all 
three axes from the common origin, sTF was translated in 
0.5 nm steps from —5 nm to +5 nm along all three axes to 
give a full range of 213 or 9 261 models for each o f the four 
sTF orientations.
(c) Experimental Scattering and Analytical Ultracentrifu- 
gation Data. X-ray scattering data from Stations 2.1 and
8.2 at the Synchrotron Radiation Source, Daresbury, and 
neutron scattering data from the LOQ Instrument at the ISIS 
facility at the Rutherford-Appleton Laboratory were obtained 
for active-site-inhibited FVIIa, sTF, and the complex between 
them (29). The full characterization of these samples is 
described in ref 29 and references therein. Solutions of 
FVIIa and the FVIIa—sTF complex at 0.2—0.8 mg/mL, 
prepared as described in ref 29, were analyzed using a 
Beckman XLA analytical ultracentrifuge operated at 40 000 
rpm (An-60 Ti rotor) and equipped with scanning absorption 
optics at the National Centre for Macromolecular Hydrody­
namics, Leicester. Traces were measured at 280 nm and 
analyzed using a digitizing pad to yield experimental s°2o)W 
values after correction for the density and viscosity of the 
buffer (38).
(d) Modeling o f  Scattering and Analytical Ultracentrifu­
gation Data. For the direct comparison of scattering curves 
with crystal structures (Figures 3 and 4 below), sphere 
models were created by placing each full atomic coordinate 
set in a three-dimensional grid of cubes of side length 0.370 
nm. By varying a cutoff such that a sphere was created at 
the center of the cube if a given number of atoms were 
present in the cube, the total volume of the resulting sphere 
model was set to be equal to the full volume calculated for 
the 433 and 219 amino acid and carbohydrate residues, 
respectively, in FVIIa and sTF (39). This procedure cor­
rected for any residues that were missing in the crystal 
structure or altered in homology models based on FIXa or 
on homologous domains. The FVIIa models contained about 
1250 spheres (63.0 nm3), and those for sTF contained about 
630 spheres (31.5 nm3).
For the comparison of scattering curves from each of the 
structures calculated from the two automated searches based 
on homology models (Figures 5 and 6 below), the cube side 
was increased to 0.452 nm while retaining the same total 
volume. This reduced the computational resources required 
for each search. The consistent generation of the sphere 
models was achieved by fixing both the origin of the grid 
and the position of the FVIIa model within this grid. The
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F ig u r e  3: Comparison o f the calculated and experimental wide-angle scattering curves 7 ( 0  for FVIIa and its complex with sTF. The 
continuous lines represent the curves calculated from the crystal structure, while the points correspond to experimental data, (a, b): curve 
fits for the X-ray and neutron data, respectively, based on the FVIIa structure seen in the FVIIa—sTF complex, (c): sphere model and 
a-carbon views o f the FVIIa structure in the FVIIa—sTF complex, in which the full oligosaccharide structures are shown in bold, (d, e): 
curve fits for the X-ray and neutron data, respectively, based on the FVIIa—sTF crystal structure, (f): a-carbon and sphere model views 
of the FVIIa—sTF structure in the same orientation as that o f (c), in which the FVIIa oligosaccharide structure is shown in bold outline in 
the former. The dashed lines shown in (b) and (e) correspond to the calculated curves depicted in (a) and (d) to show the effect o f the 
neutron instrumental corrections.
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F ig u r e  4: Scattering curves calculated from the crystal structures 
of FVIIa and FIXa. (a): the scattering curves 7 (0  calculated from 
the SP domain and the light chain in the FVIIa model of Figure 3c 
are compared with the calculated X-ray scattering curve o f FVIIa 
taken from Figure 3a. (b): the distance distribution functions P{r) 
are shown to correspond to the calculated scattering curves of FVIIa 
and FIXa, with the position of two peaks indicated by M.
FVIIa model contained 666 spheres and that for sTF 
contained 354 spheres.
The X-ray and neutron scattering curves I(Q) were 
calculated from the sphere models by an application of 
Debye’s Law adapted to spheres of a single density (22, 40). 
In neutron curve fits, the hydration shell is not detectable 
and the dry sphere models obtained directly from the grid 
transformation were used for curve fitting. For X-ray curve
Tissue Factor " ”  f t  Factor Vila
c
.AstML(#•20
'h
x
F ig u r e  5: a-Carbon trace views of the sTF and FVIIa domain 
structures. The linear domain structure for FVIIa is the starting 
model with arbitrary domain orientations that was used for the 
automated searches. The oligosaccharides at Asnl45 and Asn322 
are shown in extended conformations, in contrast to the more 
compact conformations shown in Figure 3. The C-terminal domain 
o f sTF is positioned proximate to the N-terminal Gla domain in 
FVIIa in the complex. Distance constraints based on the positions 
of Lys20, Trp45, Asp58, Tyr94, and Phel40 in sTF are indicated 
by dotted lines that represent die perpendiculars from these a-carbon 
atoms to the long x axis of the FVIIa model. The mean of the five 
perpendicular distances is denoted as D in the text. The a-carbon 
positions of the three N-linked oligosaccharides on sTF are indicated 
by •  symbols (see text). The x and z axes are as indicated; the y  
axis is perpendicular to the page.
fits, a hydration of 0.3 g of H20/g of glycoprotein and an 
electrostricted volume of 0.0245 nm3/H20 molecule were
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F ig u r e  6 : Two projection views of the outcome of the automated search for the FVIIa—sTF complex. The zx and zy projection views 
summarize the distribution of 276 sTF structures relative to the FVIIa model after the exclusion of models with large steric overlap or large 
Ra values. The zx projection is shown also in Figure 5. Below each grid, outlines of the FVIIa and sTF domains are shown in the same 
scale to show the best-fit structure for the complex, denoted by the A symbol in the grid. The +  symbol on FVIIa denotes the origin of the 
grid, and the +  symbol on sTF (dotted outline) denotes its N terminus. Note that the separation between the two + symbols matches the 
separation of the origin of the grid and the A symbol in the grid. The O and •  symbols in the grid denote the position of the N terminus 
of sTF in the 276 models of the complex. O denotes 184 complex models with D values greater than 2.S nm, while •  denotes 92 complex 
models with D less than 2.5 nm that satisfy the biochemical constraint of Figure 5 (see text). The V symbol denotes the worst-fit model 
from the 276 models. Also shown is an a-carbon view of the crystal structure of the FVIIa—sTF complex in the same orientation and scale 
as the domain outline, with sTF shown in bold.
used to readjust the sphere radius and coordinates to allow 
for the volume of the hydrated structure (23—25). For X-ray 
fits, no scattering curve corrections were applied for wave­
length spread or beam divergence as these are thought to be 
negligible. For neutron fits, a 16% wavelength spread for a 
nominal A of 1 nm and a beam divergence of 0.016 rad were 
used as an empirical correction for the calculated scattering 
curves (26).
The curve fits were assessed by calculating the radius of 
gyration Rq and that of its cross-section R x s  from Guinier 
fits of the calculated curve in the same Q ranges used in the 
experimental data analyses (29). The R  factor goodness-of- 
fit parameter was defined by analogy with crystallography
(23) for X-ray data in the Q range between 0.10 and 2.0 
nm-1 and neutron data in the Q range between 0.15 and 2.0 
nm-1 (denoted as /?2.o), and normalized using an 7(0) value 
of 1000. Sedimentation coefficients (s°2o,w values) were 
calculated directly from the hydrated sphere models used 
for X-ray scattering curve fits using the program GENDIA 
(24, 41, 42). In the automated searches, the comparison of 
the calculated and experimental curves was achieved by the 
use of filters to retain or reject models on the basis of less 
than 5% steric overlap between the domains, specified ranges 
for the calculated Rq and R x s  values and s°2o,w values, and 
low R factor values (22). For FVIIa and the complex, the 
R a  value of their models was required to be less than 3.21 
and 3.4 nm, respectively (Table 1).
RESULTS AND DISCUSSION
(a) Comparison o f  the Solution and Crystal Structures fo r  
FVIIa. In the absence of a crystal structure for free FVIIa,
the solution scattering data for free FVIIa in 5 mM Ca2+ 
were compared with the FVIIa structure found within the 
crystal structure of the FVIIa—sTF complex to determine 
the degree of agreement between them. This FVIIa structure 
in the sTF—FVIIa crystal complex showed an extended 
arrangement of the Gla, EGF-1, and EGF-2 domains with a 
tip-to-tip maximum dimension of 11.5 nm. This is compa­
rable with the length determination of 10.3 nm for FVIIa in 
solution by scattering (29). The FVIIa crystal structure 
showed that the EGF-2 and SP domains form many contacts 
with each other and may be considered as a rigid entity, and 
that the link between the Gla and EGF-1 domains is also 
well-defined. One less well defined feature is the extended 
oligopeptide link HKDDQLI between the last disulfide bridge 
of EGF-1 and the first disulfide bridge of EGF-2 domains 
(residues 84—90 in Figure 2). This forms a poorly defined 
helix in the crystal structure that may be flexible in solution 
(Figure 1). The two large N-linked oligosaccharide chains 
on opposite faces of the SP domain were not visible in the 
crystal structure of the complex, and constitute a second less 
well defined feature of the FVIIa structure. When the 
scattering curve was calculated for the FVIIa structure seen 
in the crystal structure of the complex with the addition of 
two extended oligosaccharide chains (Methods; see Figure 
5), Rg and R x s  values of 3.46 and 1.43 nm, respectively, 
were obtained that were higher than the experimental values. 
The X-ray and neutron curve fits had goodness-of-fit R2.0  
values of 7.6% and 7.9%, respectively (Table la). However, 
if  the oligosaccharide chains were reorientated more closely 
to the protein surface of the SP domain in this FVIIa
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Table 1: Modeling Analyses for Factor Vila and the Complex between Factor Vila and Soluble Tissue Factor
models /fc(nm) flxs(nm) * 2.0 (%) 5°20,w  (S)
(a) Factor Vila:
mean experimental values 3.31 ±0.08 1.53 ±0.13 3.3 ±0.1°
calculated values using models from crystal structures
FVIIa from FVIIa—sTF (extended CHO) 1 3.46 1.43 7.0,7.0* 3.0
FVIIa from FVIIa—sTF (compact CHO) 1 3.31 1.55 5.7,6.0* 3.2
FIXa-based (extended CHO) 1 3.21 1.37 6.5,7.5* 3.3
FIXa-based (compact CHO) 1 3.06 1.49 4.8,6.7* 3.5
automated search using homology models (5 x 72° steps about x, y , z axes)
linear starting model 1 3.22 1.30 4.4,6.8* 3.4
bait model 1 2.58 1.61 19.3,14.7* 3.8
number of models 15 625
models with < 5% stoic overlap 11 955 2.90 ±0.19 1.40 ±0.12 5.4 ±  2.0 3.6 ±0.12
models with Rg > 3.15 nm 1051 3.20 ±  0.03 1.31 ±0.03 4.4 ±  0.2 3.4 ±  0.03
models with Rq > 3.21 nm 317 3.24 ±  0.02 1.32 ±0.02 4.6 ±  0.2 3.4 ±  0.02
(b) FVIIa—sTF Complex:
mean experimental values 3.22 ±  0.03 1.56 ±0.02 4.4 ±  0.3°
calculated values using models from crystal structure
FVIIa—sTF complex (extended CHO) 1 3.57 1.56 8.4,7.7* 4.3
FVIIa-sTF complex (compact CHO) 1 3.47 1.60 6.5,6.8* 4.5
automated search using homology models (21 x 0.5 nm steps along x, y, z  axes;
4 orientations)
total number of models 4 x 9261
orientation 1 (models with <5% steric overlap; Rq < 3.4 nm) 276 3.35 ±  0.04 1.72 ±0.08 6.5 ±  1.2 4.5 ±0.1
best model 1 3.24 1.64 3.8, 8.3* 4.7
a Experimentally determined values (Methods). * The first and second values correspond to the X-ray and neutron R2.0 values, respectively.
structure, Rg and Rxs values of 3.31 and 1.55 nm, respec­
tively, were obtained that were in good agreement with the 
experimental values. The X-ray and neutron R2.0 values were 
better at 5.7% and 6.0%, respectively (Table la). It was 
concluded that a FVIIa structure with an extended EGF-1/ 
EGF-2 link and compact N-linked oligosaccharides (Figure 
3c) is consistent with the experimental data for free FVIIa 
in solution.
As FVIIa is 90% protein and 10% carbohydrate by weight, 
scattering inhomogeneity effects may be important. The 
X-ray data correspond to a high positive solute—solvent 
contrast, while die neutron data in 100% 2H20 correspond 
to a high negative solute—solvent contrast that inverts the 
relative contributions of high and low macromolecular 
scattering densities to the observed scattering curve. The 
similarity of the R 2.0 values for both the X-ray curve fit 
(Figure 3a) and the neutron curve fit (Figure 3b) after 
correction for instrumental effects (see dotted lines in Figure 
3b) showed that these inhomogeneity effects were unimpor­
tant.
The four domains of FVIIa are homologous to those found 
in FIXa. In the crystal structure of free porcine FIXa, three 
of its four domains were clearly visualized. The fourth (Gla) 
domain was partially resolved but could be successfully 
modeled using the prothrombin Gla domain structure (77). 
The FIXa crystal structure exhibits a sharp 110° bend 
between the long axes of the EGF-1 and EGF-2 domains in 
the light chain that is stabilized by a salt bridge unique to 
FIXa between Glu78 and Arg97 in the numbering of Figure 
2. The oligopeptide linker between EGF-1 and EGF-2 in 
FIXa is four residues shorter than that seen in FVIIa (Figure
2). The maximum linear dimension of the four FIXa 
domains is accordingly shorter at 10.5 nm than that of 11.5 
nm for FVIIa. To test whether this shorter, bent FIXa 
domain arrangement could represent the domain structure 
of free FVIIa in solution, a scattering curve was calculated 
from this FIXa crystal structure (Methods) for comparison
with the experimental FVIIa scattering data. If extended 
oligosaccharide structures were used in this model, the 
resulting 7?g and 7?xs values of 3.21 and 1.37 nm, respec­
tively, were close to the experimental values, and X-ray and 
neutron R 2.0 values of 6.5% and 7.5%, respectively, were 
obtained (Table la). When compact oligosaccharide struc­
tures were used, the resulting Rg value of 3.06 nm was in 
poorer agreement with the experimental value, but better R2.0 
values of 4.8% and 6.7% were obtained. The inconsistency 
of these two outcomes, together with visual inspection of 
the two curve fits (not shown), did not favor a bait FlXa- 
like domain arrangement as a model for the FVIIa domain 
arrangement in solution (Table la).
Comparative calculations of the scattering curve 7 (0  and 
its distance distribution function P(r) from the crystal 
structures of complexed FVIIa and free FIXa (Figure 4) 
showed more clearly that FVIIa in solution contains an 
extended light chain domain arrangement and not a bent one. 
The experimental X-ray 7 (0  for free FVIIa in Figure 3a 
showed a slight inflection at Q =  0.9 nm-1, which suggested 
that structurally distinct and separated “head” and “tail” 
moieties existed in free FVIIa. Even though the whole FVIIa 
structure contributes to all parts of the FVIIa 7 (0  curve, 
the calculation of 7 (0  for the SP domain alone gave a good 
match to the FVIIa curve between Q of 0.6—1.3 nm-1 in 
Figure 4a, while that for the light chain alone in FVIIa gave 
a good match to the FVIIa curve below Q of 0.35 nm-1 in 
the Q range where the SP curve is relatively flat in Figure 
4a. This provided an explanation of the inflection in 7 (0  
at Q =  0.9 nm-1. Similar calculations using the FIXa crystal 
structure gave neither of these matches (not shown), which 
is attributable to the closer spatial proximity of the SP domain 
to the light chain in this bent structure. More significantly, 
the P(r) curves from the crystal structures of complexed 
FVIIa and free FIXa showed a large difference (Figure 4b). 
That for FVIIa contains a main peak at M of 3.0 nm and a 
subpeak at 7.0 nm. That at 3.0 nm is assigned to interatomic
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distances mostly within the SP domain, while that at 7.0 nm 
is assigned to interatomic distances mostly within an 
extended light chain structure, the second of which has 31% 
of the height of the main peak. The calculated curve was in 
excellent agreement with the experimental P(r) curve of free 
FVIIa which shows two peaks at 3.0 and 7.0 nm, the second 
of which has a peak height of 32% of the first (see Figure 3 
in ref 29). In contrast, the P{r) curve for FIXa contained 
only a main peak at 3.0 nm (Figure 4b). This is attributable 
to the proximity of the SP domain and light chain in the 
bent FIXa structure. Thus, the difference between the two 
P{r) curves rules out a significantly bent light chain domain 
structure for free FVIIa in solution.
(b) Automated Modeling Curve Fitting fo r  the FVIIa 
Domains. Solution scattering does not yield unique struc­
tures but only compatible ones. Since the above results for 
FVIIa were based on comparisons with only two crystal 
structures, supplementary curve fits were needed in order to 
establish a more general structural description for FVIIa. 
Thus an automated curve fit analysis was performed to assess 
all possible domain arrangements (Methods). A linear 
starting model that corresponded to the most extended 
domain arrangement positioned the long axes of the Gla, 
EGF-1, and EGF-2 domains on a common long axis included 
a short linker between the EGF-1 and EGF-2 domains and 
possessed extended oligosaccharide structures. Since the 
FVIIa—sTF crystal structure was unavailable at the time the 
search was performed, this starting model was constructed 
from homologous domains found in prothrombin, FIXa, and 
factor Xa (Methods; Figure 5). This model had a length of
11.0 nm and gave an acceptable curve fit to the experimental 
X-ray data. The R g  and R x s  values were low at 3.22 and 
1.30 nm, but good X-ray and neutron goodness-of-fit R2.0 
values of 4.4% and 6.8% were obtained. In contrast, a bent 
domain model in which the EGF-1 and Gla domains were 
both rotated by 72° about the y  axis in the x — z  plane of 
Figure 5 gave very poor curve fits with /?2.o values of 19.3% 
and 14.7%.
This linear starting FVIIa model was used for an automated 
curve-fit search based on 15 625 possible domain arrange­
ments, which were evaluated using fits to the experimental 
X-ray curve. The application of a steric overlap filter left 
11 955 models (Methods; Table la). Of these models, only 
1051 had Rg values greater than 3.15 nm, and 317 had Rq 
values greater than 3.21 nm. These 317 models (which 
included the starting linear model) had individual jc-, y-, and 
2-axis rotations that were distributed over all values without 
preference for specific ranges, and gave good agreement with 
the experimental X-ray data. In conclusion, the search 
showed that only the most extended domain arrangements 
in free FVIIa were compatible with the experimental X-ray 
curve. These correspond not only to the extended FVIIa 
structure seen in the FVIIa—sTF crystal structure, but also 
to other structures that may be in equilibrium with this, 
provided that all these other structures are extended. In 
addition, this search did not rule out the presence of a short 
linker structure between EGF-1 and EGF-2 in free FVIIa, 
which becomes more elongated after complexation with sTF 
to give the FVIIa structure seen in the FVIIa—sTF complex.
(c) Comparison o f  the Crystal and Solution Structures fo r  
the FVIIa—sTF Complex. To see whether the crystal 
structure of inhibited FVIIa and subtilisin-cleaved sTF (14)
is compatible with the solution structure of the FVIIa—sTF 
complex, the scattering curve calculated from the crystal 
structure was compared with the experimental scattering 
curves for the complex formed between intact sTF and 
inhibited FVIIa in Figure 3, parts d and e. The same 
extended and compact N-linked oligosaccharide structures 
used above for free FVIIa were used in order to permit direct 
comparison with the FVIIa curve fits. Small curve fit 
differences for the complex were seen between the two 
oligosaccharide conformations, and the compact one again 
gave a better curve fit (Figure 3f). The experimental Rg 
values of free FVIIa and the FVIIa—sTF complex are similar 
within experimental error (Table 1), and this was attributed 
to the compact nature of the interaction made between FVIIa 
and sTF in their complex (29). In the present modeling, the 
calculated Rg value for the complex was larger by 0.25 nm 
than the experimental value; however, satisfactory X-ray and 
neutron R 2.0 values of 6.5—6.8% were obtained, and this 
supported the similarity of the crystal and solution structures 
of the complex (Table lb). The difference in Rq values may 
be attributed to the less extensive data collection for the 
complex compared to FVIIa in ref 29. It was concluded 
that the curve fits of Figure 3d, e ruled out the possibility of 
a major domain rearrangement between the crystal and 
solution states.
(d) Automated Modeling Curve Fitting fo r  the FVIIa— 
sTF  Complex. The feasibility of an automated curve-fit 
search to determine candidate models for a multidomain 
heterodimeric protein complex is important for the study of 
other such systems. This was therefore examined using the 
FVIIa—sTF complex as a model system, since these candi­
date models can be compared with the recently solved crystal 
structure for this complex. Such a search assumes that major 
structural rearrangements in the two associating multidomain 
structures between the free and bound states are absent. For 
sTF, supporting evidence for this was obtained by the 
comparison of scattering curves calculated for free and 
complexed sTF crystal structures (Methods), which gave 
good R 2.0 values of 2.3—3.5%. Comparisons of the calcu­
lated Rg values o f2.34—2.49 nm with the experimental value 
of 2.06 ± 0 .1 2  nm (29) showed that these were larger by 
0.28—0.43 nm. This Rq difference is attributed to the small 
size of sTF and the less extensive data collection for sTF 
compared to FVIIa in the earlier study (29), and is not 
considered significant in the present context. For FVIIa, only 
extended domain arrangements in the free and complexed 
forms were determined from the above analyses, and the 
extended linear FVIIa structure of Figure 5 was therefore 
reused here.
A comprehensive search for all sterically allowed struc­
tures of sTF relative to FVIIa in the complex would involve 
six rotational and translational parameters. Their full treat­
ment would result in too many models to analyze with 
present computational resources. Previously, automated 
curve-fit searches for two homooligomeric complexes were 
constrained by symmetry and this significantly reduced the 
number of models to be tested (22, 25, 31). As symmetry 
constraints were not available for a heterodimeric complex, 
a biochemical constraint was used instead. It is known that 
the C-terminal domain of sTF is close to the Gla domain of 
FVIIa, since the EGF-1 and Gla domains interact with sTF 
(43), and both the C-terminal domain of sTF and the Ca2+-
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rich Gla domain are proximal to the negatively charged cell 
membrane in the membrane-bound complex. This constraint 
fixed the position of sTF so that the C-terminus of sTF was 
close to the Gla domain (shown in Figures 1 and 5). 
Accordingly only translational searches of sTF in this 
orientation relative to FVIIa were performed and this 
restricted the number of models to be tested to 9261 
(Methods). Three further searches were also made with the 
sTF structure rotated in 90° steps about its longest axis 
(Methods).
Analysis of the conformational searches identified 276 
possible structures for the complex in the search based on 
the sTF orientation shown in Figure 5, where 97% of the 
9261 possible models had been eliminated by the use of steric 
overlap and Rg filters. The two filters eliminated models 
that were too compact or too elongated, respectively. The 
276 structures included those related to the known crystal 
structure of the complex. At this point, further biochemical 
constraints were found to be useful. This is detailed as 
follows:
(i) Projection views of these 276 models (Figure 6) showed 
that a sufficiently large translational range had been scanned. 
Both the R g  and R x s  values of the 276 models agreed with 
experiment and gave low R2.0  values between 3.8% and 9.4%. 
Similar results were obtained in the other three searches using 
the different sTF orientations about its long axis (not shown). 
The 276 locations of sTF relative to FVIIa in the zx  (and 
yx) projection covered a large area on the longest x  axis of 
FVIIa. The zy projection shows that the 276 locations 
correspond to an annulus that surrounds the three small Gla 
and EGF domains or the large SP domain. Analysis of all 
four 90° orientations of sTF about its longest axis (not 
shown) showed that the greatest uncertainty in the position 
of these filtered models was along the x-axis (range of 5 
nm), followed by the z-axis (range of 4 nm), then the y-axis 
translation (range of 2 nm).
(ii) Surface plasmon resonance analyses of mutants have 
shown that the sTF residues Lys20, Trp45, Asp58, Tyr94, 
and Phel40 (Figure 5) are important for binding to the Gla 
and EGF domains in FVIIa (2, 5). The biochemical 
constraint based on this was used to divide the 276 models 
into two sets. The mean value D  of the perpendicular 
distances between these five a-carbon atoms in sTF and the 
x  axis of FVIIa (Figure 5) was 3.0 ±  1.1 nm for all 276 
models. The 92 models with D  less than 2.5 nm (highlighted 
as •  in Figure 6) correspond to an annulus of sTF locations 
surrounding the Gla and EGF domains in the zy  projection. 
The zx projection showed that the 92 highlighted locations 
covered the long axis of the EGF and Gla domains.
(iii) The best X-ray fit model (A) had x, y , and z 
translations of sTF by 2.0, 1.5, and 0.5 nm, respectively, 
from the origin, with a separation between the centers of 
mass of 2.6 nm (Table lb; Figure 6), and gave an R 2.0  value 
of 3.8%. This model and others were located in the + z/+ y  
quadrant in the zy projection. This quadrant corresponds to 
the large space contained between the SP domain and the 
light chain. Comparison of the domain outlines in Figure 6 
with molecular graphic views of the crystal structure of the 
complex provided a striking confirmation of the layout of 
FVIIa and sTF in this best-fit structure (Figure 6). The 
rotational orientations of the FVIIa domains and sTF about 
their long axes were, however, distinctly different in the
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crystal structure compared to Figure 5 and could not be 
identified in this search. The worst X-ray fit model (V) and 
others were located in the —z/—y  quadrant in the zy 
projection, in which sTF is now on the opposite face of 
FVIIa.
(iv) Two final checks were performed on the best-fit model 
from the search (Figure 6). The occupancy of the three Asn 
glycosylation sites in native tissue factor would hinder 
protein—protein interactions with FVIIa, and their location 
acts as a biochemical constraint that defined disallowed 
models. In Figure 5, Asnl24 and Asnl37 are on the right 
side of sTF, while Asnl 1 is on the left, and define possible 
surface areas of sTF that do not interact with FVIIa. This 
was sterically consistent with the best-fit model from the 
search shown in Figure 5. This best-fit model was supported 
also by the 276 corresponding neutron curve fits, where the 
best model had R 2.0  — 8.3% and the worst one had R2.0  =  
10.3%.
(e) Sedimentation Coefficient Analyses fo r  FVIIa and Its 
Complex with sTF. The modeling of sedimentation coef­
ficient data from analytical ultracentrifugation provides an 
alternative determination of the dimensions of FVIIa and the 
FVIIa—sTF complex. Previously, using models based on 
hydrodynamic ellipsoids, the Perrin equations resulted in 
molecular dimensions for FVIIa of 20.4 nm x 2.8 nm x 
2.8 nm at one limit and 12.6 nm x 9.8 nm x 1.4 nm at the 
other (44, 45). Those for the FVIIa—sTF complex were 25.4 
nm x 2.6 nm x 2.6 nm at one limit and 18.6 nm x 7.8 nm 
x 1.2 nm at the other. Since X-ray and neutron scattering 
showed that both FVIIa and the FVIIa—sTF complex had 
lengths of 10.2—10.3 nm, and the crystal structure for the 
FVIIa—sTF complex is 11.5 nm long with a diameter of 4.0—
5.0 nm, the lengths from scattering are seen to be in better 
agreement with the FVIIa—sTF crystal structure than those 
from the Perrin equations. This discrepancy is now explored.
Hydrodynamic modeling was performed to assess the use 
of sedimentation coefficients s°2o,w to analyze these structures. 
First, remeasurement of the experimental s°2o,w values for 
FVIIa and the FVIIa—sTF complex gave values of 3.3 ±  
0.1 S and 4.4 ±  0.3 S, respectively, from sedimentation 
velocity runs using a Beckman XLA ultracentrifuge (Meth­
ods). While the first value is in good agreement with that 
of 3.4 ±  0.1 S reported previously using a Beckman Model 
E ultracentrifuge (44), the second value is higher than that 
of 3.9 ±  0.1 S determined previously. Second, using small 
spheres, the theoretical s°2o,w values were calculated from 
the crystallographic models and the automated search models 
for comparison with experiment (Table 1). In agreement 
with the scattering modeling, the s°2o,w calculation for the 
FVIIa model derived from the crystal structure of the 
complex was in better agreement with experiment if the 
oligosaccharides were in a compact conformation (Table la). 
Likewise the 317 best-fit FVIIa scattering models from the 
automated search gave good agreement with experiment 
(Table la). These showed that the use of small spheres was 
successful in accounting for the experimental s°2o,w value of
3.3 ± 0 .1  S. However, unlike the scattering analyses, the 
so20,w calculation could not exclude the bent FVIIa model 
derived from FIXa (Table la). In the case of the FVIIa- 
sTF complex, good agreement was also found with the 
crystal structure which gave calculated s°2o,w values of 4 .3 - 
4.5 S in good agreement with the experimental value of 4.4
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±  0.3 S (Table lb). The 276 best-fit scattering models gave 
a calculated mean value of 4.5 ±0 .1  S. It is concluded that 
the scattering and hydrodynamic calculations were consistent 
with each other, and that the earlier measurement of s°20,w 
for the complex had been underestimated.
CONCLUSIONS
(a) Structures o f  FVIIa and FVIIa—sTF. Solution scat­
tering has provided new information on the domain arrange­
ments in FVIIa and the FVIIa—sTF complex that usefully 
extends the interpretation of recent crystal structures for 
coagulation factors, both when free and when complexed. 
Multidomain structures cannot be solved unambiguously by 
scattering analyses, but the knowledge of these crystal 
structures now places limits on the scattering analyses and 
makes them more powerful in the analysis of unknown 
multidomain structures (22).
In application to FVIIa, previous scattering studies had 
indicated that the FVIIa domains were extended (29). Here, 
the direct comparison of scattering data for free FVIIa in 
solution with the extended FVIIa structure in the recent 
crystal structure of the FVIIa—sTF complex shows that they 
are consistent. In addition, several new curve-fit analyses 
rule out a bent light chain structure for FVIIa such as seen 
in the crystal structure of the homologous coagulation factor 
FIXa. In FIXa, the bend in this structure occurs at the short 
EGF-l/EGF-2 link and is attributed to a Glu-Arg interdomain 
salt bridge that is conserved in FIXa but not in either FVIIa 
or factor Xa. In FVIIa, this link is longer and is seen as a 
short poorly formed helix in the FVIIa—sTF crystal structure 
to suggest that this may be somewhat flexible and extended 
in solution, which would be consistent with the new curve 
fits presented here. Fluorescence experiments with labeled 
FVIIa have suggested that free FVIIa is more flexible than 
in the complex with sTF (44). This link is also likely to be 
flexible in factor Xa as this link is longer than that of FIXa, 
and EGF-2 but not EGF-1 was observed in the crystal 
structure of des-Gla factor Xa (75). In a second crystal form 
of des-Gla factor Xa, the EGF-1 domain is in a different 
location relative to the SP and EGF-2 domains (16). In 
addition, the NMR structure of the Gla/EGF-1 domain pair 
in factor X suggests that there is flexibility between these 
two domains as well (46). These observations imply that 
multiple related FVIIa conformations of similar energies may 
coexist in solution. The significance of the present auto­
mated FVIIa curve-fit analyses is to show that all these 
extended structures will be similar in overall length and ideal 
for the recognition of tissue factor. There would be no 
significant energy price to be paid in terms of domain 
reorientation during complex formation, and this together 
with the extensive dispersion of contact residues across the 
four FVIIa domains would account for the low nanomolar 
Kd reported for the interaction.
In application to the FVIIa-sTF complex, the scattering 
data showed that a compact complex of FVIIa with sTF was 
formed (29). The present scattering analysis was important 
to verify the similarity of its domain structure in solution 
with that in the crystal structure, despite the removal of the 
sTF residues 85—89 in the crystal structure and the existence 
of packing contacts in the crystal state. It is generally 
thought that the tight interaction of the Gla, EGF-1, EGF-2,
and SP domains in FVIIa with the domain pair in sTF locks 
the flexible FVIIa structure into a more rigid conformation. 
This would stabilize an active conformation and/or a 
reorientation of the enzymatic SP domain in FVIIa that would 
lead to its activation and the initiation of blood coagulation 
(3, 30). Data from a fluorescence energy transfer study 
suggest that this may well be the case (47). A crystal 
structure for free FVIIa would therefore be of great interest 
as this would allow the precise definition of changes in the 
SP domain in relation to FVIIa function.
Solution scattering also provided information on the two 
N-linked oligosaccharide structures of FVIIa. Since these 
lie on the outer periphery of FVIIa, scattering data are 
sensitive to their conformation. The FVIIa curve fits suggest 
that these oligosaccharides are not as extended as found in 
several other glycoproteins by similar scattering analyses (25,
28), and the same result was obtained with the FVIIa-sTF 
curve fits. Their conformations shown in Figures 3c and 5 
suggest that two sides of the SP domain are masked, while 
leaving accessible the catalytic triad at Hisl93-Asp242- 
Ser344 at the top of the structure as viewed in Figure 3f, as 
well as its contact region with sTF between the SP domain 
and the FVIIa light chain. The O-linked oligosaccharides 
on the EGF-1 domain likewise do not mask the contact 
surface of FVIIa. Inspection of the sTF structure in its 
complex shows that the N-linked oligosaccharides of sTF 
also do not hinder the contact region of sTF with FVIIa.
(b) Automated Modeling o f  Heterodimeric Complexes by 
Scattering and Ultracentrifugation. The novelty of the 
present curve-fit modeling lies in its application to a 
heterodimeric complex formed between two multidomain 
proteins (22). The joint use of both X-ray and neutron 
scattering curve fits together with analytical ultracentrifu­
gation data serves as controls for reproducibility and possible 
solute—solvent contrast effects. Previous curve-fit applica­
tions have described its calibration for proteins of known 
crystal structures and molecular weights between 23 000 and 
127 000 (23—25) and its application to single multidomain 
proteins and homodimeric and homotrimeric complexes (26—
29). In the present application, as in those previous ones, 
suitable homologous atomic structures are essential to 
constrain the curve-fit analyses. These may be available 
either directly by high sequence similarity with known atomic 
structures (homology modeling) or indirectly by protein fold 
recognition methods and analogy modeling (48, 49). For 
single multidomain proteins, further constraints are imposed 
by use of the correct stereochemical connections between 
the domains that the curve fits are directed toward determi­
nation of the domain arrangement. For homooligomeric 
complexes, further constraints are imposed through known 
symmetry relationships that the curve fits can assess the 
arrangement of the monomers within the oligomer. The 
present analysis of a heterodimeric complex, however, lacks 
symmetry constraints. After constraining the search on the 
basis of the inferred relative orientation of the two proteins 
in the complex, the use of steric overlap and Rg filters still 
left many allowed structures. However, in the search based 
in Figure 5, the use of further biochemical constraints based 
on identified contact residues between the two proteins 
(together with the known location of glycosylation sites 
which would be excluded from the protein—protein interface) 
permitted the location of sTF in the space between the SP
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domain and the light chain, in agreement with the crystal 
structure of the complex. This approach usefully narrowed 
the range of possible structures for the complex. Thus, in 
the absence of a crystal structure, it is envisaged that the 
automated modeling technique with the application of 
biochemical constraints, together with the use of electrostatic 
and surface docking methods, will result in improvements 
in structure determinations for other heterodimeric complexes 
such as ligand—receptor pairs.
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